US20070038053A1 - Signal processing for measurement of physiological analytes - Google Patents

Signal processing for measurement of physiological analytes Download PDF

Info

Publication number
US20070038053A1
US20070038053A1 US11/583,407 US58340706A US2007038053A1 US 20070038053 A1 US20070038053 A1 US 20070038053A1 US 58340706 A US58340706 A US 58340706A US 2007038053 A1 US2007038053 A1 US 2007038053A1
Authority
US
United States
Prior art keywords
signal
analyte
concentration
electrode
calibration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/583,407
Inventor
Bret Berner
Timothy Dunn
Kathleen Farinas
Michael Garrison
Ronald Kurnik
Matthew Lesho
Russell Potts
Janet Tamada
Michael Tierney
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US11/583,407 priority Critical patent/US20070038053A1/en
Publication of US20070038053A1 publication Critical patent/US20070038053A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/145Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/1468Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using chemical or electrochemical methods, e.g. by polarographic means
    • A61B5/1477Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using chemical or electrochemical methods, e.g. by polarographic means non-invasive
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/145Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14532Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/145Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/14542Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring blood gases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/145Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
    • A61B5/1486Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using enzyme electrodes, e.g. with immobilised oxidase

Definitions

  • the invention relates generally to methods for continually or continuously measuring the concentration of target chemical analytes present in a biological system. More particularly, the invention relates to methods for processing signals obtained during measurement of physiological analytes.
  • One important application of the invention involves a method for monitoring blood glucose concentrations.
  • a number of diagnostic tests are routinely performed on humans to evaluate the amount or existence of substances present in blood or other body fluids. These diagnostic tests typically rely on physiological fluid samples removed from a subject, either using a syringe or by pricking the skin.
  • One particular diagnostic test entails self-monitoring of blood glucose levels by diabetics.
  • Type I diabetes Diabetes is a major health concern, and treatment of the more severe form of the condition, Type I (insulin-dependent) diabetes, requires one or more insulin injections per day. Insulin controls utilization of glucose or sugar in the blood and prevents hyperglycemia which, if left uncorrected, can lead to ketosis. On the other hand, improper administration of insulin therapy can result in hypoglycemic episodes, which can cause coma and death. Hyperglycemia in diabetics has been correlated with several long-term effects of diabetes, such as heart disease, atherosclerosis, blindness, stroke, hypertension and kidney failure.
  • Type II diabetes The value of frequent monitoring of blood glucose as a means to avoid or at least minimize the complications of Type I diabetes is well established. Patients with Type II (non-insulin-dependent) diabetes can also benefit from blood glucose monitoring in the control of their condition by way of diet and exercise.
  • U.S. Pat. No. 5,139,023 to Stanley et al., and U.S. Pat. No. 5,443.080 to D'Angelo et al. describe transdermal blood glucose monitoring devices that rely on a permeability enhancer (e.g., a bile salt) to facilitate transdermal movement of glucose along a concentration gradient established between interstitial fluid and a receiving medium.
  • a permeability enhancer e.g., a bile salt
  • U.S. Pat. No. 5,036,861 to Sembrowich describes a passive glucose monitor that collects perspiration through a skin patch, where a cholinergic agent is used to stimulate perspiration secretion from the eccrine sweat gland. Similar perspiration collection devices are described in U.S. Pat. No. 5,076,273 to Schoendorfer and U.S. Pat. No. 5,140,985 to Schroeder.
  • the present invention provides a method for continually or continuously measuring the concentration of an analyte present in a biological system.
  • the method entails continually or continuously detecting an analyte from the biological system and deriving a raw signal therefrom, wherein the raw signal is related to the analyte concentration.
  • a number of signal processing steps are then carried out in order to convert the raw signal into an initial signal output that is indicative of an analyte amount.
  • the converted signal is then further converted into a value indicative of the concentration of analyte present in the biological system.
  • the raw signal can be obtained using any suitable sensing methodology including, for example, methods which rely on direct contact of a sensing apparatus with the biological system; methods which extract samples from the biological system by invasive, minimally invasive, and non-invasive sampling techniques, wherein the sensing apparatus is contacted with the extracted sample; methods which rely on indirect contact of a sensing apparatus with, the biological system; and the like.
  • methods are used to extract samples from the biological sample using minimally invasive or non-invasive sampling techniques.
  • the sensing apparatus used with any of the above-noted methods can employ any suitable sensing element to provide the raw signal including, but not limited to, physical, chemical, electrochemical, photochemical, spectrophotometric, polarimetric, calorimetric, radiometric, or like elements.
  • a biosensor is used which comprises an electrochemical sensing element.
  • the raw signal is obtained using a transdermal sampling system that is placed in operative contact with a skin or mucosal surface of the biological system.
  • the sampling system transdermally extracts the analyte from the biological system using any appropriate sampling technique, for example, iontophoresis.
  • the transdermal sampling system is maintained in operative contact with the skin or mucosal surface of the biological system to provide for such continual or continuous analyte measurement.
  • the analyte can be any specific substance or component that one is desirous of detecting and/or measuring in a chemical, physical, enzymatic, or optical analysis.
  • Such analytes include, but are not limited to, amino acids, enzyme substrates or products indicating a disease state or condition, other markers of disease states or conditions, drugs of abuse, therapeutic and/or pharmacologic agents, electrolytes, physiological analytes of interest (e.g., calcium, potassium, sodium, chloride, bicarbonate (Co 2 ), glucose, urea (blood urea nitrogen), lactate, hematocrit, and hemoglobin), lipids, and the like.
  • the analyte is a physiological analyte of interest, for example glucose, or a chemical that has a physiological action, for example a drug or pharmacological agent.
  • the raw signals undergo a data screening method in order to eliminate outlier signals and/or poor (incorrect) signals using a predefined set of selection criteria.
  • the raw signal can be converted in a conversion step which (i) removes or corrects for background information, (ii) integrates the raw signal over a sensing time period, (iii) performs any process which converts the raw signal from one signal type to another, or (iv) performs any combination of steps (i), (ii) and/or (iii).
  • the conversion step entails a baseline background subtraction method to remove background from the raw signal and an integration step.
  • the conversion step can be tailored for use with a sensing device that provides both active and reference (blank) signals; wherein mathematical transformations are used to individually smooth active and reference signals, and/or to subtract a weighted reference (blank) signal from the active signal.
  • the conversion step includes correction functions which account for changing conditions in the biological system and/or the biosensor system (e.g., temperature fluctuations in the biological system, temperature fluctuations in the sensor element, skin conductivity fluctuations, or combinations thereof).
  • the result of the conversion step is an initial signal output which provides a value which can be correlated with the concentration of the target analyte in the biological sample.
  • the interpretation uses a mathematical transformation to model the relationship between a measured response in the sensing device and a corresponding analyte-specific value.
  • Such mathematical transformations can entail the use of linear or nonlinear regressions, or neural network algorithms.
  • the calibration step entails calibrating the sensing device using a single- or multi-point calibration, and then converting post-calibration data using correlation factors, time corrections and constants to obtain an analyte-specific value.
  • Further signal processing can be used to refine the information obtained in the calibration step, for example, where a signal processing step is used to correct for signal differences due to variable conditions unique to the sensor element used to obtain the raw signal. In one embodiment, this further step is used to correct for signal time-dependence, particularly signal decline. In another embodiment, a constant offset term is obtained, which offset is added to the signal to account for a non-zero signal at an estimated zero analyte concentration.
  • the methods of the present invention include enhancement of skin permeability by pricking the skin with micro-needles.
  • the sampling system can be programed to begin execution of sampling and sensing at a defined time(s).
  • the monitoring system comprises, in operative combination: (a) a sampling means for continually or continuously extracting the analyte from the biological system, (b) a sensing means in operative contact with the analyte extracted by the sampling means, and (c) a microprocessor means in operative communication with the sensing means.
  • the sampling means is adapted for extracting the analyte across a skin or mucosal surface of a biological system.
  • the sensing means is used to obtain a raw signal from the extracted analyte, wherein the raw signal is specifically related to the analyte.
  • the microprocessor means is used to subject the raw signal to a conversion step, thereby converting the same into an initial signal output which is indicative of the amount of analyte extracted by the sampling means, and then perform a calibration step which correlates the initial signal output with a measurement value indicative of the concentration of analyte present in the biological system at the time of extraction.
  • the monitoring system uses iontophoresis to extract the analyte from the biological system.
  • the monitoring system is used to extract a glucose analyte from the biological system.
  • the microprocessor can be programed to begin execution of sampling and sensing at a defined time(s).
  • FIG. 1A depicts a top plan view of an iontophoretic collection reservoir and electrode assembly for use in a transdermal sampling device constructed according to the present invention.
  • FIG. 1B depicts the side view of the iontophoretic collection reservoir and electrode assembly shown in FIG. 1A .
  • FIG. 2 is a pictorial representation of an iontophoretic sampling device which includes the iontophoretic collection reservoir and electrode assembly of FIGS. 1A and 1B .
  • FIG. 3 is a representation of one embodiment of a bimodal electrode design.
  • the figure presents an overhead and schematic view of the electrode assembly 33 .
  • the bimodal electrode is shown at 30 and can be, for example, a Ag/AgCl iontophoretic/counter electrode.
  • the sensing or working electrode (made from, for example, platinum) is shown at 31 .
  • the reference electrode is shown at 32 and can be, for example, a Ag/AgCl electrode.
  • the components are mounted on a suitable nonconductive substrate 34 , for example, plastic or ceramic.
  • the conductive leads 37 leading to the connection pad 35 are covered by a second nonconductive piece 36 of similar or different material. In this example of such an electrode the working electrode area is approximately 1.35 cm 2 .
  • the dashed line in FIG. 3 represents the plane of the cross-sectional schematic view presented in FIG. 4 .
  • FIG. 4 is a representation of a cross-sectional schematic view of the bimodal electrodes as they may be used in conjunction with a reference electrode and a hydrogel pad.
  • the components are as follows: bimodal electrodes 40 and 41 ; sensing electrodes 42 and 43 ; reference electrodes 44 and 45 ; a substrate 46 ; and hydrogel pads 47 and 48 .
  • FIG. 5 is an exploded pictorial representation of components from a preferred embodiment of the automatic sampling system of the present invention.
  • analyte and target analyte are used herein to denote any physiological analyte of interest that is a specific substance or component that is being detected and/or measured in a chemical, physical, enzymatic, or optical analysis.
  • a detectable signal e.g., a chemical signal or electrochemical signal
  • analyte and derivatives thereof are used interchangeably herein, and are intended to have the same meaning, and thus encompass any substance of interest.
  • the analyte is a physiological analyte of interest, for example, glucose, or a chemical that has a physiological action, for example, a drug or pharmacological agent.
  • Interstitial fluid may comprise the analyte (for example, glucose).
  • sampling device or “sampling system” refers to any device for obtaining a sample from a biological system for the purpose of determining the concentration of an analyte of interest.
  • sampling means invasive, minimally invasive or non-invasive extraction of a substance from the biological system, generally across a membrane such as skin or mucosa.
  • the membrane can be natural or artificial, and can be of plant or animal nature, such as natural or artificial skin, blood vessel tissue, intestinal tissue, and the like.
  • the sampling means are in operative contact with a “reservoir,” or “collection reservoir,” wherein the sampling means is used for extracting the analyte from the biological system into the reservoir to obtain the analyte in the reservoir.
  • a “biological system” includes both living and artificially maintained systems.
  • minimally invasive and noninvasive sampling techniques include iontophoresis, sonophoresis, suction, electroporation, thermal poration, passive diffusion, microfine (miniature) lances or cannulas, subcutaneous implants or insertions, and laser devices.
  • Sonophoresis uses ultrasound to increase the permeability of the skin (see, e.g., Menon et al. (1994) Skin Pharmacology 7:130-139).
  • Suitable sonophoresis sampling systems are described in International Publication No. WO 91/12772, published 5 Sep. 1991.
  • Passive diffusion sampling devices are described, for example, in International Publication Nos.: WO 97/38126 (published 16 Oct.
  • Laser devices use a small laser beam to burn a hole through the upper layer of the patient's skin (see, e.g., Jacques et al. (1978) J. Invest. Dermatology 88:88-93).
  • Examples of invasive sampling techniques include traditional needle and syringe or vacuum sample tube devices.
  • the term “collection reservoir” is used to describe any suitable containment means for containing a sample extracted from a biological system.
  • the collection reservoir can be a receptacle containing a material which is ionically conductive (e.g., water with ions therein), or alternatively, it can be a material, such as, a sponge-like material or hydrophilic polymer, used to keep the water in place.
  • a material which is ionically conductive e.g., water with ions therein
  • Such collection reservoirs can be in the form of a hydrogel (for example, in the form of a disk or pad). Hydrogels are typically referred to as “collection inserts.”
  • Other suitable collection reservoirs include, but are not limited to, tubes, vials, capillary collection devices, cannulas, and miniaturized etched, ablated or molded flow paths.
  • a “housing” for the sampling system can further include suitable electronics (e.g., microprocessor, memory, display and other circuit components) and power sources for operating the sampling system in an automatic fashion.
  • suitable electronics e.g., microprocessor, memory, display and other circuit components
  • a “monitoring system,” as used herein, refers to a system useful for continually or continuously measuring a physiological analyte present in a biological system.
  • a system typically includes, but is not limited to, sampling means, sensing means, and a microprocessor means in operative communication with the sampling means and the sensing means.
  • artificial refers to an aggregation of cells of monolayer thickness or greater which are grown or cultured in vivo or in vitro, and which function as a tissue of an organism but are not actually derived, or excised, from a pre-existing source or host.
  • subject encompasses any warm-blooded animal, particularly including a member of the class Mammalia such as, without limitation, humans and nonhuman primates such as chimpanzees and other apes and monkey species; farm animals such as cattle, sheep, pigs, goats and horses; domestic mammals such as dogs and cats; laboratory animals including rodents such as mice, rats and guinea pigs, and the like.
  • the term does not denote a particular age or sex. Thus, adult and newborn subjects, as well as fetuses, whether male or female, are intended to be covered.
  • continuous measurement intends a series of two or more measurements obtained from a particular biological system, which measurements are obtained using a single device maintained in operative contact with the biological system over the time period in which the series of measurements is obtained. The term thus includes continuous measurements.
  • transdermal includes both transdermal and transmucosal techniques, i.e., extraction of a target analyte across skin or mucosal tissue. Aspects of the invention which are described herein in the context of “transdermal,” unless otherwise specified, are meant to apply to both transdermal and transmucosal techniques.
  • transdermal extraction intends any noninvasive, or at least minimally invasive sampling method, which entails extracting and/or transporting an analyte from beneath a tissue surface across skin or mucosal tissue.
  • the term thus includes extraction of an analyte using iontophoresis (reverse iontophoresis), electroosmosis, sonophoresis, microdialysis, suction, and passive diffusion.
  • iontophoresis reverse iontophoresis
  • electroosmosis electroosmosis
  • sonophoresis electroosmosis
  • microdialysis suction
  • passive diffusion passive diffusion.
  • transdermally extracted also encompasses extraction techniques which employ thermal poration, electroporation, microfine lances, microfine canulas, subcutaneous implants or insertions, and the like.
  • iontophoresis intends a method for transporting substances across tissue by way of an application of electrical energy to the tissue.
  • a reservoir is provided at the tissue surface to serve as a container of material to be transported.
  • Iontophoresis can be carried out using standard methods known to those of skill in the art, for example, by establishing an electrical potential using a direct current (DC) between fixed anode and cathode “iontophoretic electrodes,” alternating a direct current between anode and cathode iontophoretic electrodes, or using a more complex waveform such as applying a current with alternating polarity (AP) between iontophoretic electrodes (so that each electrode is alternately an anode or a cathode)
  • DC direct current
  • AP alternating alternating polarity
  • reverse iontophoresis refers to the movement of a substance from a biological fluid across a membrane by way of an applied electric potential or current.
  • a reservoir is. provided at the tissue surface to receive the extracted material.
  • Electroosmosis refers to the movement of a substance through a membrane by way of an electric field-induced convective flow.
  • the terms iontophoresis, reverse iontophoresis, and electroosmosis will be used interchangeably herein to refer to movement of any ionically charged or uncharged substance across a membrane (e.g., an epithelial membrane) upon application of an electric potential to the membrane through an ionically conductive medium.
  • sensing device encompasses any device that can be used to measure the concentration of an analyte, or derivative thereof, of interest.
  • Preferred sensing devices for detecting blood analytes generally include electrochemical devices and chemical devices. Examples of electrochemical devices include the Clark electrode system (see, e.g., Updike, et al., (1967) Nature 214:986-988), and other amperometric, coulometric, or potentiometric electrochemical devices. Examples of chemical devices include conventional enzyme-based reactions as used in the Lifescan® glucose monitor (Johnson and Johnson, New Brunswick, N.J.) (see, e.g., U.S. Pat. No. 4,935,346 to Phillips, et al.).
  • a “biosensor” or “biosensor device” includes, but is not limited to, a “sensor element” which includes, but is not limited to, a “biosensor electrode” or “sensing electrode” or “working electrode” which refers to the electrode that is monitored to determine the amount of electrical signal at a point in time or over a given time period, which signal is then correlated with the concentration of a chemical compound.
  • the sensing electrode comprises a reactive surface which converts the analyte, or a derivative thereof, to electrical signal.
  • the reactive surface can be comprised of any electrically conductive material such as, but not limited to, platinum-group metals (including, platinum, palladium, rhodium, ruthenium, osmium, and iridium), nickel, copper, silver, and carbon, as well as, oxides, dioxides, combinations or alloys thereof.
  • platinum-group metals including, platinum, palladium, rhodium, ruthenium, osmium, and iridium
  • nickel copper
  • silver and carbon
  • oxides, dioxides, combinations or alloys thereof oxides, dioxides, combinations or alloys thereof.
  • the “sensor element” can include components in addition to a biosensor electrode, for example, it can include a “reference electrode,” and a “counter electrode.”
  • the term “reference electrode” is used herein to mean an electrode that provides a reference potential, e.g., a potential can be established between a reference electrode and a working electrode.
  • the term “counter electrode” is used herein to mean an electrode in an electrochemical circuit which acts as a current source or sink to complete the electrochemical circuit. Although it is not essential that a counter electrode be employed where a reference electrode is included in the circuit and the electrode is capable of performing the function of a counter electrode, it is preferred to have separate counter and reference electrodes because the reference potential provided by the reference electrode is most stable when it is at equilibrium. If the reference electrode is required to act further as a counter electrode, the current flowing through the reference electrode may disturb this equilibrium. Consequently, separate electrodes functioning as counter and reference electrodes are most preferred.
  • the “counter electrode” of the “sensor element” comprises a “bimodal electrode.”
  • the term “bimodal electrode” as used herein typically refers to an electrode which is capable of functioning non-simultaneously as, for example, both the counter electrode (of the “sensor element”) and the iontophoretic electrode (of the “sampling means”).
  • reactive surface and “reactive face” are used interchangeably herein to mean the surface of the sensing electrode that: (1) is in contact with the surface of an electrolyte containing material (e.g. gel) which contains an analyte or through which an analyte, or a derivative thereof, flows from a source thereof; (2) is comprised of a catalytic material (e.g., carbon, platinum, palladium, rhodium, ruthenium, or nickel and/or oxides, dioxides and combinations or alloys thereof) or a material that provides sites for electrochemical reaction; (3) converts a chemical signal (e.g.
  • an electrolyte containing material e.g. gel
  • a catalytic material e.g., carbon, platinum, palladium, rhodium, ruthenium, or nickel and/or oxides, dioxides and combinations or alloys thereof
  • a material that provides sites for electrochemical reaction e.g.
  • an electrical signal e.g., an electrical current
  • the term “collection reservoir” and “collection insert” are used to describe any suitable containment means for containing a sample extracted from a biological system.
  • the reservoir can include a material which is ionically conductive (e.g., water with ions therein), wherein another material such as a sponge-like material or hydrophilic polymer is used to keep the water in place.
  • Such collection reservoirs can be in the form of a hydrogel (for example, in the shape of a disk or pad).
  • Other suitable collection reservoirs include, but are not limited to, tubes, vials, capillary collection devices, cannulas, and miniaturized etched, ablated or molded flow paths.
  • an “ionically conductive material” refers to any material that provides ionic conductivity, and through which electrochemically active species can diffuse.
  • the ionically conductive material can be, for example, a solid, liquid, or semi-solid (e.g., in the form of a gel) material that contains an electrolyte, which can be composed primarily of water and ions (e.g., sodium chloride), and generally comprises 50% or more water by weight.
  • the material can be in the form of a gel, a sponge or pad (e.g., soaked with an electrolytic solution), or any other material that can contain an electrolyte and allow passage therethrough of electrochemically active species, especially the analyte of interest.
  • physiological effect encompasses effects produced in the subject that achieve the intended purpose of a therapy.
  • a physiological effect means that the symptoms of the 5 subject. being treated are prevented or alleviated.
  • a physiological effect would be one that results in the prolongation of survival in a patient.
  • a “laminate”, as used herein, refers to structures comprised of at least two bonded layers.
  • the layers may be bonded by welding or through the use of adhesives.
  • welding include, but are not limited to, the following: ultrasonic welding, heat bonding, and inductively coupled localized heating followed by localized flow.
  • common adhesives include, but are not limited to, pressure sensitive adhesives, thermoset adhesives, cyanocrylate adhesives, epoxies, contact adhesives, and heat sensitive adhesives.
  • a “collection assembly”, as used herein, refers to structures comprised of several layers, where the assembly includes at least one collection insert, for example a hydrogel.
  • An example of a collection assembly of the present invention is a mask layer, collection inserts, and a retaining layer where the layers are held in appropriate, functional relationship to each other but are not necessarily a laminate, i.e., the layers may not be bonded together.
  • the layers may, for example, be held together by interlocking geometry or friction.
  • An “autosensor assembly”, as used herein, refers to structures generally comprising a mask layer, collection inserts, a retaining layer, an electrode assembly, and a support tray.
  • the autosensor assembly may also include liners. The layers of the assembly are held in appropriate, functional relationship to each other.
  • the mask and retaining layers are preferably composed of materials that are substantially impermeable to the analyte (chemical signal) to be detected (e.g., glucose); however, the material can be permeable to other substances.
  • substantially impermeable is meant that the material reduces or eliminates chemical signal transport (e.g., by diffusion).
  • the material can allow for a low level of chemical signal transport, with the proviso that chemical signal that passes through the material does not cause significant edge effects at the sensing electrode.
  • substantially planar as used herein, includes a planar surface that contacts a slightly curved surface, for example, a forearm or upper arm of a subject.
  • a “substantially planar” surface is, for example, a surface having a shape to which skin can conform, i.e., contacting contact between the skin and the surface.
  • printed is meant a substantially uniform deposition of an electrode formulation onto one surface of a substrate (i.e., the base support). It will be appreciated by those skilled in the art that a variety of techniques may be used to effect substantially uniform deposition of a material onto a substrate, e.g., Gravure-type printing, extrusion coating, screen coating, spraying, painting, or the like.
  • enzyme intends any compound or material which catalyzes a reaction between molecules to produce one or more reaction products.
  • the term thus includes protein enzymes, or enzymatically active portions (fragments) thereof, which proteins and/or protein fragments may be isolated from a natural source, or recombinantly or synthetically produced.
  • the term also encompasses designed synthetic enzyme mimetics.
  • time-dependent signal decline refers to a detectable decrease in measured signal over time when no decrease or change in analyte concentration is actually occurring.
  • the decrease in signal over time may be due to a number of different phenomena.
  • signal-to-noise ratio describes the relationship between the actual signal intended to be measured and the variation in signal in the absence of the analyte.
  • S/N and “SNR” are also used to refer to the signal-to-noise ratio.
  • Noise refers to any undesirable signal which is measured along with the intended signal.
  • the present invention relates to use of a device for transdermally extracting and measuring the concentration of a target analyte present in a biological system.
  • the sensing device comprises a biosensor.
  • a sampling device is used to extract small amounts of a target analyte from the biological system, and then sense and/or quantify the concentration of the target analyte. Measurement with the biosensor and/or sampling with the sampling device can be carried out in a continual or continuous manner. Continual or continuous measurements allow for closer monitoring of target analyte concentration fluctuations.
  • the analyte can be any specific substance or component that one is desirous of detecting and/or measuring in a chemical, physical, enzymatic, or optical analysis.
  • Such analytes include, but are not limited to, amino acids, enzyme substrates or products indicating a disease state or condition, other markers of disease states or conditions, drugs of abuse, therapeutic and/or pharmacologic agents (e.g., theophylline, anti-HIV drugs, lithium, anti-epileptic drugs, cyclosporin, chemotherapeutics), electrolytes, physiological analytes of interest (e.g., urate/uric acid, carbonate, calcium, potassium, sodium, chloride, bicarbonate (CO 2 ), glucose, urea (blood urea nitrogen), lactate/lactic acid, hydroxybutyrate, cholesterol, triglycerides, creatine, creatinine, insulin, hematocrit, and hemoglobin), blood gases (carbon dioxide, oxygen, pH), lipids, heavy metals (e.
  • an enzyme can be disposed in the collection reservoir, or, if several collection reservoirs are used, the enzyme can be disposed in several or all of the reservoirs.
  • the selected enzyme is capable of catalyzing a reaction with the extracted analyte (in this case glucose) to the extent that a product of this reaction can be sensed, e.g., can be detected electrochemically from the generation of a current which current is detectable and proportional to the concentration or amount of the analyte which is reacted.
  • a suitable enzyme is glucose oxidase which oxidizes glucose to gluconic acid and hydrogen peroxide.
  • Glucose oxidase (GOx) is readily available commercially and has well known catalytic characteristics. However, other enzymes can also be used, so long as they specifically catalyze a reaction with an analyte or substance of interest to generate a detectable product in proportion to the amount of analyte so reacted.
  • a biosensor electrode that detects hydrogen peroxide can be used to detect ethanol using an alcohol oxidase enzyme system, or similarly uric acid with urate oxidase system, urea with a urease system, cholesterol with a cholesterol oxidase system, and theophylline with a xanthine oxidase system.
  • the oxidase enzyme (used for hydrogen peroxide-based detection) can be replaced with another redox system, for example, the dehydrogenase-enzyme NAD-NADH, which offers a separate route to detecting additional analytes.
  • Dehydrogenase-based sensors can use working electrodes made of gold or carbon (via mediated chemistry). Examples of analytes suitable for this type of monitoring include, but are not limited to, cholesterol, ethanol, hydroxybutyrate, phenylalanine, triglycerides, and urea.
  • the enzyme can be eliminated and detection can rely on direct electrochemical or potentiometric detection of an analyte.
  • Such analytes include, without limitation, heavy metals (e.g., cobalt, iron, lead, nickel, zinc), oxygen, carbonate/carbon dioxide, chloride, fluoride, lithium, pH, potassium, sodium, and urea.
  • the sampling system described herein can be used for therapeutic drug monitoring, for example, monitoring anti-epileptic drugs (e.g., phenytion), chemotherapy (e.g., adriamycin), hyperactivity (e.g., ritalin), and anti-organ-rejection (e.g., cyclosporin).
  • anti-epileptic drugs e.g., phenytion
  • chemotherapy e.g., adriamycin
  • hyperactivity e.g., ritalin
  • anti-organ-rejection e.g., cyclosporin
  • An initial step entails obtaining a raw signal from a sensing device, which signal is related to a target analyte present in the biological system.
  • the raw signal can be obtained using any suitable sensing methodology including, for example, methods which rely on direct contact of a sensing apparatus with the biological system; methods which extract samples from the biological system by invasive, minimally invasive, and non-invasive sampling techniques, wherein the sensing apparatus is contacted with the extracted sample; methods which rely on indirect contact of a sensing apparatus with the biological system; and the like.
  • methods are used to extract samples from the biological sample using minimally invasive or non-invasive sampling techniques.
  • the sensing apparatus used with any of the above-noted methods can employ any suitable sensing element to provide the signal including, but not limited to, physical, chemical, electrochemical, photochemical, spectrophotometric, polarimetric, colorimetric, radiometric, or like elements.
  • a biosensor is used which comprises an electrochemical sensing element.
  • the signal can undergo a data screening method (Step B) in order to eliminate outlier signals and/or poor (incorrect) signals using a predefined set of selection criteria.
  • the raw signal can be converted in a conversion step (Step C) which can (i) remove or correct for background information, (ii) integrate the signal over a sensing time period, (iii) perform any process which converts the signal from one signal type to another, or (iv) perform any combination of steps (i), (ii) and/or (iii).
  • the conversion step entails a baseline background subtraction method to remove background from the raw signal and an integration step.
  • the conversion step can be tailored for use with a sensing device that provides both active and reference (blank) signals; wherein mathematical transformations are used to individually smooth active and reference signals, and/or to subtract a weighted reference (blank) signal from the active signal.
  • the conversion step includes correction functions which account for changing conditions in the biological system and/or the biosensor system (e.g., temperature fluctuations in the biological system, temperature fluctuations in the sensor element, skin conductivity fluctuations, or combinations thereof).
  • the result of the conversion step is an initial signal output which provides a value which can be correlated with the concentration of the target analyte in the biological sample.
  • Step D the raw signal obtained from Step A, or the initial signal obtained from Step B and/or Step C, is converted into an analyte-specific value of known units to provide an interpretation of the signal obtained from the sensing device.
  • the interpretation uses a one-to-one mathematical transformation to model the relationship between a measured response in the sensing device and a corresponding analyte-specific value.
  • the calibration step is used herein to relate, for example, an electrochemical signal (detected by a biosensor) with the concentration of a target analyte in a biological system.
  • the calibration step entails calibrating the sensing device using a single- or multi-point calibration, and then converting post-calibration data using correlation factors, time corrections and constants to obtain an analyte-specific value.
  • Further signal processing can be used to refine the information obtained in the calibration step, for example, where a signal processing step is used to correct for signal differences due to variable conditions unique to the sensor element used to obtain the raw signal.
  • this further step is used to correct for signal time-dependence, particularly signal decline.
  • a constant offset term is obtained, which offset is added to the signal to account for a non-zero signal at an estimated zero analyte concentration.
  • the analyte value obtained using the above techniques can optionally be used in a subsequent step (Step E) to predict future (time forecasting) or past (calibration) measurements of the target analyte concentration in the biological system.
  • Step E a subsequent step
  • a series of analyte values are obtained by performing any combination of Steps A, B, C, and/or D in an iterative manner. This measurement series is then used to predict unmeasured analyte values at different points in time, future or past. In this manner, lag times inherent in certain sampling and/or sensing techniques can be reduced or eliminated to provide real time measurement predictions.
  • analyte values obtained using the above techniques can be used in a subsequent step (Step F) to control an aspect of the biological system.
  • the analyte value obtained in Step D is used to determine when, and at what level, a constituent should be added to the biological system in order to control an aspect of the biological system.
  • the analyte value can be used in a feedback control loop to control a physiological effect in the biological system.
  • Steps A through F are each independently useful in analyte sensing systems and can, of course, be used in a wide variety of combinations selected for a particular biological system, target analyte, and/or sensing technique.
  • a measurement sequence can include Steps A, C, D, E and F
  • a measurement sequence can include Steps A, B, C and D, and the like.
  • the determination of particularly suitable combinations is within the skill of the ordinarily skilled artisan when directed by the instant disclosure.
  • Steps C through F are preferably embodied as one or more mathematical functions as described herein below. These functions can thus be carried out using a microprocessor in a monitoring system.
  • the invention is expressly exemplified for use in a non-invasive, transdermal sampling system which uses an electrochemical biosensor to quantify or qualify glucose or a glucose metabolite.
  • Step A Obtaining the Raw Signal.
  • the raw signal can be obtained using any sensing device that is operatively contacted with the biological system.
  • sensing devices can employ physical, chemical, electrochemical, spectrophotometric, polarimetric, calorimetric, radiometric, or like measurement techniques.
  • the sensing device can be in direct or indirect contact with the biological system, or used with a sampling device which extracts samples from the biological system using invasive, minimally invasive or non-invasive sampling techniques.
  • a minimally invasive or non-invasive sampling device is used to obtain samples from the biological system, and the sensing device comprises a biosensor with an electrochemical sensing element.
  • a sampling device is used to obtain continual transdermal or transmucosal samples from a biological system, and the analyte of interest is glucose.
  • a non-invasive glucose monitoring device is used to measure changes in glucose levels in an animal subject over a wide range of glucose concentrations.
  • the sampling method is based on transdermal glucose extraction and the sensing method is based on electrochemical detection technology.
  • the device can be contacted with the biological system continuously, and automatically obtains glucose samples in order to measure glucose concentration at preprogrammed intervals.
  • Sampling is carried out continually by non-invasively extracting glucose through the skin of the patient. More particularly, an iontophoretic current is applied to a surface of the skin of a subject. When the current is applied, ions or charged molecules pull along other uncharged molecules or particles such as glucose which are drawn into a collection reservoir placed on the surface of the skin.
  • the collection reservoir may comprise any ionically conductive material and is preferably in the form of a hydrogel which is comprised of a hydrophilic material, water and an electrolyte.
  • the collection reservoir may further contain an enzyme which catalyzes a reaction of glucose to form an easily detectable species.
  • the enzyme is preferably glucose oxidase (GOx) which catalyzes the reaction between glucose and oxygen and results in the production of hydrogen peroxide.
  • the hydrogen peroxide reacts at a catalytic surface of a biosensor electrode, resulting in the generation of electrons which create a detectable biosensor current (raw signal).
  • a measurement is taken, which measurement is related to the amount of glucose drawn into the collection reservoir over a given period of time.
  • the reaction is allowed to continue until substantially all of the glucose in the collection reservoir has been subjected to a reaction and is therefore no longer detectable, and the biosensor current generated is related to the concentration of glucose in the subject at the approximate time of sample collection.
  • the process is repeated and a subsequent measurement is obtained. More specifically, the iontophoretic current is again applied, glucose is drawn through the skin surface into the collection reservoir, and the reaction is catalyzed in order to create a biosensor current.
  • sampling (extraction) and sensing operations are integrated such that glucose is extracted into the hydrogel collection pad where it contacts the GOx enzyme.
  • the GOx enzyme converts glucose and oxygen in the hydrogel to hydrogen peroxide which diffuses to the sensor and is catalyzed by the sensor to regenerate oxygen and form electrons.
  • the electrons generate an electrical signal that can be measured, analyzed, and correlated to blood glucose.
  • one or more additional “active” collection reservoirs can be used to obtain measurements.
  • two active collection reservoirs are used, and an average is taken between signals from the reservoirs for each measurement time point.
  • Obtaining multiple signals, and then averaging reads from each signals, allows for signal smoothing of unusual data points from a sensor that otherwise may not have been detected by data screening techniques.
  • skin site variability can be detected, and “lag” and/or “lead” differences in blood glucose changes relative to extracted glucose changes can be mitigated.
  • a second collection reservoir can be provided which does not contain the GOx enzyme. This second reservoir can serve as an internal reference (blank) for the sensing device, where a biosensor is used to measure the “blank” signal from the reference reservoir which signal is then used in a blank subtraction step as described below.
  • a generalized method for continual monitoring of a physiological analyte is disclosed in International Publication No. WO 97/24059, published 10 Jul. 1997, which publication is incorporated herein by reference.
  • the analyte is extracted into a reservoir containing a hydrogel which is preferably comprised of a hydrophilic material of the type described in International Publication No. WO 97/02811, published 30 Jan. 1997, which publication is incorporated herein by reference.
  • Suitable hydrogel materials include polyethylene oxide, polyacrylic acid, polyvinylalcohol and related hydrophilic polymeric materials combined with water to form an aqueous gel.
  • a biosensor electrode is positioned on a surface of the hydrogel opposite the surface contacting the skin.
  • the sensor electrode acts as a detector which detects current generated by hydrogen peroxide in the redox reaction, or more specifically detects current which is generated by the electrons generated by the redox reaction catalyzed by the platinum surface of the electrode.
  • the details of such electrode assemblies and devices for iontophoretic extraction of glucose are disclosed in International Publication No. WO 96/00110, published 4 Jan. 1996, and International Publication No. WO 97/10499, published 2 Mar. 1997, which publications are also incorporated herein by reference.
  • an iontophoretic collection reservoir and electrode assembly for use in a transdermal sensing device is generally indicated at 2 .
  • the assembly comprises two iontophoretic collection reservoirs, 4 and 6 , each having a conductive medium 8 , and 10 (preferably cylindrical hydrogel pads), respectively disposed therein.
  • First ( 12 ) and second ( 14 ) ring-shaped iontophoretic electrodes are respectively contacted with conductive medium 8 and 10 .
  • the first iontophoretic electrode 12 surrounds three biosensor electrodes which are also contacted with the conductive medium 8 , a working electrode 16 , a reference electrode 18 , and a counter electrode 20 .
  • a guard ring 22 separates the biosensor electrodes from the iontophoretic electrode 12 to minimize noise from the iontophoretic circuit.
  • Conductive contacts provide communication between the electrodes and an associated power source and control means as described in detail below.
  • a similar biosensor electrode arrangement can be contacted with the conductive medium 10 , or the medium can not have a sensor means contacted therewith.
  • FIG. 2 an exploded view of the key components from a preferred embodiment of an iontophoretic sampling system is presented.
  • the iontophoretic collection reservoir and electrode assembly 2 of FIGS. 1A and 1B is shown in exploded view in combination with a suitable iontophoretic sampling device housing 32 .
  • the housing can be a plastic case or other suitable structure which preferably is configured to be worn on a subjects arm in a manner similar to a wrist watch.
  • conductive media 8 and 10 are separable from the assembly 2 ; however, when the assembly 2 and the housing 32 are assembled to provide an operational iontophoretic sampling device 30 , the media are in contact with the electrodes to provide a electrical contact therewith.
  • the electrode assemblies can include bimodal electrodes as shown in FIG. 3 .
  • the sampling system components include two biosensor/iontophoretic electrode assemblies, 504 and 506 , each of which have an annular iontophoretic electrode, respectively indicated at 508 and 510 , which encircles a biosensor 512 and 514 .
  • the electrode assemblies 504 and 506 are printed onto a polymeric substrate 516 which is maintained within a sensor tray 518 .
  • a collection reservoir assembly 520 is arranged over the electrode assemblies, wherein the collection reservoir assembly comprises two hydrogel inserts 522 and 524 retained by a gel retaining layer 526 and a mask layer 528 .
  • the electrode assemblies can include bimodal electrodes as shown in FIG. 3 . Modifications and additions to the embodiment of FIG. 5 will be apparent to those skilled in the art in light of the teachings of the present specification.
  • the components described herein are intended for use in a automatic sampling device which is configured to be worn like an ordinary wristwatch.
  • the wristwatch housing (not shown) contains conductive leads which communicate with the iontophoretic electrodes and the biosensor electrodes to control cycling and provide power to the iontophoretic electrodes, and to detect electrochemical signals produced at the biosensor electrode surfaces.
  • the wristwatch housing can further include suitable electronics (e.g., microprocessor, memory, display and other circuit components) and power sources for operating the automatic sampling system.
  • a power source e.g., one or more rechargeable or nonrechargeable batteries
  • a power source can be disposed within the housing 32 or within the straps 34 which hold the device in contact with a skin or mucosal surface of a subject.
  • an electric potential (either direct current or a more complex waveform) is applied between the two iontophoretic electrodes 12 and 14 such that current flows from the first iontophoretic electrode 12 , through the first conductive medium 8 into the skin or mucosal surface, and then back out through the second conductive medium 10 to the second iontophoretic electrode 14 .
  • the current flow is sufficient to extract substances including an analyte of interest through the skin into one or both of collection reservoirs 4 and 6 .
  • the electric potential may be applied using any suitable technique, for example, the applied current density may be in the range of about 0.01 to 0.5 mA/cm 2 .
  • the device is used for continual or continuous monitoring, and the polarity of iontophoretic electrodes 12 and 14 is alternated at a rate of about one switch every 10 seconds to about one switch every hour so that each electrode is alternately a cathode or an anode.
  • the housing 32 can further include an optional temperature sensing element (e.g., a thermistor, thermometer, or thermocouple device) which monitors the temperature at the collection reservoirs to enable temperature correction of sensor signals as described in detail below.
  • the housing can also include an optional conductance sensing element (e.g., an integrated pair of electrodes) which monitors conductance at the skin or mucosal surface to enable data screening correction or invalidation of sensor signals as also described in detail below.
  • the iontophoretic sampling device 30 is controlled by a controller 36 (e.g., a microprocessor), which interfaces with the iontophoretic electrodes, the sensor electrodes, the power supply, the optional temperature and/or conductance sensing elements, a display and other electronics.
  • the controller 36 can include a programmable a controlled circuit source/sink drive for driving the iontophoretic electrodes. Power and reference voltage are provided to the sensor electrodes, and signal amplifiers can be used to process the signal from the working electrode or electrodes. In general, the controller discontinues the iontophoretic current drive during sensing periods.
  • a sensor confidence loop can be provided for continually monitoring the sampling system to insure proper operations.
  • the sampling device can operate in an alternating polarity mode using first and second bimodal electrodes ( FIG. 4, 40 and 41 ) and two collection reservoirs ( FIG. 4, 47 and 48 ).
  • Each bi-modal electrode ( FIG. 3, 30 ; FIG. 4, 40 and 41 ) serves two functions depending on the phase of the operation: (1) an electro-osmotic electrode (or iontophoretic electrode) used to electrically draw analyte from a source into a collection reservoir comprising water and an electrolyte, and to the area of the electrode subassembly; and (2) as a counter electrode to the first sensing electrode at which the chemical compound is catalytically converted at the face of the sensing electrode to produce an electrical signal.
  • an electro-osmotic electrode or iontophoretic electrode
  • the reference ( FIG. 4, 44 and 45 ; FIG. 3, 32 ) and sensing electrodes ( FIG. 4, 42 and 43 ; FIG. 3, 31 ), as well as, the bimodal electrode ( FIG. 4, 40 and 41 ; FIG. 3, 30 ) are connected to a standard potentiostat circuit during sensing. In general, practical limitations of the system require that the bimodal electrode will not act as both a counter and iontophoretic electrode simultaneously.
  • the general operation of an iontophoretic sampling system is the cyclical repetition of two phases: (1) a reverse-iontophoretic phase, followed by a (2) sensing phase.
  • the reverse iontophoretic phase the first bimodal electrode ( FIG. 4, 40 ) acts as an iontophoretic cathode and the second bimodal electrode ( FIG. 4, 41 ) acts as an iontophoretic anode to complete the circuit.
  • Analyte is collected in the reservoirs, for example, a hydrogel ( FIG. 4, 47 and 48 ).
  • the iontophoretic current is turned off.
  • the sensing phase in the case of glucose, a potential is applied between the reference electrode ( FIG.
  • the chemical signal reacts catalytically on the catalytic face of the first sensing electrode ( FIG. 4 . 42 ) producing an electrical current, while the first bi-modal electrode ( FIG. 4, 40 ) acts as a counter electrode to complete the electrical circuit.
  • the electrode described is particularly adapted for use in conjunction with a hydrogel collection reservoir system for monitoring glucose levels in a subject through the reaction of collected glucose with the enzyme glucose oxidase present in the hydrogel matrix.
  • the bi-modal electrode is preferably comprised of Ag/AgCl.
  • the electrochemical reaction which occurs at the surface of this electrode serves as a facile source or sink for electrical current. This property is especially important for the iontophoresis function of the electrode. Lacking this reaction, the iontophoresis current could cause the hydrolysis of water to occur at the iontophoresis electrodes causing pH changes and possible gas bubble formation. The pH changes to acidic or basic pH could cause skin irritation or burns.
  • the ability of an Ag/AgCl electrode to easily act as a source of sink current is also an advantage for its counter electrode function. For a three electrode electrochemical cell to function properly, the current generation capacity of the counter electrode should not limit the speed of the reaction at the sensing electrode. In the case of a large sensing electrode, the counter electrode should be able to source proportionately larger currents.
  • the design of the sampling system provides for a larger sensing electrode (see for example, FIG. 3 ) than previously designed. Consequently, the size of the bimodal electrode should be sufficient so that when acting as a counter electrode with respect to the sensing electrode the counter electrode does not become limiting the rate of catalytic reaction at the sensing electrode catalytic surface.
  • the power source provides a current flow to the first bi-modal electrode to facilitate the extraction of the chemical signal into the reservoir.
  • the power source is used to provide voltage to the first sensing electrode to drive the conversion of chemical signal retained in reservoir to electrical signal at the catalytic face of the sensing electrode.
  • the power source also maintains a fixed potential at the electrode where, for example hydrogen peroxide is converted to molecular oxygen, hydrogen ions, and electrons, which is compared with the potential of the reference electrode during the sensing phase. While one sensing electrode is operating in the sensing mode it is electrically connected to the adjacent bimodal electrode which acts as a counter electrode at which electrons generated at the sensing electrode are consumed.
  • the electrode sub-assembly can be operated by electrically connecting the bimodal electrodes such that each electrode is capable of functioning as both an iontophoretic electrode and counter electrode along with appropriate sensing electrode(s) and reference electrode(s), to create standard potentiostat circuitry.
  • a potentiostat is an electrical circuit used in electrochemical measurements in three electrode electrochemical cells.
  • a potential is applied between the reference electrode and the sensing electrode.
  • the current generated at the sensing electrode flows through circuitry to the counter electrode (i.e., no current flows through the reference electrode to alter its equilibrium potential).
  • Two independent potentiostat circuits can be used to operate the two biosensors.
  • the electrical current measured at the sensing electrode subassembly is the current that is correlated with an amount of chemical signal.
  • Ag/AgCl electrodes are provided herein which are capable of repeatedly forming a reversible couple which operates without unwanted electrochemical side reactions (which could give rise to changes in pH, and liberation of hydrogen and oxygen due to water hydrolysis).
  • the Ag/AgCl electrodes of the present sampling system are thus formulated to withstand repeated cycles of current passage in the range of about 0.01 to 1.0 mA per cm 2 of electrode area.
  • the Ag/AgCl components are dispersed within a suitable polymer binder to provide an electrode composition which is not susceptible to attack (e.g., plasticization) by components in the collection reservoir, e.g., the hydrogel composition.
  • the electrode compositions are also formulated using analytical- or electronic-grade reagents and solvents, and the polymer binder composition is selected to be free of electrochemically active contaminants which could diffuse to the biosensor to produce a background current.
  • the Ag/AgCl iontophoretic electrodes must be capable of continual cycling over extended periods of time, the absolute amounts of Ag and AgCl available in the electrodes, and the overall Ag/AgCl availability ratio, can be adjusted to provide for the passage of high amounts of charge. Although not limiting in the sampling system described herein, the Ag/AgCl ratio can approach unity.
  • the iontophoretic electrodes are configured to provide an approximate electrode area of 0.3 to 1.0 cm 2 , preferably about 0.85 cm 2 .
  • Electrodes provide for reproducible, repeated cycles of charge passage at current densities ranging from about 0.01 to 1.0 mA/cm 2 of electrode area. More particularly, electrodes constructed according to the above formulation parameters, and having an approximate electrode area of 0.85 cm 2 , are capable of a reproducible 5 total charge passage (in both anodic and cathodic directions) of 270 mC, at a current of about 0.3 mA (current density of 0.35 mA/cm 2 ) for 48 cycles in a 24 hour period.
  • the Ag/AgCl electrode composition is affixed to a suitable rigid or flexible nonconductive surface as described above with respect to the biosensor electrode composition.
  • a silver (Ag) underlayer is first applied to the surface in order to provide uniform conduction.
  • the Ag/AgCl electrode composition is then applied over the Ag underlayer in any suitable pattern or geometry using various thin film techniques, such as sputtering, evaporation, vapor phase deposition, or the like, or using various thick film techniques, such as film laminating, electroplating, or the like.
  • the Ag/AgCl composition can be applied using screen printing, pad printing, inkjet methods, transfer roll printing, or similar techniques.
  • both the Ag underlayer and the Ag/AgCl electrode are applied using a low temperature screen print onto a polymeric substrate.
  • This low temperature screen print can be carried out at about 125 to 160° C, and the screening can be carried out using a suitable mesh, ranging from about 100-400 mesh.
  • the microprocessor generally uses a series of program sequences to control the operations of the sampling device, which program sequences can be stored in the microprocessor's read only memory (ROM). Embedded software (firmware) controls activation of measurement and display operations, calibration of analyte readings, setting and display of high and low analyte value alarms, display and setting of time and date functions, alarm time, and display of stored readings. Sensor signals obtained from the sensor electrodes are processed before storage and display by one or more signal processing functions or algorithms which are described in detail below.
  • the microprocessor can also include an electronically erasable, programmable, read only memory (EEPROM) for storing calibration parameters (as described in detail below), user settings and all downloadable sequences.
  • EEPROM electronically erasable, programmable, read only memory
  • Step B Data Screening Methodologies.
  • the raw signal obtained from the above-described glucose monitoring device can be screened to detect deviations from expected behavior which are indicative of poor or incorrect signals that will not correlate with blood glucose. Signals that are identified as poor or incorrect in this data screen may be discarded or otherwise corrected for prior to any signal processing and/or conversion in order to maintain data integrity.
  • an objective set of selection criteria is established which can then be used to accept or discard signals from the sensing device. These selection criteria are device- and analyte-specific, and can be arrived at empirically by way of testing various devices in particular applications.
  • the iontophoretic extraction device can include two collection reservoirs.
  • each reservoir contains an iontophoretic electrode and a sensing electrode. Signals from both the active and the blank reservoirs are screened, and an error in either the active, or the active and blank signal can be used to invalidate or correct the measurement from the cycle.
  • signals from one or more of the active reservoirs are screened, and an error can be used to invalidate or correct the measurement from the cycle.
  • a temperature sensor is used to monitor changes in temperature over time.
  • a maximum temperature change over time (d(temp)/d(time)) threshold value can then be used in a data screen to invalidate a measurement.
  • d(temp)/d(time) can, of course, be set at any objective level, which in turn can be empirically determined depending upon the particular extraction/sensing device used, how the temperature measurement is obtained, and the analyte being detected.
  • Absolute temperature threshold criteria can also be employed, wherein detection of high and/or low temperature extremes can be used in a data screen to invalidate a measurement.
  • Temperature monitoring can be carried out using a separate, associated temperature sensing device, or, preferably using a temperature sensor that is integral with the sensing device.
  • a temperature sensor that is integral with the sensing device.
  • a large number of temperature sensing elements are known in the art (e.g., thermometers, thermistors, thermocouples, and the like) which can be used to monitor the temperature in the collection reservoirs.
  • Another data screen entails monitoring physiological conditions in the biological system, particularly monitoring for a perspiration threshold.
  • perspiration contains glucose, and perspiration occurring rapidly and in sufficient quantities may affect the detected signal either before or during biosensor measurement.
  • a sensor can be used to monitor perspiration levels for a given measurement cycle at time points before, during, and/or after iontophoresis, and before, during, and/or after glucose sensing. Detection of perspiration levels that exceed an objective threshold is then used in a data screen to invalidate poor measurements.
  • skin conductance can be readily measured with a device contacted with the skin. Skin conductivity is related to perspiration. In one embodiment, if skin conductance as measured by a conductivity detector is greater than a predetermined level, then the corresponding measurement is invalidated.
  • iontophoretic sampling for example, there is a skin equilibration period before which measurements will generally be less accurate. During this equilibration period, the system voltage can be assessed and compared against an objective high voltage threshold. If this high voltage limit is exceeded, a data screen is used to exclude the corresponding analyte measurement, since the iontophoretic current was not at a target value due to high skin resistance (as indicted by the high voltage level).
  • the electrochemical signal during each sensing cycle is expected to behave as a smooth, monotonically decreasing signal which represents depletion of the hydrogen peroxide by the sensor electrode. Significant departure from this expected behavior is indicative of a poor or incorrect measurement (e.g., a non-monotonically decreasing signal is indicative of excessive noise in the biosensor signal), and thus monitoring signal behavior during sensing operations provides yet a further data screen for invalidating or correcting measurements.
  • Raw signal thresholds can also be used in the data screening method of the present invention. For example, any sensor reading that is less than some minimum threshold can indicate that the sampling/sensing device is not operating correctly, for example, where the biosensor electrode is disconnected. In addition, any chemical sensor will have a maximum range in which the device can operate reliably. A reading greater than some maximal value, then, indicates that the measurement is off-scale, and thus possibly invalid. Accordingly, minimum and maximum signal thresholds are used herein as data screens to invalidate or correct measurements. Such minimum and maximum thresholds can likewise be applied to background measurements.
  • a general class of screens can be applied that detect changes in signal, background, or voltage measurements. These screens are useful to assess the consistency of measurements and can detect problems or inconsistencies in the measurements. Error messages can be relayed to a display screen on the monitoring device, and/or, recorded to a log. Examples of such screens include the following:
  • a large change in the peak of a sensor reading indicates a noisy signal.
  • the peak of any given cathodal half cycle is defined as the difference between the first biosensor point and the temperature corrected average of the last two points from the previous anodal half cycle. If the percentage difference between successive peaks from the same sensor is greater than a predetermined value, for example, 30%, then an error is indicated.
  • background Background Precision. Divergent readings at the end of biosensing indicate an unstable biosensor signal. Because these readings are used to assess background current for a particular cycle, an unstable signal may lead to an erroneous data point. If the difference between the last two anodal points (where the last two anodal points are typically the last two biosensor currents measured after anodal extraction) used to calculate the baseline is greater than or equal to a predetermined value, for example, 6 nA (or, e.g., a percentage of the first anodal point relative to the second anodal point), then an error is indicated.
  • a predetermined value for example, 6 nA (or, e.g., a percentage of the first anodal point relative to the second anodal point
  • (v) voltage—Reference Electrode Check When the electrode assembly includes a reference electrode (as when, for example, a bimodal electrode is employed) this check establishes the connectivity of the reference electrode to the sampling device and to the working electrode. The biosensor is activated such that a current should flow from the working electrode to the reference electrode. If the current measured is less than a threshold value, then an error is indicated and the measurement sequence can be terminated.
  • a reference electrode as when, for example, a bimodal electrode is employed
  • Step C The Conversion Step.
  • the above-described iontophoretic sampling device is used to extract the analyte from the biological system, and a raw amperometric signal (e.g., nanoampere (nA) signal) is generated from the associated electrochemical biosensor device.
  • a raw amperometric signal e.g., nanoampere (nA) signal
  • This raw signal can optionally be subjected to a data screening step (Step B) to eliminate poor or incorrect signals, or can be entered directly into a conversion step to obtain an initial signal output which is indicative of the amount of analyte extracted by the sampling system.
  • the raw or screened raw signal is processed in the conversion step in order to remove or correct for background information present in the signal.
  • the background signal is the “baseline background,” which, in the context of electrochemical detection, is a current (nA) generated by the sensing device independent of the presence or absence of the analyte of interest.
  • This baseline background interferes with measurement of analyte of interest, and the amount of baseline background can vary with time, temperature and other variable factors.
  • electrochemically active interfering species and/or residual analyte can be present in the device which will further interfere with measurement of the analyte of interest.
  • This background can be transient background, which is a current generated independent of the presence or absence of the analyte of interest and which decreases over the time of sensor activation on the time scale of a measurement, eventually converging with the baseline background signal.
  • a baseline background subtraction method is used during the conversion step in order to reduce or eliminate such background interferences from the measured initial signal output.
  • the subtraction method entails activation of the electrochemical sensor for a sufficient period of time to substantially reduce or eliminate residual analyte and/or electrochemical signal that is not due to the analyte (glucose).
  • a measurement is taken from the sensor which measurement can then be used to establish a baseline background signal value.
  • This background signal value is subtracted from an actual signal measurement value (which includes both analyte-specific and background components) to obtain a corrected measurement value.
  • Measurement of the baseline background signal value is taken close in time to the actual signal measurement in order to account for temperature fluctuations, background signal drift, and like variables in the baseline background subtraction procedure.
  • the baseline background signal value can be integrated for use with coulometric signal processing, or used as a discrete signal value in amperometric signal processing.
  • continual measurement by the iontophoretic sampling device provides a convenient source for the baseline background measurement, that is, after an initial measurement cycle has be completed, the baseline background measurement can be taken from a previous measurement (sensing) cycle.
  • the conversion step is used to correct for changing conditions in the biological system and/or the biosensor system (e.g., temperature fluctuations in the biological system, temperature fluctuations in the biosensor element, or combinations thereof). Temperature can affect the signal in a number of ways, such as by changing background, reaction constants, and/or diffusion coefficients. Accordingly, a number of optional temperature correction functions can be used in order to reduce these temperature-related effects on the signal.
  • the following temperature correction step can be carried out. More particularly, to compensate for temperature fluctuations, temperature measurements can be taken at each measurement time point within the measurement cycle, and this information can be used to base a temperature correction algorithm which adjusts the background current at every time point depending on the difference in temperature between that time point and the temperature when the previous background current was measured. This particular temperature correction algorithm is based on an Arrhenius relationship between the background current and temperature.
  • (i bkgnd, corrected ) is the temperature corrected baseline current
  • (i bkgnd, ⁇ 0 ) is the baseline current at some reference temperature T ⁇ 0 , for example, the baseline background measurement temperature
  • K 1 ) is the temperature correction constant
  • T ⁇ ) is the temperature at time ⁇ .
  • (i bkgnd, ⁇ 0 ) is usually defined as the “previous” baseline current.
  • the K 1 temperature correction adjusts the baseline current in an Arrhenius fashion depending upon whether the temperature increases or decreases during or between biosensor cycles. Determination of the constant K 1 can be obtained by plotting the natural log of the background current versus the reciprocal of the temperature for a learning set of data, and then using a best fit analysis to fit this plot with a line having a slope ( ⁇ K 1 ).
  • Raw or screened amperometric signals from Step A or Step B, respectively can optionally be refined in the conversion step to provide integrated coulometric signals.
  • any of the above amperometric signals e.g., the current generated by the sensor
  • integration is carried out by operating the biosensor in a coulometric (charge-measuring) mode. Measuring the total amount of charge that passes through the biosensor electrode during a measurement period is equivalent to mathematically integrating the current over time.
  • coulometric charge-measuring
  • a functionally equivalent coulometric measurement can be mathematically obtained in the method of the invention by taking discrete current measurements at selected, preferably small, time intervals, and then using any of a number of algorithms to approximate the integral of the time-current curve.
  • An additional temperature correction algorithm can be used herein to compensate for temperature dependence of a transient background (blank) signal. That is, in the active/blank sampling system exemplified hereinabove, the analyte measurement (blood glucose) is generated by integrating an active signal and subtracting therefrom a blank signal (see the blank subtraction method, infra). The blank integral may be “artifactually” high or low depending upon whether blank signal was measured at a higher or lower temperature than the active signal.
  • Y blank , corrected Y blank ⁇ exp ⁇ [ - K ⁇ ⁇ 2 ⁇ ( 1 T act n _ - 1 T blank n _ ) ] wherein: (Y blank, corrected ) is the corrected blank integral; (Y blank ) is the uncorrected blank integral (in nC); (K 2 ) is the “blank integral correction constant”; and (T n act ) and (T n blank ) are the average temperature of the active and blank signal, respectively.
  • the average temperature is obtained from averaging the first n temperatures, such that (n) is also an adjustable parameter. Determination of the constant K 2 can be obtained from an Arrhenius plot of the log of the blank integral against 1/T n blank , using the reciprocal of the average of the first n temperature values, and then using a best fit analysis to fit this plot with a line having a slope ( ⁇ K 2 ).
  • temperature correction functions can be used to correct for temperature differences between multiple active signals, or between active and blank signals.
  • blank subtraction is used to cancel out much of the temperature-dependence in the active signal.
  • temperature transients during the monitoring period will result in varying background currents, which can result in signal errors when the current is multiplied by the total integration time in the instant conversion step. This is particularly true where the active and blank integrals are disjointed in time, and thus possibly comprised of sets of background current values that occurred at different temperatures.
  • temperature measurements taken in the active and blank reservoirs at alternating anodal and cathodal phases during a measurement cycle are used in a subtraction method in order to reduce the impact of temperature fluctuations on the signals.
  • the active/blank reservoir iontophoretic sampling system can be run under conditions which alternate the active and blank reservoirs between anodal and cathodal phases during a measurement cycle. This allows the blank anodal signal to be measured at the same time as the active, cathode signal, and temperature variations will likely have similar impact on the two signals.
  • the conversion step can include a blank subtraction step, combined data from two active reservoirs, and/or a smoothing step.
  • the blank subtraction step is used to subtract the blank signal from the active signal in order to remove signal components that are not related to the analyte, thus obtaining a cleaner analyte signal.
  • the two raw signals can be averaged or a summed value of the two raw signals can be used.
  • mathematical transformations are carried out which individually smooth signals obtained from the active and blank collection reservoirs. These smoothing algorithms help improve the signal-to-noise ratio in the biosensor, by allowing one to correct the signal measurements obtained from the device to reduce unwanted noise while maintaining the actual signal sought.
  • a blank subtraction step is used in the active-blank iontophoretic sampling system of the invention as follows. Signals from the blank (second) reservoir, taken at, or about the same time as signals from the active (first) reservoir, are used to substantially eliminate signal components from the active signal that are not specifically related to the analyte.
  • the blank reservoir contains all of the same components as the active reservoir except for the GOx enzyme, and the blank signal should thus exhibit similar electrochemical current to the active signal, except for the signal associated with the analyte.
  • Y t Y t, act ⁇ d*Y t, blank
  • (Y t,act ) is the active signal (in nC) at time t
  • (Y t,blank ) is the blank signal (in nC) at time t
  • (Y t ) is the “blank subtracted” signal at time t
  • the summed signal can be “weighted” to account for different contributions of signal from each reservoir.
  • each reservoir is capable of generating raw signal and each contains all of the same components.
  • Y t, ⁇ aY t, act1 +bY t, act2
  • a is the time-dependent fractional weight for the first active signal
  • (Y t, act1 ) is the first active signal (in nC) at time t
  • “b” is the time-dependent fractional weight for the second active signal
  • (Y t,act2 ) is the second active signal (in nC) at time t
  • (Y t, ⁇ ) is the summed signal at time t.
  • the active signal obtained from the first (active) reservoir can be smoothed using a smoothing function.
  • the reference (blank) signal obtained from the second reservoir can also be smoothed using a similar recursive smoothing function.
  • the blank signal can be subtracted from the active signal in order to obtain a signal that is indicative of the glucose reaction only.
  • the blank signal should exhibit a similar electrochemical current to the active signal, except for the signal associated with the glucose analyte.
  • This smoothing can alternatively be carried out on discrete (nA) sensor signals, with or without temperature and/or background subtraction corrections. Smoothing can also be carried out on active signals or on averages of two or more active signals. Further modifications to these functions will occur to those of ordinary skill in the art, in light of the present enabling disclosure.
  • Step D The Calibration Step.
  • any of the raw signals obtained from Step A, the screened raw signal obtained from Step B, or the initial output signal obtained from Step C (or from Steps B and C), can be converted into an analyte-specific value using a calibration step which correlates the signal obtained from the sensing device with the concentration of the analyte present in the biological system.
  • a calibration step which correlates the signal obtained from the sensing device with the concentration of the analyte present in the biological system.
  • calibration techniques can be used to interpret such signals. These calibration techniques apply mathematical, statistical and/or pattern recognition techniques to the problem of signal processing in chemical analyses, for example, using neural networks, genetic algorithm signal processing, linear regression, multiple-linear regression, partial linear regression, deconvolution, or principal components analysis of statistical (test) measurements.
  • One method of calibration involves estimation techniques.
  • the calibration set e.g., reference set
  • Numerous suitable estimation techniques useful in the practice of the invention are known in the art. These techniques can be used to provide constant parameters, which can then be used in a mathematical transformation to obtain a measurement value indicative of the concentration of analyte present in the biological system at the times of measurement.
  • the calibration step may be carried out using artificial neural networks or genetic algorithms.
  • the structure of a particular neural network algorithm used in the practice of the invention can vary widely; however, the network should contain an input layer, one or more hidden layers, and one output layer.
  • Such networks can be optimized on training data set, and then applied to a population. There are an infinite number of suitable network types, transfer functions, training criteria, testing and application methods, which will occur to the ordinarily skilled artisan upon reading the instant specification.
  • a preferred neural network algorithm would use, for example, inputs selected from the following to provide a blood glucose measurement: elapsed time since calibration; signal from the active reservoir; signal from the blank reservoir; signal from two active reservoirs (either averaged or summed); calibration time; measured temperature; applied iontophoretic voltage; skin conductance; blood glucose concentration, determined by an independent means, at a defined calibration point; background; background referenced to calibration; and, when operating in the training mode, measured glucose.
  • the calibration step can include a universal calibration process, a single-point calibration process, or a multi-point calibration process.
  • a universal calibration process is used, wherein the above mathematical techniques are used to derive a correlation factor (or correlation algorithm) that allows for accurate, dependable quantification of analyte concentration by accounting for varying backgrounds and signal interferences irrespective of the particular biological system being monitored.
  • the universal calibrant is selected to provide a close correlation (i.e., quantitative association) between a particular instrument response and a particular analyte concentration, wherein the two variables are correlated.
  • a single-point calibration is used. More particularly, the single-point calibration process can be used to calibrate measurements obtained by iontophoretic sampling methodologies using a reference measurement obtained by conventional (invasive) methods.
  • Single-point calibration allows one to account for variables that are unique to the particular biological system being monitored, and the particular sensing device that is being used.
  • the transdermal sampling device is generally contacted with the biological system (placed on the surface of a subject's skin) upon waking. After the device is put in place, it is preferable to wait a period of time in order allow the device to begin normal operations.
  • sampling system can be pre-programmed to begin execution of its signal measurements (or other functions) at a designated time.
  • One application of this feature is to have the sampling system in contact with a subject and to program the sampling system to begin sequence execution during the night so that it is available for calibration immediately upon waking.
  • One advantage of this feature is that it removes any need to wait for the sampling system to warm-up before calibrating it.
  • a blood sample can be extracted when the device has attained normal operations, such that the invasive blood sample extraction is taken in a corresponding time period with a measurement cycle.
  • Actual blood glucose levels can then be determined using any conventional method (e.g., calorimetric, electrochemical, spectrophotometric, or the like) to analyze the extracted sample.
  • This actual value is then used as a reference value in the single-point calibration process, wherein the actual value is compared against the corresponding measured value obtained with the transdermal sampling device.
  • a multi-point calibration process is used, wherein the above-described single-point calibration process is repeated at least once to provide a plurality of point calibrations.
  • the multi-point calibration process can be carried out at various time intervals over the course of a continual or continuous measuring period.
  • the signals obtained from Step B and/or Step C, supra can be subjected to further signal processing prior to calibration as follows.
  • the corrected signal should theoretically be directly proportional to the amount of analyte (glucose) present in the iontophoretically extracted sample.
  • a non-zero intercept is obtained in the correlation between signal and reference glucose value.
  • a constant offset term (which can be positive or negative) is obtained which can be added to the converted signal to account for a non-zero signal at an estimated zero blood glucose concentration.
  • the offset can be added to the active sensor signal; or, in the case of an iontophoretic sampling system that obtains both active and blank signals, the offset can be added to the blank-subtracted active signal.
  • the calibration step can be carried out using, for example, the single-point calibration method described hereinabove.
  • E cal is the blank-subtracted smoothed sensor signal (in nC) at calibration
  • BG cal is the reference blood glucose concentration (in mg/dL) at calibration
  • (b gain ) is the conversion factor [(mg/dL)/nC]
  • (OS) is the offset calibration factor constant (in nC) which can be calculated using standard regression analysis
  • ( ⁇ ) is the calibration offset (in mg/dL).
  • Other signal values, such as Y t can be substituted for E t , and E cal depending upon the amount of prior signal processing performed (see, e.g., Step C, supra).
  • Further signal processing can also be used to correct for time-dependent behavior related to the particular sensor element that is used in the sensing operation.
  • signal measurements of certain types exhibit change over time for reasons which are not fully understood.
  • the present invention is not premised on any particular theory with respect to why such time-dependent change occurs. Rather, the invention recognizes that time-dependent behavior can occur, and corrects for this behavior using one or more mathematical functions.
  • a corrected measurement can be calculated using a mathematical function which compensates for time-dependent decline in the biosensor signal between measurements during the period of continual or continuous measuring of the analyte concentration.
  • a corrected measurement can be calculated using a mathematical function which compensates for time-dependent decline in the biosensor signal between measurements, during the period of continual or continuous measuring of the analyte concentration, by correlating signal at the beginning of the measurement series to a unit of decay.
  • the correction function uses an additive decay parameter ( ⁇ ) and a decay correction factor ( ⁇ ).
  • additive decay parameter
  • decay correction factor
  • This equation allows a time-dependent multiplicative correction to be applied to the integrated signal in a manner that amplifies, to a greater extent, those signals that have been observed to decay at a greater rate (e.g., empirically, signals that give lower BGain tend to decay faster).
  • Use of the BGAIN factor, as described herein, can insure that a reasonable calibration factor is obtained.
  • EG t ( [ BG c ⁇ ⁇ a ⁇ ⁇ l - ⁇ ⁇ ⁇ t c ⁇ ⁇ a ⁇ ⁇ l E c ⁇ ⁇ a ⁇ ⁇ l + OS - ⁇ ⁇ ⁇ t c ⁇ ⁇ a ⁇ ⁇ l ] + ⁇ ⁇ ⁇ t ) * ( E t + OS ) + ⁇ ⁇ ⁇ t
  • ⁇ BGAIN [ BG c ⁇ ⁇ a ⁇ ⁇ l - ⁇ ⁇ ⁇ t c ⁇ ⁇ a ⁇ ⁇ l E c ⁇ ⁇ ⁇ ⁇ ⁇ l + OS - ⁇ ⁇ ⁇ t c ⁇ ⁇ a ⁇ ⁇ l ]
  • BG cal is the true blood glucose at the calibration point
  • BGAIN 1 [ BG cal - ⁇ 1 ⁇ t cal E cal + OS - ⁇ 1 ⁇ t cal ] if ⁇ ⁇ t ⁇ t 12
  • BGAIN 2 [ BG cal - ⁇ 1 ⁇ t 12 - ⁇ 2 ⁇ ( t cal - t 12 ) E cal + OS - ⁇ 1 ⁇ t 12 - ⁇ 2 ⁇ ( t cal - t 12 ) ] if ⁇ ⁇ t 12 ⁇ t cal ⁇ t 23
  • BGAIN 3 [ BG cal - ⁇ 1 ⁇ t 12 - ⁇ ⁇ ⁇ 2 ⁇ ( t cal - t 12 ) - ⁇ ⁇ ⁇ 3 ⁇ ( t cal - t 23 ) E cal + OS - ⁇ 1 ⁇ t 12 - ⁇ 2 ⁇ (
  • the time segmentation allows for greater flexibility in predicting non-linear signal decay terms.
  • Steps A through D can be combined in a variety of ways to provide for improved signal processing during analyte measurement.
  • an active/blank sampling system is used to obtain the raw signal in Step A. These raw signals are then screened in Step B to obtain screened data. These screened data are then subjected to a temperature correction using the K 1 temperature correction, and then converted using the baseline subtraction and integration methods of Step C. The converted data are also smoothed (both active and blank) using the smoothing functions of Step C, the smoothed data are temperature corrected using the K 2 temperature correction, and a blank subtraction is carried out.
  • the smoothed and corrected data are then converted to the analyte concentration in the biological system using the calibration methods of Step D to perform a single-point calibration, wherein the data is also refined using the offset and time-dependent behavior corrections to obtain a highly accurate analyte concentration value.
  • a “sensor consistency check” can be employed that detects whether the signals from the reservoirs are changing in concert with one another. This check compares the percentage change from the calibration signal for each reservoir, then calculates the difference in percentage change in signal between the two reservoirs. If this difference is greater than some threshold, then the signals are not “tracking” one another and this data point can be screened as in Step B. This check verifies consistency between the two sensors. A large difference can indicate noise in the signals.
  • a “Calibration Factor Check” may be employed. This check provides control over unreasonable finger prick measurements or incorrect entries and provides additional assurance that a reasonable calibration slope has been generated.
  • BGAIN is less than or equal to a predetermined threshold value, or if the CAL RATIO is greater than or equal to a predetermined threshold value, then a calibration error is indicated. Such an error can be displayed to the user, for example, a calibration window can appear on the monitor's display appear. Such an error indicates to the users that the user must perform the calibration again.
  • CAL RATIO [ BG cal E cal + OS ] wherein, BG cal is the true blood glucose at the calibration point; E cal is the analyte signal at calibration; and (OS) is the constant offset term which accounts for a non-zero signal at an estimated zero blood glucose concentration. Step E: Time Forecasting Measurements.
  • the corrected analyte value obtained using the above techniques can be used to predict future (e.g., time forecasting) or past (e.g., calibration) target analyte concentrations in the biological system.
  • a series of analyte values are obtained by performing any combination of Steps A, B, C, and/or D, supra, in an iterative manner. These measurements are then used to predict unmeasured analyte values at different points in time, future or past.
  • the above-described iontophoretic sampling process is carried out in order to obtain three or more measurements of the target analyte. Using these measurements, an additional measurement can be calculated.
  • the additional measurement is preferably calculated using a series function.
  • the actual (real-time) glucose level in a subject differs from the measured glucose level obtained using a sampling device that extracts glucose from the subject using iontophoresis.
  • the difference is due, in part, to a lag time between extracting the glucose analyte and obtaining a measurement from the extracted glucose.
  • This lag time can vary depending on factors such as the particular subject using the device, the particular area of skin from which glucose is extracted, the type of collection reservoir used, and the amount of current applied.
  • the method of the present invention can utilize data obtained from previous measurements and a mathematical function in order to predict what a future analyte concentration will be. In this case, the predicted future reading can be used as a “real-time value” of the analyte level.
  • mathematical methods can be used to predict past measurements, such as in the context of making a calibration. More particularly, measurements obtained using the above-described transdermal sampling device can be calibrated against one or more reference measurements obtained by conventional (blood extraction) methods. In such calibration processes, actual blood glucose levels are determined using conventional analytical methods (e.g., calorimetric, electrochemical, spectrophotometric, or the like) to analyze an extracted blood sample. These actual measurements are then compared with corresponding measurements obtained with the transdermal sampling device, and a conversion factor is then determined. In normal operations, the transdermal sampling device is generally first contacted with the biological system (placed on the surface of a subject's skin) upon waking.
  • conventional analytical methods e.g., calorimetric, electrochemical, spectrophotometric, or the like
  • the device After the device is put in place, it is preferable to wait a period of time in order allow the device to attain normal operating parameters, after which time the device can be calibrated.
  • a blood sample is extracted at the time when the device is first applied (as would normally be most convenient)
  • This problem can be overcome using prediction methods which allow one to perform a conventional blood glucose test (via a blood sample extraction) when the device is first applied, and then calibrate the device at a later time against the results of the conventional glucose test.
  • a number of mathematical methods for predicting future or past measurements can be used in the practice of the invention. For example, linear or nonlinear regression analyses, time series analyses, or neural networks can be used to predict such measurements. However, it is preferred that a novel combination of exponential smoothing and a Taylor series analysis be used herein to predict the future or past measurement.
  • physiological variables may be predicted using the above techniques. For example, these prediction methods can be used to time forecast those physiological variables that cannot be measured in real-time, or that demonstrate frequent fluctuations in their data.
  • physiological functions and the variables that characterize them include, but are not limited to, cerebral blood flow (in the treatment of stroke patients) which is related to blood viscosity and the concentrations of plasma proteins and clotting factors in the blood stream (Hachinski, V. and Norris, J. W., “The Acute Stroke,” Philadelphia, F A Davis, 1985); pulmonary function (in asthma patients) as measured by lung volumes in the different phases of respiration (Thurlbeck, W. M. (1990) Clin. Chest Med.
  • Step F Controlling a Physiological Effect.
  • analyte value obtained using the above techniques can also be used to control an aspect of the biological system. e.g., a physiological effect.
  • an analyte value obtained as described above is used to determine when, and at what level, a constituent should be added to the biological system in order to control the concentration of the target analyte.
  • Step E allows for accurate predictions of either real-time or future blood glucose values. This is of particular value in predicting hypoglycemic episodes which can lead to diabetic shock, or even coma. Having a series of measurements obtained from the continual iontophoretic sampling device, and the capability to predict future values, allows a subject to detect blood glucose swings or trends indicative of hypoglycemic or hyperglycemic episodes prior to their reaching a critical level, and to compensate therefor by way of exercise, diet or insulin administration.
  • a feedback control application of the present invention entails using a function to predict real-time blood glucose levels, or measurement values of blood glucose levels at a different time, and then the same to control a pump for insulin delivery to treat hyperglycemia.
  • an iontophoretic sampling device was used to extract a series of 525 blood glucose samples from an experimental population of human subjects, and non-processed measurement values were compared against measurement values obtained using the data screening and correction algorithm of the present invention.
  • iontophoretic sampling was performed on subjects using a GlucowatchTM (Cygnus, Inc., Redwood City, Calif.) iontophoretic sampling system.
  • This transdermal sampling device which is designed to be worn like a wrist watch, uses iontophoresis (electroosmosis) to extract glucose analyte into a collection pad worn beneath the watch.
  • Glucose collected into the GlucoWatchTM sampling system triggers an electrochemical reaction with a reagent in the pad, giving rise to a current which is sensed, measured, and converted to a blood glucose concentration. Measurements are taken on a continual basis, wherein combined extraction and sensing (measurement cycles) were set at 30 minutes.
  • Iontophoresis was carried out using two collection pads contacted with Ag/AgCl iontophoretic electrodes, an iontophoretic current density of 0.3 mA/cm 2 , and the electrical polarity of the electrodes was switched halfway through the 30 minute measurement cycle. Sensing was carried out using platinum-based biosensor electrodes which were contacted with the collection pads.
  • a description of the GlucowatchTM sampling system can be found in publication to Conn, T. E. (Jan. 15, 1997) “ Evaluation of a Non-Invasive Glucose Monitoring System for People with Diabetes ,” given at the Institute of Electrical and Electronics Engineers (IEEE) meeting entitled “Engineering in Medicine & Biology,” Stanford, Calif., which publication is incorporated herein by reference.
  • EG t b gain ⁇ [ E t ⁇ ( 1 + ⁇ i ⁇ t ) + OS ] + ⁇ i ⁇ t - ⁇ ⁇ ⁇
  • ⁇ : ⁇ ⁇ b gain BG cal + ⁇ - ⁇ cal ⁇ t E cal ⁇ ( 1 + ⁇ i ⁇ t cal ) + OS and (t cal ) is the calibration point
  • (EG t ) is the estimated blood glucose concentration at time t
  • E t ) is the analyte signal at time t
  • OS is the constant offset term which accounts for a non-zero signal at an estimated zero blood glucose concentration (as described above)
  • ⁇ ) is a correction term for a linear time-dependent signal decline in the time segments and can have multiple time segments (e
  • MPE(%) mean absolute % error
  • PE EG t - BG t BG t
  • Effective measurements should have a MPE(%) of about 25% or less.
  • the results of the MPE(%) are also depicted in Table 1 As can be seen, the combination of data screening methods and the correction algorithm of the present invention met this effective criteria.

Abstract

A method is provided for continually or continuously measuring the concentration of target chemical analytes present in a biological system, and processing analyte-specific signals to obtain a measurement value that is closely correlated with the concentration of the target chemical analyte in the biological system. One important application of the invention involves a method for signal processing in a system for monitoring blood glucose values.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • This application is a divisional of U.S. patent application Ser. No. 10/384,443, filed Mar. 7, 2003, which is a continuation of U.S. patent application Ser. No. 09/894,783, filed Feb. 27, 2001, now U.S. Pat. No. 6,595,919, which is a continuation of U.S. patent application Ser. No. 09/309,728, filed May 11, 1999, now U.S. Pat. No. 6,233,471, which claims priority to U.S. Provisional Patent Application Ser. No. 60/085,344, filed May 13, 1998, and which applications are incorporated herein by reference in their entireties.
  • FIELD OF THE INVENTION
  • The invention relates generally to methods for continually or continuously measuring the concentration of target chemical analytes present in a biological system. More particularly, the invention relates to methods for processing signals obtained during measurement of physiological analytes. One important application of the invention involves a method for monitoring blood glucose concentrations.
  • BACKGROUND OF THE INVENTION
  • A number of diagnostic tests are routinely performed on humans to evaluate the amount or existence of substances present in blood or other body fluids. These diagnostic tests typically rely on physiological fluid samples removed from a subject, either using a syringe or by pricking the skin. One particular diagnostic test entails self-monitoring of blood glucose levels by diabetics.
  • Diabetes is a major health concern, and treatment of the more severe form of the condition, Type I (insulin-dependent) diabetes, requires one or more insulin injections per day. Insulin controls utilization of glucose or sugar in the blood and prevents hyperglycemia which, if left uncorrected, can lead to ketosis. On the other hand, improper administration of insulin therapy can result in hypoglycemic episodes, which can cause coma and death. Hyperglycemia in diabetics has been correlated with several long-term effects of diabetes, such as heart disease, atherosclerosis, blindness, stroke, hypertension and kidney failure.
  • The value of frequent monitoring of blood glucose as a means to avoid or at least minimize the complications of Type I diabetes is well established. Patients with Type II (non-insulin-dependent) diabetes can also benefit from blood glucose monitoring in the control of their condition by way of diet and exercise.
  • Conventional blood glucose monitoring methods generally require the drawing of a blood sample (e.g., by fingerprick) for each test, and a determination of the glucose level using an instrument that reads glucose concentrations by electrochemical or calorimetric methods. Type I diabetics must obtain several fingerprick blood glucose measurements each day in order to maintain tight glycemic control. However, the pain and inconvenience associated with this blood sampling, along with the fear of hypoglycemia, has led to poor patient compliance, despite strong evidence that tight control dramatically reduces long-term diabetic complications. In fact, these considerations can often lead to an abatement of the monitoring process by the diabetic. See, e.g., The Diabetes Control and Complications Trial Research Group (1993) New Engl. J. Med. 329:977-1036.
  • Recently, various methods for determining the concentration of blood analytes without drawing blood have been developed. For example, U.S. Patent No. 5,267,152 to Yang et al. describes a noninvasive technique of measuring blood glucose concentration using near-IR radiation diffuse-reflection laser spectroscopy. Similar near-IR spectrometric devices are also described in U.S. Pat. No. 5,086,229 to Rosenthal et al. and U.S. Pat. No. 4,975,581 to Robinson et al.
  • U.S. Pat. No. 5,139,023 to Stanley et al., and U.S. Pat. No. 5,443.080 to D'Angelo et al. describe transdermal blood glucose monitoring devices that rely on a permeability enhancer (e.g., a bile salt) to facilitate transdermal movement of glucose along a concentration gradient established between interstitial fluid and a receiving medium. U.S. Pat. No. 5,036,861 to Sembrowich describes a passive glucose monitor that collects perspiration through a skin patch, where a cholinergic agent is used to stimulate perspiration secretion from the eccrine sweat gland. Similar perspiration collection devices are described in U.S. Pat. No. 5,076,273 to Schoendorfer and U.S. Pat. No. 5,140,985 to Schroeder.
  • In addition, U.S. Pat. No. 5,279,543 to Glikfeld et al. describes the use of iontophoresis to noninvasively sample a substance through skin into a receptacle on the skin surface. Glikfeld teaches that this sampling procedure can be coupled with a glucose-specific biosensor or glucose-specific electrodes in order to monitor blood glucose. Finally, International Publication No. WO 96/00110, published 4 Jan. 1996, describes an iontophoretic apparatus for transdermal monitoring of a target substance, wherein an iontophoretic electrode is used to move an analyte into a collection reservoir and a biosensor is used to detect the target analyte present in the reservoir.
  • SUMMARY OF THE INVENTION
  • The present invention provides a method for continually or continuously measuring the concentration of an analyte present in a biological system. The method entails continually or continuously detecting an analyte from the biological system and deriving a raw signal therefrom, wherein the raw signal is related to the analyte concentration. A number of signal processing steps are then carried out in order to convert the raw signal into an initial signal output that is indicative of an analyte amount. The converted signal is then further converted into a value indicative of the concentration of analyte present in the biological system.
  • The raw signal can be obtained using any suitable sensing methodology including, for example, methods which rely on direct contact of a sensing apparatus with the biological system; methods which extract samples from the biological system by invasive, minimally invasive, and non-invasive sampling techniques, wherein the sensing apparatus is contacted with the extracted sample; methods which rely on indirect contact of a sensing apparatus with, the biological system; and the like. In preferred embodiments of the invention, methods are used to extract samples from the biological sample using minimally invasive or non-invasive sampling techniques. The sensing apparatus used with any of the above-noted methods can employ any suitable sensing element to provide the raw signal including, but not limited to, physical, chemical, electrochemical, photochemical, spectrophotometric, polarimetric, calorimetric, radiometric, or like elements. In preferred embodiments of the invention, a biosensor is used which comprises an electrochemical sensing element.
  • In one particular embodiment of the invention, the raw signal is obtained using a transdermal sampling system that is placed in operative contact with a skin or mucosal surface of the biological system. The sampling system transdermally extracts the analyte from the biological system using any appropriate sampling technique, for example, iontophoresis. The transdermal sampling system is maintained in operative contact with the skin or mucosal surface of the biological system to provide for such continual or continuous analyte measurement.
  • The analyte can be any specific substance or component that one is desirous of detecting and/or measuring in a chemical, physical, enzymatic, or optical analysis. Such analytes include, but are not limited to, amino acids, enzyme substrates or products indicating a disease state or condition, other markers of disease states or conditions, drugs of abuse, therapeutic and/or pharmacologic agents, electrolytes, physiological analytes of interest (e.g., calcium, potassium, sodium, chloride, bicarbonate (Co2), glucose, urea (blood urea nitrogen), lactate, hematocrit, and hemoglobin), lipids, and the like. In preferred embodiments, the analyte is a physiological analyte of interest, for example glucose, or a chemical that has a physiological action, for example a drug or pharmacological agent.
  • Accordingly, it is an object of the invention to provide a method for continually or continuously measuring an analyte present in a biological system, wherein raw signals are obtained from a suitable sensing apparatus, and then subjected to signal processing is techniques. More particularly, the raw signals undergo a data screening method in order to eliminate outlier signals and/or poor (incorrect) signals using a predefined set of selection criteria. In addition, or alternatively, the raw signal can be converted in a conversion step which (i) removes or corrects for background information, (ii) integrates the raw signal over a sensing time period, (iii) performs any process which converts the raw signal from one signal type to another, or (iv) performs any combination of steps (i), (ii) and/or (iii). In preferred embodiments, the conversion step entails a baseline background subtraction method to remove background from the raw signal and an integration step. In other embodiments, the conversion step can be tailored for use with a sensing device that provides both active and reference (blank) signals; wherein mathematical transformations are used to individually smooth active and reference signals, and/or to subtract a weighted reference (blank) signal from the active signal. In still further embodiments, the conversion step includes correction functions which account for changing conditions in the biological system and/or the biosensor system (e.g., temperature fluctuations in the biological system, temperature fluctuations in the sensor element, skin conductivity fluctuations, or combinations thereof). The result of the conversion step is an initial signal output which provides a value which can be correlated with the concentration of the target analyte in the biological sample.
  • It is also an object of the invention to provide a signal processing calibration step, wherein the raw or initial signals obtained as described above are converted into an analyte-specific value of known units to provide an interpretation of the signal obtained from the sensing device. The interpretation uses a mathematical transformation to model the relationship between a measured response in the sensing device and a corresponding analyte-specific value. Such mathematical transformations can entail the use of linear or nonlinear regressions, or neural network algorithms. In one embodiment, the calibration step entails calibrating the sensing device using a single- or multi-point calibration, and then converting post-calibration data using correlation factors, time corrections and constants to obtain an analyte-specific value. Further signal processing can be used to refine the information obtained in the calibration step, for example, where a signal processing step is used to correct for signal differences due to variable conditions unique to the sensor element used to obtain the raw signal. In one embodiment, this further step is used to correct for signal time-dependence, particularly signal decline. In another embodiment, a constant offset term is obtained, which offset is added to the signal to account for a non-zero signal at an estimated zero analyte concentration.
  • Further, the methods of the present invention include enhancement of skin permeability by pricking the skin with micro-needles. In addition, the sampling system can be programed to begin execution of sampling and sensing at a defined time(s).
  • It is yet a further object of the invention to provide a monitoring system for continually or continuously measuring an analyte present in a biological system. The monitoring system comprises, in operative combination: (a) a sampling means for continually or continuously extracting the analyte from the biological system, (b) a sensing means in operative contact with the analyte extracted by the sampling means, and (c) a microprocessor means in operative communication with the sensing means. The sampling means is adapted for extracting the analyte across a skin or mucosal surface of a biological system. The sensing means is used to obtain a raw signal from the extracted analyte, wherein the raw signal is specifically related to the analyte. The microprocessor means is used to subject the raw signal to a conversion step, thereby converting the same into an initial signal output which is indicative of the amount of analyte extracted by the sampling means, and then perform a calibration step which correlates the initial signal output with a measurement value indicative of the concentration of analyte present in the biological system at the time of extraction. In one embodiment, the monitoring system uses iontophoresis to extract the analyte from the biological system. In other embodiments, the monitoring system is used to extract a glucose analyte from the biological system. Further, the microprocessor can be programed to begin execution of sampling and sensing at a defined time(s).
  • Additional objects, advantages and novel features of the invention will be set forth in part in the description which follows, and in part will become apparent to those skilled in the art upon examination of the following, or may be learned by practice of the invention.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1A depicts a top plan view of an iontophoretic collection reservoir and electrode assembly for use in a transdermal sampling device constructed according to the present invention.
  • FIG. 1B depicts the side view of the iontophoretic collection reservoir and electrode assembly shown in FIG. 1A.
  • FIG. 2 is a pictorial representation of an iontophoretic sampling device which includes the iontophoretic collection reservoir and electrode assembly of FIGS. 1A and 1B.
  • FIG. 3 is a representation of one embodiment of a bimodal electrode design. The figure presents an overhead and schematic view of the electrode assembly 33. In the figure, the bimodal electrode is shown at 30 and can be, for example, a Ag/AgCl iontophoretic/counter electrode. The sensing or working electrode (made from, for example, platinum) is shown at 31. The reference electrode is shown at 32 and can be, for example, a Ag/AgCl electrode. The components are mounted on a suitable nonconductive substrate 34, for example, plastic or ceramic. The conductive leads 37 leading to the connection pad 35 are covered by a second nonconductive piece 36 of similar or different material. In this example of such an electrode the working electrode area is approximately 1.35 cm2. The dashed line in FIG. 3 represents the plane of the cross-sectional schematic view presented in FIG. 4.
  • FIG. 4 is a representation of a cross-sectional schematic view of the bimodal electrodes as they may be used in conjunction with a reference electrode and a hydrogel pad. In the figure, the components are as follows: bimodal electrodes 40 and 41; sensing electrodes 42 and 43; reference electrodes 44 and 45; a substrate 46; and hydrogel pads 47 and 48.
  • FIG. 5 is an exploded pictorial representation of components from a preferred embodiment of the automatic sampling system of the present invention.
  • DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
  • Before describing the present invention in detail, it is to be understood that this invention is not limited to particular compositions or biological systems as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting.
  • It must be noted that, as used in this specification and the appended claims, the singular forms “a”, “an” and “the” include plural referents unless the content clearly dictates otherwise. Thus, for example, reference to “a time-dependent variable” includes a mixture of two or more such variables, reference to “an electrochemically active species” includes two or more such species, reference to “an analyte” includes mixtures of analytes, and the like.
  • All publications, patents and patent applications cited herein, whether supra or infra, are hereby incorporated by reference in their entirety.
  • Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention pertains. Although any methods and materials similar or equivalent to those described herein can be used in the practice for testing of the present invention, the preferred materials and methods are described herein.
  • In describing and claiming the present invention, the following terminology will be used in accordance with the definitions set out below.
  • Definitions
  • The terms “analyte” and “target analyte” are used herein to denote any physiological analyte of interest that is a specific substance or component that is being detected and/or measured in a chemical, physical, enzymatic, or optical analysis. A detectable signal (e.g., a chemical signal or electrochemical signal) can be obtained, either directly or indirectly, from such an analyte or derivatives thereof. Furthermore, the terms “analyte” and “substance” are used interchangeably herein, and are intended to have the same meaning, and thus encompass any substance of interest. In preferred embodiments, the analyte is a physiological analyte of interest, for example, glucose, or a chemical that has a physiological action, for example, a drug or pharmacological agent. Interstitial fluid may comprise the analyte (for example, glucose).
  • A “sampling device” or “sampling system” refers to any device for obtaining a sample from a biological system for the purpose of determining the concentration of an analyte of interest. As used herein, the term “sampling” means invasive, minimally invasive or non-invasive extraction of a substance from the biological system, generally across a membrane such as skin or mucosa. The membrane can be natural or artificial, and can be of plant or animal nature, such as natural or artificial skin, blood vessel tissue, intestinal tissue, and the like. Typically, the sampling means are in operative contact with a “reservoir,” or “collection reservoir,” wherein the sampling means is used for extracting the analyte from the biological system into the reservoir to obtain the analyte in the reservoir. A “biological system” includes both living and artificially maintained systems. Examples of minimally invasive and noninvasive sampling techniques include iontophoresis, sonophoresis, suction, electroporation, thermal poration, passive diffusion, microfine (miniature) lances or cannulas, subcutaneous implants or insertions, and laser devices. Sonophoresis uses ultrasound to increase the permeability of the skin (see, e.g., Menon et al. (1994) Skin Pharmacology 7:130-139). Suitable sonophoresis sampling systems are described in International Publication No. WO 91/12772, published 5 Sep. 1991. Passive diffusion sampling devices are described, for example, in International Publication Nos.: WO 97/38126 (published 16 Oct. 1997); WO 97/42888, WO 97/42886, WO 97/42885, and WO 97/42882 (all published 20 Nov. 1997); and WO 97/43962 (published 27 Nov. 1997). Laser devices use a small laser beam to burn a hole through the upper layer of the patient's skin (see, e.g., Jacques et al. (1978) J. Invest. Dermatology 88:88-93). Examples of invasive sampling techniques include traditional needle and syringe or vacuum sample tube devices.
  • The term “collection reservoir” is used to describe any suitable containment means for containing a sample extracted from a biological system. For example, the collection reservoir can be a receptacle containing a material which is ionically conductive (e.g., water with ions therein), or alternatively, it can be a material, such as, a sponge-like material or hydrophilic polymer, used to keep the water in place. Such collection reservoirs can be in the form of a hydrogel (for example, in the form of a disk or pad). Hydrogels are typically referred to as “collection inserts.” Other suitable collection reservoirs include, but are not limited to, tubes, vials, capillary collection devices, cannulas, and miniaturized etched, ablated or molded flow paths.
  • A “housing” for the sampling system can further include suitable electronics (e.g., microprocessor, memory, display and other circuit components) and power sources for operating the sampling system in an automatic fashion.
  • A “monitoring system,” as used herein, refers to a system useful for continually or continuously measuring a physiological analyte present in a biological system. Such a system typically includes, but is not limited to, sampling means, sensing means, and a microprocessor means in operative communication with the sampling means and the sensing means.
  • The term “artificial,” as used herein, refers to an aggregation of cells of monolayer thickness or greater which are grown or cultured in vivo or in vitro, and which function as a tissue of an organism but are not actually derived, or excised, from a pre-existing source or host.
  • The term “subject” encompasses any warm-blooded animal, particularly including a member of the class Mammalia such as, without limitation, humans and nonhuman primates such as chimpanzees and other apes and monkey species; farm animals such as cattle, sheep, pigs, goats and horses; domestic mammals such as dogs and cats; laboratory animals including rodents such as mice, rats and guinea pigs, and the like. The term does not denote a particular age or sex. Thus, adult and newborn subjects, as well as fetuses, whether male or female, are intended to be covered.
  • As used herein, the term “continual measurement” intends a series of two or more measurements obtained from a particular biological system, which measurements are obtained using a single device maintained in operative contact with the biological system over the time period in which the series of measurements is obtained. The term thus includes continuous measurements.
  • The term “transdermal,” as used herein, includes both transdermal and transmucosal techniques, i.e., extraction of a target analyte across skin or mucosal tissue. Aspects of the invention which are described herein in the context of “transdermal,” unless otherwise specified, are meant to apply to both transdermal and transmucosal techniques.
  • The term “transdermal extraction,” or “transdermally extracted” intends any noninvasive, or at least minimally invasive sampling method, which entails extracting and/or transporting an analyte from beneath a tissue surface across skin or mucosal tissue. The term thus includes extraction of an analyte using iontophoresis (reverse iontophoresis), electroosmosis, sonophoresis, microdialysis, suction, and passive diffusion. These methods can, of course, be coupled with application of skin penetration enhancers or skin permeability enhancing technique such as tape stripping or pricking with micro-needles. The term “transdermally extracted” also encompasses extraction techniques which employ thermal poration, electroporation, microfine lances, microfine canulas, subcutaneous implants or insertions, and the like.
  • The term “iontophoresis” intends a method for transporting substances across tissue by way of an application of electrical energy to the tissue. In conventional iontophoresis, a reservoir is provided at the tissue surface to serve as a container of material to be transported. Iontophoresis can be carried out using standard methods known to those of skill in the art, for example, by establishing an electrical potential using a direct current (DC) between fixed anode and cathode “iontophoretic electrodes,” alternating a direct current between anode and cathode iontophoretic electrodes, or using a more complex waveform such as applying a current with alternating polarity (AP) between iontophoretic electrodes (so that each electrode is alternately an anode or a cathode)
  • The term “reverse iontophoresis” refers to the movement of a substance from a biological fluid across a membrane by way of an applied electric potential or current. In reverse iontophoresis, a reservoir is. provided at the tissue surface to receive the extracted material.
  • “Electroosmosis” refers to the movement of a substance through a membrane by way of an electric field-induced convective flow. The terms iontophoresis, reverse iontophoresis, and electroosmosis, will be used interchangeably herein to refer to movement of any ionically charged or uncharged substance across a membrane (e.g., an epithelial membrane) upon application of an electric potential to the membrane through an ionically conductive medium.
  • The term “sensing device,” “sensing means,” or “biosensor device” encompasses any device that can be used to measure the concentration of an analyte, or derivative thereof, of interest. Preferred sensing devices for detecting blood analytes generally include electrochemical devices and chemical devices. Examples of electrochemical devices include the Clark electrode system (see, e.g., Updike, et al., (1967) Nature 214:986-988), and other amperometric, coulometric, or potentiometric electrochemical devices. Examples of chemical devices include conventional enzyme-based reactions as used in the Lifescan® glucose monitor (Johnson and Johnson, New Brunswick, N.J.) (see, e.g., U.S. Pat. No. 4,935,346 to Phillips, et al.).
  • A “biosensor” or “biosensor device” includes, but is not limited to, a “sensor element” which includes, but is not limited to, a “biosensor electrode” or “sensing electrode” or “working electrode” which refers to the electrode that is monitored to determine the amount of electrical signal at a point in time or over a given time period, which signal is then correlated with the concentration of a chemical compound. The sensing electrode comprises a reactive surface which converts the analyte, or a derivative thereof, to electrical signal. The reactive surface can be comprised of any electrically conductive material such as, but not limited to, platinum-group metals (including, platinum, palladium, rhodium, ruthenium, osmium, and iridium), nickel, copper, silver, and carbon, as well as, oxides, dioxides, combinations or alloys thereof. Some catalytic materials, membranes, and fabrication technologies suitable for the construction of amperometric biosensors were described by Newman, J. D., et al. (Analytical Chemistry 67(24), 4594-4599, 1995).
  • The “sensor element” can include components in addition to a biosensor electrode, for example, it can include a “reference electrode,” and a “counter electrode.” The term “reference electrode” is used herein to mean an electrode that provides a reference potential, e.g., a potential can be established between a reference electrode and a working electrode. The term “counter electrode” is used herein to mean an electrode in an electrochemical circuit which acts as a current source or sink to complete the electrochemical circuit. Although it is not essential that a counter electrode be employed where a reference electrode is included in the circuit and the electrode is capable of performing the function of a counter electrode, it is preferred to have separate counter and reference electrodes because the reference potential provided by the reference electrode is most stable when it is at equilibrium. If the reference electrode is required to act further as a counter electrode, the current flowing through the reference electrode may disturb this equilibrium. Consequently, separate electrodes functioning as counter and reference electrodes are most preferred.
  • In one embodiment, the “counter electrode” of the “sensor element” comprises a “bimodal electrode.” The term “bimodal electrode” as used herein typically refers to an electrode which is capable of functioning non-simultaneously as, for example, both the counter electrode (of the “sensor element”) and the iontophoretic electrode (of the “sampling means”).
  • The terms “reactive surface,” and “reactive face” are used interchangeably herein to mean the surface of the sensing electrode that: (1) is in contact with the surface of an electrolyte containing material (e.g. gel) which contains an analyte or through which an analyte, or a derivative thereof, flows from a source thereof; (2) is comprised of a catalytic material (e.g., carbon, platinum, palladium, rhodium, ruthenium, or nickel and/or oxides, dioxides and combinations or alloys thereof) or a material that provides sites for electrochemical reaction; (3) converts a chemical signal (e.g. hydrogen peroxide) into an electrical signal (e.g., an electrical current); and (4) defines the electrode surface area that, when composed of a reactive material, is sufficient to drive the electrochemical reaction at a rate sufficient to generate a detectable, reproducibly measurable, electrical signal that is correlatable with the amount of analyte present in the electrolyte.
  • The term “collection reservoir” and “collection insert” are used to describe any suitable containment means for containing a sample extracted from a biological system. The reservoir can include a material which is ionically conductive (e.g., water with ions therein), wherein another material such as a sponge-like material or hydrophilic polymer is used to keep the water in place. Such collection reservoirs can be in the form of a hydrogel (for example, in the shape of a disk or pad). Other suitable collection reservoirs include, but are not limited to, tubes, vials, capillary collection devices, cannulas, and miniaturized etched, ablated or molded flow paths.
  • An “ionically conductive material” refers to any material that provides ionic conductivity, and through which electrochemically active species can diffuse. The ionically conductive material can be, for example, a solid, liquid, or semi-solid (e.g., in the form of a gel) material that contains an electrolyte, which can be composed primarily of water and ions (e.g., sodium chloride), and generally comprises 50% or more water by weight. The material can be in the form of a gel, a sponge or pad (e.g., soaked with an electrolytic solution), or any other material that can contain an electrolyte and allow passage therethrough of electrochemically active species, especially the analyte of interest.
  • The term “physiological effect” encompasses effects produced in the subject that achieve the intended purpose of a therapy. In preferred embodiments, a physiological effect means that the symptoms of the 5 subject. being treated are prevented or alleviated. For example, a physiological effect would be one that results in the prolongation of survival in a patient.
  • A “laminate”, as used herein, refers to structures comprised of at least two bonded layers. The layers may be bonded by welding or through the use of adhesives. Examples of welding include, but are not limited to, the following: ultrasonic welding, heat bonding, and inductively coupled localized heating followed by localized flow. Examples of common adhesives include, but are not limited to, pressure sensitive adhesives, thermoset adhesives, cyanocrylate adhesives, epoxies, contact adhesives, and heat sensitive adhesives.
  • A “collection assembly”, as used herein, refers to structures comprised of several layers, where the assembly includes at least one collection insert, for example a hydrogel. An example of a collection assembly of the present invention is a mask layer, collection inserts, and a retaining layer where the layers are held in appropriate, functional relationship to each other but are not necessarily a laminate, i.e., the layers may not be bonded together. The layers may, for example, be held together by interlocking geometry or friction.
  • An “autosensor assembly”, as used herein, refers to structures generally comprising a mask layer, collection inserts, a retaining layer, an electrode assembly, and a support tray. The autosensor assembly may also include liners. The layers of the assembly are held in appropriate, functional relationship to each other.
  • The mask and retaining layers are preferably composed of materials that are substantially impermeable to the analyte (chemical signal) to be detected (e.g., glucose); however, the material can be permeable to other substances. By “substantially impermeable” is meant that the material reduces or eliminates chemical signal transport (e.g., by diffusion). The material can allow for a low level of chemical signal transport, with the proviso that chemical signal that passes through the material does not cause significant edge effects at the sensing electrode.
  • “Substantially planar” as used herein, includes a planar surface that contacts a slightly curved surface, for example, a forearm or upper arm of a subject. A “substantially planar” surface is, for example, a surface having a shape to which skin can conform, i.e., contacting contact between the skin and the surface.
  • By the term “printed” as used herein is meant a substantially uniform deposition of an electrode formulation onto one surface of a substrate (i.e., the base support). It will be appreciated by those skilled in the art that a variety of techniques may be used to effect substantially uniform deposition of a material onto a substrate, e.g., Gravure-type printing, extrusion coating, screen coating, spraying, painting, or the like.
  • The term “enzyme” intends any compound or material which catalyzes a reaction between molecules to produce one or more reaction products. The term thus includes protein enzymes, or enzymatically active portions (fragments) thereof, which proteins and/or protein fragments may be isolated from a natural source, or recombinantly or synthetically produced. The term also encompasses designed synthetic enzyme mimetics.
  • The term “time-dependent signal decline” refers to a detectable decrease in measured signal over time when no decrease or change in analyte concentration is actually occurring. The decrease in signal over time may be due to a number of different phenomena.
  • The term “signal-to-noise ratio” describes the relationship between the actual signal intended to be measured and the variation in signal in the absence of the analyte. The terms “S/N” and “SNR” are also used to refer to the signal-to-noise ratio. “Noise,” as used herein, refers to any undesirable signal which is measured along with the intended signal.
  • General Methods
  • The present invention relates to use of a device for transdermally extracting and measuring the concentration of a target analyte present in a biological system. In preferred embodiments, the sensing device comprises a biosensor. In other preferred embodiments, a sampling device is used to extract small amounts of a target analyte from the biological system, and then sense and/or quantify the concentration of the target analyte. Measurement with the biosensor and/or sampling with the sampling device can be carried out in a continual or continuous manner. Continual or continuous measurements allow for closer monitoring of target analyte concentration fluctuations.
  • The analyte can be any specific substance or component that one is desirous of detecting and/or measuring in a chemical, physical, enzymatic, or optical analysis. Such analytes include, but are not limited to, amino acids, enzyme substrates or products indicating a disease state or condition, other markers of disease states or conditions, drugs of abuse, therapeutic and/or pharmacologic agents (e.g., theophylline, anti-HIV drugs, lithium, anti-epileptic drugs, cyclosporin, chemotherapeutics), electrolytes, physiological analytes of interest (e.g., urate/uric acid, carbonate, calcium, potassium, sodium, chloride, bicarbonate (CO2), glucose, urea (blood urea nitrogen), lactate/lactic acid, hydroxybutyrate, cholesterol, triglycerides, creatine, creatinine, insulin, hematocrit, and hemoglobin), blood gases (carbon dioxide, oxygen, pH), lipids, heavy metals (e.g., lead, copper), and the like. In preferred embodiments, the analyte is a physiological analyte of interest, for example glucose, or a chemical that has a physiological action, for example a drug or pharmacological agent.
  • In order to facilitate detection of the analyte, an enzyme can be disposed in the collection reservoir, or, if several collection reservoirs are used, the enzyme can be disposed in several or all of the reservoirs. The selected enzyme is capable of catalyzing a reaction with the extracted analyte (in this case glucose) to the extent that a product of this reaction can be sensed, e.g., can be detected electrochemically from the generation of a current which current is detectable and proportional to the concentration or amount of the analyte which is reacted. A suitable enzyme is glucose oxidase which oxidizes glucose to gluconic acid and hydrogen peroxide. The subsequent detection of hydrogen peroxide on an appropriate biosensor electrode generates two electrons per hydrogen peroxide molecule which create a current which can be detected and related to the amount of glucose entering the device. Glucose oxidase (GOx) is readily available commercially and has well known catalytic characteristics. However, other enzymes can also be used, so long as they specifically catalyze a reaction with an analyte or substance of interest to generate a detectable product in proportion to the amount of analyte so reacted.
  • In like manner, a number of other analyte-specific enzyme systems can be used in the invention, which enzyme systems operate on much the same general techniques. For example, a biosensor electrode that detects hydrogen peroxide can be used to detect ethanol using an alcohol oxidase enzyme system, or similarly uric acid with urate oxidase system, urea with a urease system, cholesterol with a cholesterol oxidase system, and theophylline with a xanthine oxidase system.
  • In addition, the oxidase enzyme (used for hydrogen peroxide-based detection) can be replaced with another redox system, for example, the dehydrogenase-enzyme NAD-NADH, which offers a separate route to detecting additional analytes. Dehydrogenase-based sensors can use working electrodes made of gold or carbon (via mediated chemistry). Examples of analytes suitable for this type of monitoring include, but are not limited to, cholesterol, ethanol, hydroxybutyrate, phenylalanine, triglycerides, and urea. Further, the enzyme can be eliminated and detection can rely on direct electrochemical or potentiometric detection of an analyte. Such analytes include, without limitation, heavy metals (e.g., cobalt, iron, lead, nickel, zinc), oxygen, carbonate/carbon dioxide, chloride, fluoride, lithium, pH, potassium, sodium, and urea. Also, the sampling system described herein can be used for therapeutic drug monitoring, for example, monitoring anti-epileptic drugs (e.g., phenytion), chemotherapy (e.g., adriamycin), hyperactivity (e.g., ritalin), and anti-organ-rejection (e.g., cyclosporin).
  • The methods for measuring the concentration of a target analyte can be generalized as follows. An initial step (Step A) entails obtaining a raw signal from a sensing device, which signal is related to a target analyte present in the biological system. The raw signal can be obtained using any suitable sensing methodology including, for example, methods which rely on direct contact of a sensing apparatus with the biological system; methods which extract samples from the biological system by invasive, minimally invasive, and non-invasive sampling techniques, wherein the sensing apparatus is contacted with the extracted sample; methods which rely on indirect contact of a sensing apparatus with the biological system; and the like. In preferred embodiments of the invention, methods are used to extract samples from the biological sample using minimally invasive or non-invasive sampling techniques. The sensing apparatus used with any of the above-noted methods can employ any suitable sensing element to provide the signal including, but not limited to, physical, chemical, electrochemical, photochemical, spectrophotometric, polarimetric, colorimetric, radiometric, or like elements. In preferred embodiments of the invention, a biosensor is used which comprises an electrochemical sensing element.
  • After the raw signal has been obtained, the signal can undergo a data screening method (Step B) in order to eliminate outlier signals and/or poor (incorrect) signals using a predefined set of selection criteria. In addition, or alternatively, the raw signal can be converted in a conversion step (Step C) which can (i) remove or correct for background information, (ii) integrate the signal over a sensing time period, (iii) perform any process which converts the signal from one signal type to another, or (iv) perform any combination of steps (i), (ii) and/or (iii). In preferred embodiments, the conversion step entails a baseline background subtraction method to remove background from the raw signal and an integration step. In other embodiments, the conversion step can be tailored for use with a sensing device that provides both active and reference (blank) signals; wherein mathematical transformations are used to individually smooth active and reference signals, and/or to subtract a weighted reference (blank) signal from the active signal. In still further embodiments, the conversion step includes correction functions which account for changing conditions in the biological system and/or the biosensor system (e.g., temperature fluctuations in the biological system, temperature fluctuations in the sensor element, skin conductivity fluctuations, or combinations thereof). The result of the conversion step is an initial signal output which provides a value which can be correlated with the concentration of the target analyte in the biological sample.
  • In a calibration step (Step D), the raw signal obtained from Step A, or the initial signal obtained from Step B and/or Step C, is converted into an analyte-specific value of known units to provide an interpretation of the signal obtained from the sensing device. The interpretation uses a one-to-one mathematical transformation to model the relationship between a measured response in the sensing device and a corresponding analyte-specific value. Thus, the calibration step is used herein to relate, for example, an electrochemical signal (detected by a biosensor) with the concentration of a target analyte in a biological system. In one embodiment, the calibration step entails calibrating the sensing device using a single- or multi-point calibration, and then converting post-calibration data using correlation factors, time corrections and constants to obtain an analyte-specific value. Further signal processing can be used to refine the information obtained in the calibration step, for example, where a signal processing step is used to correct for signal differences due to variable conditions unique to the sensor element used to obtain the raw signal. In one embodiment, this further step is used to correct for signal time-dependence, particularly signal decline. In another embodiment, a constant offset term is obtained, which offset is added to the signal to account for a non-zero signal at an estimated zero analyte concentration.
  • The analyte value obtained using the above techniques can optionally be used in a subsequent step (Step E) to predict future (time forecasting) or past (calibration) measurements of the target analyte concentration in the biological system. For example, a series of analyte values are obtained by performing any combination of Steps A, B, C, and/or D in an iterative manner. This measurement series is then used to predict unmeasured analyte values at different points in time, future or past. In this manner, lag times inherent in certain sampling and/or sensing techniques can be reduced or eliminated to provide real time measurement predictions.
  • In another optional step, analyte values obtained using the above techniques can be used in a subsequent step (Step F) to control an aspect of the biological system. In one embodiment, the analyte value obtained in Step D is used to determine when, and at what level, a constituent should be added to the biological system in order to control an aspect of the biological system. In a preferred embodiment, the analyte value can be used in a feedback control loop to control a physiological effect in the biological system.
  • The above general methods (Steps A through F) are each independently useful in analyte sensing systems and can, of course, be used in a wide variety of combinations selected for a particular biological system, target analyte, and/or sensing technique. For example, in certain applications, a measurement sequence can include Steps A, C, D, E and F, in other applications, a measurement sequence can include Steps A, B, C and D, and the like. The determination of particularly suitable combinations is within the skill of the ordinarily skilled artisan when directed by the instant disclosure. Furthermore, Steps C through F are preferably embodied as one or more mathematical functions as described herein below. These functions can thus be carried out using a microprocessor in a monitoring system. Although these methods are broadly applicable to measuring any chemical analyte and/or substance in a biological system, the invention is expressly exemplified for use in a non-invasive, transdermal sampling system which uses an electrochemical biosensor to quantify or qualify glucose or a glucose metabolite.
  • Step A: Obtaining the Raw Signal.
  • The raw signal can be obtained using any sensing device that is operatively contacted with the biological system. Such sensing devices can employ physical, chemical, electrochemical, spectrophotometric, polarimetric, calorimetric, radiometric, or like measurement techniques. In addition, the sensing device can be in direct or indirect contact with the biological system, or used with a sampling device which extracts samples from the biological system using invasive, minimally invasive or non-invasive sampling techniques. In preferred embodiments, a minimally invasive or non-invasive sampling device is used to obtain samples from the biological system, and the sensing device comprises a biosensor with an electrochemical sensing element. In particularly preferred embodiments, a sampling device is used to obtain continual transdermal or transmucosal samples from a biological system, and the analyte of interest is glucose.
  • More specifically, a non-invasive glucose monitoring device is used to measure changes in glucose levels in an animal subject over a wide range of glucose concentrations. The sampling method is based on transdermal glucose extraction and the sensing method is based on electrochemical detection technology. The device can be contacted with the biological system continuously, and automatically obtains glucose samples in order to measure glucose concentration at preprogrammed intervals.
  • Sampling is carried out continually by non-invasively extracting glucose through the skin of the patient. More particularly, an iontophoretic current is applied to a surface of the skin of a subject. When the current is applied, ions or charged molecules pull along other uncharged molecules or particles such as glucose which are drawn into a collection reservoir placed on the surface of the skin. The collection reservoir may comprise any ionically conductive material and is preferably in the form of a hydrogel which is comprised of a hydrophilic material, water and an electrolyte.
  • The collection reservoir may further contain an enzyme which catalyzes a reaction of glucose to form an easily detectable species. The enzyme is preferably glucose oxidase (GOx) which catalyzes the reaction between glucose and oxygen and results in the production of hydrogen peroxide. The hydrogen peroxide reacts at a catalytic surface of a biosensor electrode, resulting in the generation of electrons which create a detectable biosensor current (raw signal). Based on the amount of biosensor current created over a given period of time, a measurement is taken, which measurement is related to the amount of glucose drawn into the collection reservoir over a given period of time. In a preferred embodiment, the reaction is allowed to continue until substantially all of the glucose in the collection reservoir has been subjected to a reaction and is therefore no longer detectable, and the biosensor current generated is related to the concentration of glucose in the subject at the approximate time of sample collection.
  • When the reaction is complete, the process is repeated and a subsequent measurement is obtained. More specifically, the iontophoretic current is again applied, glucose is drawn through the skin surface into the collection reservoir, and the reaction is catalyzed in order to create a biosensor current. These sampling (extraction) and sensing operations are integrated such that glucose is extracted into the hydrogel collection pad where it contacts the GOx enzyme. The GOx enzyme converts glucose and oxygen in the hydrogel to hydrogen peroxide which diffuses to the sensor and is catalyzed by the sensor to regenerate oxygen and form electrons. The electrons generate an electrical signal that can be measured, analyzed, and correlated to blood glucose. Optionally, one or more additional “active” collection reservoirs (each containing the GOx enzyme) can be used to obtain measurements. In one embodiment, two active collection reservoirs are used, and an average is taken between signals from the reservoirs for each measurement time point. Obtaining multiple signals, and then averaging reads from each signals, allows for signal smoothing of unusual data points from a sensor that otherwise may not have been detected by data screening techniques. Furthermore, skin site variability can be detected, and “lag” and/or “lead” differences in blood glucose changes relative to extracted glucose changes can be mitigated. In another embodiment, a second collection reservoir can be provided which does not contain the GOx enzyme. This second reservoir can serve as an internal reference (blank) for the sensing device, where a biosensor is used to measure the “blank” signal from the reference reservoir which signal is then used in a blank subtraction step as described below.
  • A generalized method for continual monitoring of a physiological analyte is disclosed in International Publication No. WO 97/24059, published 10 Jul. 1997, which publication is incorporated herein by reference. As noted in that publication, the analyte is extracted into a reservoir containing a hydrogel which is preferably comprised of a hydrophilic material of the type described in International Publication No. WO 97/02811, published 30 Jan. 1997, which publication is incorporated herein by reference. Suitable hydrogel materials include polyethylene oxide, polyacrylic acid, polyvinylalcohol and related hydrophilic polymeric materials combined with water to form an aqueous gel.
  • In the above non-invasive glucose monitoring device, a biosensor electrode is positioned on a surface of the hydrogel opposite the surface contacting the skin. The sensor electrode acts as a detector which detects current generated by hydrogen peroxide in the redox reaction, or more specifically detects current which is generated by the electrons generated by the redox reaction catalyzed by the platinum surface of the electrode. The details of such electrode assemblies and devices for iontophoretic extraction of glucose are disclosed in International Publication No. WO 96/00110, published 4 Jan. 1996, and International Publication No. WO 97/10499, published 2 Mar. 1997, which publications are also incorporated herein by reference.
  • Referring now to FIGS. 1A and 1B, an iontophoretic collection reservoir and electrode assembly for use in a transdermal sensing device is generally indicated at 2. The assembly comprises two iontophoretic collection reservoirs, 4 and 6, each having a conductive medium 8, and 10 (preferably cylindrical hydrogel pads), respectively disposed therein. First (12) and second (14) ring-shaped iontophoretic electrodes are respectively contacted with conductive medium 8 and 10. The first iontophoretic electrode 12 surrounds three biosensor electrodes which are also contacted with the conductive medium 8, a working electrode 16, a reference electrode 18, and a counter electrode 20. A guard ring 22 separates the biosensor electrodes from the iontophoretic electrode 12 to minimize noise from the iontophoretic circuit. Conductive contacts provide communication between the electrodes and an associated power source and control means as described in detail below. A similar biosensor electrode arrangement can be contacted with the conductive medium 10, or the medium can not have a sensor means contacted therewith.
  • Referring now to FIG. 2, an exploded view of the key components from a preferred embodiment of an iontophoretic sampling system is presented. In FIG. 2, the iontophoretic collection reservoir and electrode assembly 2 of FIGS. 1A and 1B is shown in exploded view in combination with a suitable iontophoretic sampling device housing 32. The housing can be a plastic case or other suitable structure which preferably is configured to be worn on a subjects arm in a manner similar to a wrist watch. As can be seen, conductive media 8 and 10 (hydrogel pads) are separable from the assembly 2; however, when the assembly 2 and the housing 32 are assembled to provide an operational iontophoretic sampling device 30, the media are in contact with the electrodes to provide a electrical contact therewith.
  • In one embodiment, the electrode assemblies can include bimodal electrodes as shown in FIG. 3.
  • Referring now to FIG. 5, an exploded view of the key components from one embodiment of an iontophoretic sampling system (e.g., one embodiment of an autosensor assembly) is presented. The sampling system components include two biosensor/iontophoretic electrode assemblies, 504 and 506, each of which have an annular iontophoretic electrode, respectively indicated at 508 and 510, which encircles a biosensor 512 and 514. The electrode assemblies 504 and 506 are printed onto a polymeric substrate 516 which is maintained within a sensor tray 518. A collection reservoir assembly 520 is arranged over the electrode assemblies, wherein the collection reservoir assembly comprises two hydrogel inserts 522 and 524 retained by a gel retaining layer 526 and a mask layer 528.
  • In one embodiment, the electrode assemblies can include bimodal electrodes as shown in FIG. 3. Modifications and additions to the embodiment of FIG. 5 will be apparent to those skilled in the art in light of the teachings of the present specification.
  • The components described herein are intended for use in a automatic sampling device which is configured to be worn like an ordinary wristwatch. As described in International Publication No. WO 96/00110, published 4 Jan. 1996, the wristwatch housing (not shown) contains conductive leads which communicate with the iontophoretic electrodes and the biosensor electrodes to control cycling and provide power to the iontophoretic electrodes, and to detect electrochemical signals produced at the biosensor electrode surfaces. The wristwatch housing can further include suitable electronics (e.g., microprocessor, memory, display and other circuit components) and power sources for operating the automatic sampling system.
  • Modifications and additions to the embodiment of FIG. 2 will be apparent to those skilled in the art in light of the teachings of the present specification.
  • A power source (e.g., one or more rechargeable or nonrechargeable batteries) can be disposed within the housing 32 or within the straps 34 which hold the device in contact with a skin or mucosal surface of a subject. In use, an electric potential (either direct current or a more complex waveform) is applied between the two iontophoretic electrodes 12 and 14 such that current flows from the first iontophoretic electrode 12, through the first conductive medium 8 into the skin or mucosal surface, and then back out through the second conductive medium 10 to the second iontophoretic electrode 14. The current flow is sufficient to extract substances including an analyte of interest through the skin into one or both of collection reservoirs 4 and 6. The electric potential may be applied using any suitable technique, for example, the applied current density may be in the range of about 0.01 to 0.5 mA/cm2. In a preferred embodiment, the device is used for continual or continuous monitoring, and the polarity of iontophoretic electrodes 12 and 14 is alternated at a rate of about one switch every 10 seconds to about one switch every hour so that each electrode is alternately a cathode or an anode. The housing 32 can further include an optional temperature sensing element (e.g., a thermistor, thermometer, or thermocouple device) which monitors the temperature at the collection reservoirs to enable temperature correction of sensor signals as described in detail below. The housing can also include an optional conductance sensing element (e.g., an integrated pair of electrodes) which monitors conductance at the skin or mucosal surface to enable data screening correction or invalidation of sensor signals as also described in detail below.
  • After a suitable iontophoretic extraction period, one or both of the sensor electrode sets can be activated in order to detect extracted substances including the analyte of interest. Operation of the iontophoretic sampling device 30 is controlled by a controller 36 (e.g., a microprocessor), which interfaces with the iontophoretic electrodes, the sensor electrodes, the power supply, the optional temperature and/or conductance sensing elements, a display and other electronics. For example, the controller 36 can include a programmable a controlled circuit source/sink drive for driving the iontophoretic electrodes. Power and reference voltage are provided to the sensor electrodes, and signal amplifiers can be used to process the signal from the working electrode or electrodes. In general, the controller discontinues the iontophoretic current drive during sensing periods. A sensor confidence loop can be provided for continually monitoring the sampling system to insure proper operations.
  • In a further aspect, the sampling device can operate in an alternating polarity mode using first and second bimodal electrodes (FIG. 4, 40 and 41) and two collection reservoirs (FIG. 4, 47 and 48). Each bi-modal electrode (FIG. 3, 30; FIG. 4, 40 and 41) serves two functions depending on the phase of the operation: (1) an electro-osmotic electrode (or iontophoretic electrode) used to electrically draw analyte from a source into a collection reservoir comprising water and an electrolyte, and to the area of the electrode subassembly; and (2) as a counter electrode to the first sensing electrode at which the chemical compound is catalytically converted at the face of the sensing electrode to produce an electrical signal.
  • The reference (FIG. 4, 44 and 45; FIG. 3, 32) and sensing electrodes (FIG. 4, 42 and 43; FIG. 3, 31), as well as, the bimodal electrode (FIG. 4, 40 and 41; FIG. 3, 30) are connected to a standard potentiostat circuit during sensing. In general, practical limitations of the system require that the bimodal electrode will not act as both a counter and iontophoretic electrode simultaneously.
  • The general operation of an iontophoretic sampling system is the cyclical repetition of two phases: (1) a reverse-iontophoretic phase, followed by a (2) sensing phase. During the reverse iontophoretic phase, the first bimodal electrode (FIG. 4, 40) acts as an iontophoretic cathode and the second bimodal electrode (FIG. 4, 41) acts as an iontophoretic anode to complete the circuit. Analyte is collected in the reservoirs, for example, a hydrogel (FIG. 4, 47 and 48). At the end of the reverse iontophoretic phase, the iontophoretic current is turned off. During the sensing phase, in the case of glucose, a potential is applied between the reference electrode (FIG. 4, 44) and the sensing electrode (FIG. 4, 42). The chemical signal reacts catalytically on the catalytic face of the first sensing electrode (FIG. 4. 42) producing an electrical current, while the first bi-modal electrode (FIG. 4, 40) acts as a counter electrode to complete the electrical circuit.
  • The electrode described is particularly adapted for use in conjunction with a hydrogel collection reservoir system for monitoring glucose levels in a subject through the reaction of collected glucose with the enzyme glucose oxidase present in the hydrogel matrix.
  • The bi-modal electrode is preferably comprised of Ag/AgCl. The electrochemical reaction which occurs at the surface of this electrode serves as a facile source or sink for electrical current. This property is especially important for the iontophoresis function of the electrode. Lacking this reaction, the iontophoresis current could cause the hydrolysis of water to occur at the iontophoresis electrodes causing pH changes and possible gas bubble formation. The pH changes to acidic or basic pH could cause skin irritation or burns. The ability of an Ag/AgCl electrode to easily act as a source of sink current is also an advantage for its counter electrode function. For a three electrode electrochemical cell to function properly, the current generation capacity of the counter electrode should not limit the speed of the reaction at the sensing electrode. In the case of a large sensing electrode, the counter electrode should be able to source proportionately larger currents.
  • The design of the sampling system provides for a larger sensing electrode (see for example, FIG. 3) than previously designed. Consequently, the size of the bimodal electrode should be sufficient so that when acting as a counter electrode with respect to the sensing electrode the counter electrode does not become limiting the rate of catalytic reaction at the sensing electrode catalytic surface.
  • Two methods exist to ensure that the counter electrode does not limit the current at the sensing electrode: (1) the bi-modal electrode is made much larger than the sensing electrode, or (2) a facile counter reaction is provided.
  • During the reverse iontophoretic phase, the power source provides a current flow to the first bi-modal electrode to facilitate the extraction of the chemical signal into the reservoir. During the sensing phase, the power source is used to provide voltage to the first sensing electrode to drive the conversion of chemical signal retained in reservoir to electrical signal at the catalytic face of the sensing electrode. The power source also maintains a fixed potential at the electrode where, for example hydrogen peroxide is converted to molecular oxygen, hydrogen ions, and electrons, which is compared with the potential of the reference electrode during the sensing phase. While one sensing electrode is operating in the sensing mode it is electrically connected to the adjacent bimodal electrode which acts as a counter electrode at which electrons generated at the sensing electrode are consumed.
  • The electrode sub-assembly can be operated by electrically connecting the bimodal electrodes such that each electrode is capable of functioning as both an iontophoretic electrode and counter electrode along with appropriate sensing electrode(s) and reference electrode(s), to create standard potentiostat circuitry.
  • A potentiostat is an electrical circuit used in electrochemical measurements in three electrode electrochemical cells. A potential is applied between the reference electrode and the sensing electrode. The current generated at the sensing electrode flows through circuitry to the counter electrode (i.e., no current flows through the reference electrode to alter its equilibrium potential). Two independent potentiostat circuits can be used to operate the two biosensors. For the purpose of the present sampling system, the electrical current measured at the sensing electrode subassembly is the current that is correlated with an amount of chemical signal.
  • With regard to continual operation for extended periods of time, Ag/AgCl electrodes are provided herein which are capable of repeatedly forming a reversible couple which operates without unwanted electrochemical side reactions (which could give rise to changes in pH, and liberation of hydrogen and oxygen due to water hydrolysis). The Ag/AgCl electrodes of the present sampling system are thus formulated to withstand repeated cycles of current passage in the range of about 0.01 to 1.0 mA per cm2 of electrode area. With regard to high electrochemical purity, the Ag/AgCl components are dispersed within a suitable polymer binder to provide an electrode composition which is not susceptible to attack (e.g., plasticization) by components in the collection reservoir, e.g., the hydrogel composition. The electrode compositions are also formulated using analytical- or electronic-grade reagents and solvents, and the polymer binder composition is selected to be free of electrochemically active contaminants which could diffuse to the biosensor to produce a background current.
  • Since the Ag/AgCl iontophoretic electrodes must be capable of continual cycling over extended periods of time, the absolute amounts of Ag and AgCl available in the electrodes, and the overall Ag/AgCl availability ratio, can be adjusted to provide for the passage of high amounts of charge. Although not limiting in the sampling system described herein, the Ag/AgCl ratio can approach unity. In order to operate within the preferred system which uses a biosensor having a geometric area of 0.1 to 3 cm2, the iontophoretic electrodes are configured to provide an approximate electrode area of 0.3 to 1.0 cm2, preferably about 0.85 cm2. These electrodes provide for reproducible, repeated cycles of charge passage at current densities ranging from about 0.01 to 1.0 mA/cm2 of electrode area. More particularly, electrodes constructed according to the above formulation parameters, and having an approximate electrode area of 0.85 cm2, are capable of a reproducible 5 total charge passage (in both anodic and cathodic directions) of 270 mC, at a current of about 0.3 mA (current density of 0.35 mA/cm2) for 48 cycles in a 24 hour period.
  • Once formulated, the Ag/AgCl electrode composition is affixed to a suitable rigid or flexible nonconductive surface as described above with respect to the biosensor electrode composition. A silver (Ag) underlayer is first applied to the surface in order to provide uniform conduction. The Ag/AgCl electrode composition is then applied over the Ag underlayer in any suitable pattern or geometry using various thin film techniques, such as sputtering, evaporation, vapor phase deposition, or the like, or using various thick film techniques, such as film laminating, electroplating, or the like. Alternatively, the Ag/AgCl composition can be applied using screen printing, pad printing, inkjet methods, transfer roll printing, or similar techniques. Preferably, both the Ag underlayer and the Ag/AgCl electrode are applied using a low temperature screen print onto a polymeric substrate. This low temperature screen print can be carried out at about 125 to 160° C, and the screening can be carried out using a suitable mesh, ranging from about 100-400 mesh.
  • User control can be carried out using push buttons located on the housing 32, and an optional liquid crystal display (LCD) can provide visual prompts, readouts and visual alarm indications. The microprocessor generally uses a series of program sequences to control the operations of the sampling device, which program sequences can be stored in the microprocessor's read only memory (ROM). Embedded software (firmware) controls activation of measurement and display operations, calibration of analyte readings, setting and display of high and low analyte value alarms, display and setting of time and date functions, alarm time, and display of stored readings. Sensor signals obtained from the sensor electrodes are processed before storage and display by one or more signal processing functions or algorithms which are described in detail below. The microprocessor can also include an electronically erasable, programmable, read only memory (EEPROM) for storing calibration parameters (as described in detail below), user settings and all downloadable sequences.
  • Step B: Data Screening Methodologies.
  • The raw signal obtained from the above-described glucose monitoring device can be screened to detect deviations from expected behavior which are indicative of poor or incorrect signals that will not correlate with blood glucose. Signals that are identified as poor or incorrect in this data screen may be discarded or otherwise corrected for prior to any signal processing and/or conversion in order to maintain data integrity. In the method of the invention, an objective set of selection criteria is established which can then be used to accept or discard signals from the sensing device. These selection criteria are device- and analyte-specific, and can be arrived at empirically by way of testing various devices in particular applications.
  • In the particular context of transdermal blood glucose monitoring using iontophoretic extraction and electrochemical detection, the following data screens can be employed. As discussed above, the iontophoretic extraction device can include two collection reservoirs. Thus, in active/blank systems, wherein one reservoir is active (contains the GOx enzyme) and one reservoir is blank, each reservoir contains an iontophoretic electrode and a sensing electrode. Signals from both the active and the blank reservoirs are screened, and an error in either the active, or the active and blank signal can be used to invalidate or correct the measurement from the cycle. In multiple active systems (wherein two or more reservoirs contain the GOx enzyme and iontophoretic and sensing electrodes), signals from one or more of the active reservoirs are screened, and an error can be used to invalidate or correct the measurement from the cycle.
  • As with any chemical sensing method, transient changes in temperature during or between measurement cycles, or between measurements of blank and active signals, can alter background signal, reaction constants and/or diffusion coefficients. Accordingly, a temperature sensor is used to monitor changes in temperature over time. A maximum temperature change over time (d(temp)/d(time)) threshold value can then be used in a data screen to invalidate a measurement. Such a threshold value can, of course, be set at any objective level, which in turn can be empirically determined depending upon the particular extraction/sensing device used, how the temperature measurement is obtained, and the analyte being detected. Absolute temperature threshold criteria can also be employed, wherein detection of high and/or low temperature extremes can be used in a data screen to invalidate a measurement. Temperature monitoring can be carried out using a separate, associated temperature sensing device, or, preferably using a temperature sensor that is integral with the sensing device. A large number of temperature sensing elements are known in the art (e.g., thermometers, thermistors, thermocouples, and the like) which can be used to monitor the temperature in the collection reservoirs.
  • Another data screen entails monitoring physiological conditions in the biological system, particularly monitoring for a perspiration threshold. In this regard, perspiration contains glucose, and perspiration occurring rapidly and in sufficient quantities may affect the detected signal either before or during biosensor measurement. Accordingly, a sensor can be used to monitor perspiration levels for a given measurement cycle at time points before, during, and/or after iontophoresis, and before, during, and/or after glucose sensing. Detection of perspiration levels that exceed an objective threshold is then used in a data screen to invalidate poor measurements. Although a number of different mechanisms can be used, skin conductance can be readily measured with a device contacted with the skin. Skin conductivity is related to perspiration. In one embodiment, if skin conductance as measured by a conductivity detector is greater than a predetermined level, then the corresponding measurement is invalidated.
  • Yet further data screens which are used in the practice of the invention take into consideration the expected behavior of the sampling/sensing device. In iontophoretic sampling, for example, there is a skin equilibration period before which measurements will generally be less accurate. During this equilibration period, the system voltage can be assessed and compared against an objective high voltage threshold. If this high voltage limit is exceeded, a data screen is used to exclude the corresponding analyte measurement, since the iontophoretic current was not at a target value due to high skin resistance (as indicted by the high voltage level).
  • In addition, the electrochemical signal during each sensing cycle is expected to behave as a smooth, monotonically decreasing signal which represents depletion of the hydrogen peroxide by the sensor electrode. Significant departure from this expected behavior is indicative of a poor or incorrect measurement (e.g., a non-monotonically decreasing signal is indicative of excessive noise in the biosensor signal), and thus monitoring signal behavior during sensing operations provides yet a further data screen for invalidating or correcting measurements.
  • Raw signal thresholds can also be used in the data screening method of the present invention. For example, any sensor reading that is less than some minimum threshold can indicate that the sampling/sensing device is not operating correctly, for example, where the biosensor electrode is disconnected. In addition, any chemical sensor will have a maximum range in which the device can operate reliably. A reading greater than some maximal value, then, indicates that the measurement is off-scale, and thus possibly invalid. Accordingly, minimum and maximum signal thresholds are used herein as data screens to invalidate or correct measurements. Such minimum and maximum thresholds can likewise be applied to background measurements.
  • A general class of screens can be applied that detect changes in signal, background, or voltage measurements. These screens are useful to assess the consistency of measurements and can detect problems or inconsistencies in the measurements. Error messages can be relayed to a display screen on the monitoring device, and/or, recorded to a log. Examples of such screens include the following:
  • (i) signal—Peak Stability. A large change in the peak of a sensor reading indicates a noisy signal. The peak of any given cathodal half cycle is defined as the difference between the first biosensor point and the temperature corrected average of the last two points from the previous anodal half cycle. If the percentage difference between successive peaks from the same sensor is greater than a predetermined value, for example, 30%, then an error is indicated.
  • (ii) background—Background Precision. Divergent readings at the end of biosensing indicate an unstable biosensor signal. Because these readings are used to assess background current for a particular cycle, an unstable signal may lead to an erroneous data point. If the difference between the last two anodal points (where the last two anodal points are typically the last two biosensor currents measured after anodal extraction) used to calculate the baseline is greater than or equal to a predetermined value, for example, 6 nA (or, e.g., a percentage of the first anodal point relative to the second anodal point), then an error is indicated.
  • (iii) background—Background Stability. This check is to determine if the background current is changing too excessively, which indicates a noisy signal and can result in inaccurate glucose readings. If the percentage difference between successive background measurements is greater than or equal to a predetermined value, for example, 15%, then an error is indicated.
  • (iv) voltage—Voltage Stability. If the glucose monitoring device is mechanically disturbed, there can be a larger change (e.g., larger relative to when the monitor is functioning under normal conditions) in iontophoresis voltage. This could lead to an aberrant reading. If the percentage difference between successive cathodal or anodal iontophoresis voltages is grater than a predetermined value, for example, 15%, then an error is indicated.
  • (v) voltage—Reference Electrode Check. When the electrode assembly includes a reference electrode (as when, for example, a bimodal electrode is employed) this check establishes the connectivity of the reference electrode to the sampling device and to the working electrode. The biosensor is activated such that a current should flow from the working electrode to the reference electrode. If the current measured is less than a threshold value, then an error is indicated and the measurement sequence can be terminated.
  • As will be appreciated by one of ordinary skill in the art upon reading this specification, a large number of other data screens can be employed without departing from the spirit of the present invention.
  • Step C: The Conversion Step.
  • Continuing with the method of the invention, the above-described iontophoretic sampling device is used to extract the analyte from the biological system, and a raw amperometric signal (e.g., nanoampere (nA) signal) is generated from the associated electrochemical biosensor device. This raw signal can optionally be subjected to a data screening step (Step B) to eliminate poor or incorrect signals, or can be entered directly into a conversion step to obtain an initial signal output which is indicative of the amount of analyte extracted by the sampling system.
  • I. Ways of Obtaining Integrated Signals
  • 1. Baseline Background.
  • In one embodiment, the raw or screened raw signal is processed in the conversion step in order to remove or correct for background information present in the signal. For example, many sensor devices will have a signal whether or not an analyte of interest is present, i.e., the background signal. One such background signal is the “baseline background,” which, in the context of electrochemical detection, is a current (nA) generated by the sensing device independent of the presence or absence of the analyte of interest. This baseline background interferes with measurement of analyte of interest, and the amount of baseline background can vary with time, temperature and other variable factors. In addition, electrochemically active interfering species and/or residual analyte can be present in the device which will further interfere with measurement of the analyte of interest.
  • This background can be transient background, which is a current generated independent of the presence or absence of the analyte of interest and which decreases over the time of sensor activation on the time scale of a measurement, eventually converging with the baseline background signal.
  • Accordingly, in one embodiment of the invention, a baseline background subtraction method is used during the conversion step in order to reduce or eliminate such background interferences from the measured initial signal output. The subtraction method entails activation of the electrochemical sensor for a sufficient period of time to substantially reduce or eliminate residual analyte and/or electrochemical signal that is not due to the analyte (glucose). After the device has been activated for a suitable period of time, and a stable signal is obtained, a measurement is taken from the sensor which measurement can then be used to establish a baseline background signal value. This background signal value is subtracted from an actual signal measurement value (which includes both analyte-specific and background components) to obtain a corrected measurement value. This baseline background subtraction method can be expressed using the following function:
    i(τ)=i raw(τ)−i bkgnd(τ)
    wherein: (iraw(τ)) is the current measured by the sensor (in nA) at time τ; (τ) is the time after activation of the sensor; (ibkgnd(τ)) is the background current (in nA); and (i(τ)) is the corrected current (in nA). Measurement of the baseline background signal value is taken close in time to the actual signal measurement in order to account for temperature fluctuations, background signal drift, and like variables in the baseline background subtraction procedure. The baseline background signal value can be integrated for use with coulometric signal processing, or used as a discrete signal value in amperometric signal processing. In particular embodiments of the invention, continual measurement by the iontophoretic sampling device provides a convenient source for the baseline background measurement, that is, after an initial measurement cycle has be completed, the baseline background measurement can be taken from a previous measurement (sensing) cycle.
  • 2. Temperature Correcting Baseline Background.
  • In yet another embodiment of the invention, the conversion step is used to correct for changing conditions in the biological system and/or the biosensor system (e.g., temperature fluctuations in the biological system, temperature fluctuations in the biosensor element, or combinations thereof). Temperature can affect the signal in a number of ways, such as by changing background, reaction constants, and/or diffusion coefficients. Accordingly, a number of optional temperature correction functions can be used in order to reduce these temperature-related effects on the signal.
  • In order to correct for the effect that temperature fluctuations or differences may have on the baseline background subtracted signal, the following temperature correction step can be carried out. More particularly, to compensate for temperature fluctuations, temperature measurements can be taken at each measurement time point within the measurement cycle, and this information can be used to base a temperature correction algorithm which adjusts the background current at every time point depending on the difference in temperature between that time point and the temperature when the previous background current was measured. This particular temperature correction algorithm is based on an Arrhenius relationship between the background current and temperature.
  • The temperature correction algorithm assumes an Arrhenius-type temperature dependence on the background current, such as: i bkgrid = A exp [ - K 1 T ]
    wherein: (ibkgnd) is the background current; (A) is a constant; (K1) is termed the “Arrhenius slope” and is an indication of how sensitive the current is to changes in temperature; and (T) is the temperature in ° K.
  • Plotting the natural log of the background current versus the reciprocal of temperature provides a linear function having a slope of (−K1). Using a known or derived value of K1 allows the baseline current at any time (τ) to be corrected using the following function (which is referred to herein as the “K1 temperature correction”): i bkgnd , corrected = i bkgnd , τ 0 exp [ - K 1 ( 1 T τ - 1 T τ 0 ) ]
    wherein: (ibkgnd, corrected) is the temperature corrected baseline current; (ibkgnd, τ0) is the baseline current at some reference temperature Tτ0, for example, the baseline background measurement temperature; (K1) is the temperature correction constant; and (Tτ) is the temperature at time τ. For the purposes of the invention, (ibkgnd, τ0) is usually defined as the “previous” baseline current. As can be seen, instead of making a time-independent estimation of the baseline current, the K1 temperature correction adjusts the baseline current in an Arrhenius fashion depending upon whether the temperature increases or decreases during or between biosensor cycles. Determination of the constant K1 can be obtained by plotting the natural log of the background current versus the reciprocal of the temperature for a learning set of data, and then using a best fit analysis to fit this plot with a line having a slope (−K1).
  • Raw or screened amperometric signals from Step A or Step B, respectively (whether or not subjected to the above-described baseline background subtraction and/or K1 temperature correction), can optionally be refined in the conversion step to provide integrated coulometric signals. In one particular embodiment of the invention, any of the above amperometric signals (e.g., the current generated by the sensor) can be converted to a coulometric signal (nanocoulombs (nC)) , which represents the integration of the current generated by the sensor over time to obtain the charge that was produced by the electrochemical reaction.
  • In one embodiment, integration is carried out by operating the biosensor in a coulometric (charge-measuring) mode. Measuring the total amount of charge that passes through the biosensor electrode during a measurement period is equivalent to mathematically integrating the current over time. By operating in the coulometric mode, changes in diffusion constants resulting from temperature fluctuations, possible changes in the diffusion path length caused by uneven or non-uniform reservoir thickness, and changes in sensor sensitivity, have little effect on the integrated signal, whereas these parameters may have a greater effect on single point (current) measurements. Alternatively, a functionally equivalent coulometric measurement can be mathematically obtained in the method of the invention by taking discrete current measurements at selected, preferably small, time intervals, and then using any of a number of algorithms to approximate the integral of the time-current curve. For example, integrated signal can be obtained as follows: Y = τ 1 τ 2 i ( τ ) τ
    wherein: (Y) is the integrated signal (in nC); and (i(τ)) is a current at time τ, and can be equal to iraw(τ) for an uncorrected raw signal, or iraw(τ)−ibkgnd(τ) for a baseline background subtracted signal, or iraw(τ)−i bkgnd, corrected(τ) for a baseline background subtracted and temperature corrected signal.
  • 3. Temperature Correction of Active versus Blank Integrals.
  • An additional temperature correction algorithm can be used herein to compensate for temperature dependence of a transient background (blank) signal. That is, in the active/blank sampling system exemplified hereinabove, the analyte measurement (blood glucose) is generated by integrating an active signal and subtracting therefrom a blank signal (see the blank subtraction method, infra). The blank integral may be “artifactually” high or low depending upon whether blank signal was measured at a higher or lower temperature than the active signal. In order to normalize the blank integral to the temperature at which the active signal was measured, the following function can be used (which is referred to herein as the “K2 temperature correction”): Y blank , corrected = Y blank exp [ - K 2 ( 1 T act n _ - 1 T blank n _ ) ]
    wherein: (Yblank, corrected) is the corrected blank integral; (Yblank) is the uncorrected blank integral (in nC); (K2) is the “blank integral correction constant”; and (Tn act) and (Tn blank) are the average temperature of the active and blank signal, respectively. The average temperature is obtained from averaging the first n temperatures, such that (n) is also an adjustable parameter. Determination of the constant K2 can be obtained from an Arrhenius plot of the log of the blank integral against 1/Tn blank, using the reciprocal of the average of the first n temperature values, and then using a best fit analysis to fit this plot with a line having a slope (−K2).
  • Alternative temperature corrections which can be performed during the conversion step are as follows. In one embodiment, an integral average temperature correction is used wherein, for each measurement cycle, the integral average temperature is determined by the function: < T >= 1 T f 0 T f T t
    and then correcting for the temperature at subsequent time points using the function: Y t , corrected = Y t exp [ - a ( < T t > - < T ref > < T ref > ) ]
    wherein: (Yt) is the uncorrected signal at time t; (Yt, corrected) is the corrected signal at time t; (<T t>) is the integral average temperature at time t; (<Tref>) is the integral average temperature at the reference time (e.g., the calibration time); (t) is the time after sensor measurement is first initiated; and (a) is an adjustable parameter which is fit to the data.
  • In other embodiments, temperature correction functions can be used to correct for temperature differences between multiple active signals, or between active and blank signals. For example, in the active/blank sensing device exemplified herein, blank subtraction is used to cancel out much of the temperature-dependence in the active signal. However, temperature transients during the monitoring period will result in varying background currents, which can result in signal errors when the current is multiplied by the total integration time in the instant conversion step. This is particularly true where the active and blank integrals are disjointed in time, and thus possibly comprised of sets of background current values that occurred at different temperatures.
  • 4. Anodal Subtraction.
  • In yet another alternative temperature correction, temperature measurements taken in the active and blank reservoirs at alternating anodal and cathodal phases during a measurement cycle are used in a subtraction method in order to reduce the impact of temperature fluctuations on the signals. In this regard, the active/blank reservoir iontophoretic sampling system can be run under conditions which alternate the active and blank reservoirs between anodal and cathodal phases during a measurement cycle. This allows the blank anodal signal to be measured at the same time as the active, cathode signal, and temperature variations will likely have similar impact on the two signals. The temperature correction function thus subtracts an adjusted anodal signal (taken at the same time as the cathodal signal) from the cathodal signal in order to account for the effect of temperature on the background. More particularly, a number of related temperature correction functions which involve fractional subtraction of blank anode signals can be summarized as follows: Y = Y act , cath - d * Y blank , an Y = Y act , cath - d * [ Y blank , an - ( Y act , an - Y blank , cath ) ] Y = Y act , cath - d * [ Y blank , an - ( Y act , an - Y blank , cath ) ] ave t 1 , t 2 Y = Y act , cath - d * [ Y blank , an - ( Y blank , an - Y blank , cath ) ] ave t 1 -- t 2 Y = Y act , cath - d * ( Y blank , an - AOS ) * [ Y blank , cath Y act , an - AOS ] ave t 1 , t 2 Y = Y act , cath - d * ( Y blank , an - AOS ) * [ Y blank , cath Y act , an - AOS ] ave t 1 -- t 1
    wherein: (Yact, catch) is the active signal in the cathodal phase (in nC) ; (Yblank, an) is the blank signal in the anodal phase (in nC); (Yact, an) is the active signal in the anodal phase (in nC); (Yblank, catch) is the blank signal in the cathodal phase (in nC); (Y) is the “blank anode subtracted” signal; (ave t1, t2) is the average of signals taken at two time points t1, and t2; (ave t1-t2) is the average of signals taken over the time period of t1-t2; (d) is a universal fractional weight and is generally a function of time; and (AOS) is a universal anodal offset which can be empirically obtained using standard mathematical techniques, and optionally adjusted using data taken from two previous time points, t1 and t2 (i.e., ave t1, t2) or using the average of data taken over the time period of t1-t2 (i.e., ave t1-t2).
  • In still further embodiments of the invention, the conversion step can include a blank subtraction step, combined data from two active reservoirs, and/or a smoothing step.
  • The blank subtraction step is used to subtract the blank signal from the active signal in order to remove signal components that are not related to the analyte, thus obtaining a cleaner analyte signal. When raw signal is obtained from two active reservoirs the two raw signals can be averaged or a summed value of the two raw signals can be used. In the smoothing step, mathematical transformations are carried out which individually smooth signals obtained from the active and blank collection reservoirs. These smoothing algorithms help improve the signal-to-noise ratio in the biosensor, by allowing one to correct the signal measurements obtained from the device to reduce unwanted noise while maintaining the actual signal sought.
  • More particularly, a blank subtraction step is used in the active-blank iontophoretic sampling system of the invention as follows. Signals from the blank (second) reservoir, taken at, or about the same time as signals from the active (first) reservoir, are used to substantially eliminate signal components from the active signal that are not specifically related to the analyte. In this regard, the blank reservoir contains all of the same components as the active reservoir except for the GOx enzyme, and the blank signal should thus exhibit similar electrochemical current to the active signal, except for the signal associated with the analyte. Accordingly, the following function can be used to subtract the blank signal from the active signal:
    Y t =Y t, act −d*Y t, blank
    wherein: (Yt,act) is the active signal (in nC) at time t; (Yt,blank) is the blank signal (in nC) at time t; (Yt) is the “blank subtracted” signal at time t; and (d) is the time-dependent fractional weight for the blank signal, and d preferably =1. In relation to the equation shown above that is used to subtract the blank signal from the active signal, when two active reservoirs are used d preferably=−1, or, more generally, as shown in the equation below, the summed signal can be “weighted” to account for different contributions of signal from each reservoir.
  • In the case of two active reservoirs, each reservoir is capable of generating raw signal and each contains all of the same components. For example, where two collection reservoirs are used for detecting glucose both reservoirs contain glucose oxidase. Accordingly, the following function can be used:
    Y t,ε =aY t, act1 +bY t, act2
    wherein: “a” is the time-dependent fractional weight for the first active signal; (Yt, act1) is the first active signal (in nC) at time t; “b” is the time-dependent fractional weight for the second active signal; (Yt,act2) is the second active signal (in nC) at time t; (Yt,ε) is the summed signal at time t.
  • II. General Procedures for Smoothing Integrated Signals.
  • In the smoothing step, the active signal obtained from the first (active) reservoir can be smoothed using a smoothing function. In multiple active systems, the same smoothing can be applied to each signal before summing. In one embodiment, the function can be expressed as a recursive function as follows:
    E t,act =w act Y t,act+(1−w act)(E t−1,act)
    wherein: (Yt, act) is the measurement of the active signal (in nC) at time t; (Et, act) is the estimate of the active signal (in nC) at time t for t>1 (at t=1, Et, act=Yt, act) and (wact) is the “estimate weight” for the active biosensor, wherein 0≦wact≦1.
  • The reference (blank) signal obtained from the second reservoir can also be smoothed using a similar recursive smoothing function. This function can be expressed as follows:
    E t,blank =w t,blank Y t,blank+(1−w blank)(E t−1,blank)
    wherein: (Yt, blank) is the measurement of the blank signal (in nC) at time t; (Et, blank) is the estimate of the blank signal (in nC) at time t for t>1 (at t=1, Et, blank=Yt,blank) ; and (Wblank) is the “estimate weight” for the blank biosensor, wherein 0≦wblank≦1.
  • Once the active and blank signals have been individually smoothed, the blank signal can be subtracted from the active signal in order to obtain a signal that is indicative of the glucose reaction only. As discussed above, the blank signal should exhibit a similar electrochemical current to the active signal, except for the signal associated with the glucose analyte. In the practice of the invention, this blank subtraction step can subtract the value of the smoothed blank signal per se, or a weighted blank signal can be subtracted from the active signal, using the following function to obtain a fractional subtraction:
    E t =E t, act −d*E t,blank
    wherein: (Et,act) is the estimate of the active signal (in nC) at time t; (Et, blank) is the estimate of the blank signal (in nC) at time t; (Et) is the “blank subtracted” smoothed sensor signal at time t; and (d) is the time-dependent fractional weight for the blank signal.
  • The same recursive function can be used wherein the order of the smoothing and blank subtraction steps are reversed such that: (Yt, act) is the integral of the active signal (in nC) at time t; (Yt, blank) is the integral of the blank signal (in nC) at time t; (Yt) is the “blank subtracted” sensor signal (in nC) at time t; (d) is the time-dependent fractional weight for the blank signal; and
    Y t =Y t,act −d*E t,blank
    E t =wY t+(1−w)(E t−1)
  • This smoothing can alternatively be carried out on discrete (nA) sensor signals, with or without temperature and/or background subtraction corrections. Smoothing can also be carried out on active signals or on averages of two or more active signals. Further modifications to these functions will occur to those of ordinary skill in the art, in light of the present enabling disclosure.
  • Step D: The Calibration Step.
  • Continuing with the method of the invention, any of the raw signals obtained from Step A, the screened raw signal obtained from Step B, or the initial output signal obtained from Step C (or from Steps B and C), can be converted into an analyte-specific value using a calibration step which correlates the signal obtained from the sensing device with the concentration of the analyte present in the biological system. A wide variety of calibration techniques can be used to interpret such signals. These calibration techniques apply mathematical, statistical and/or pattern recognition techniques to the problem of signal processing in chemical analyses, for example, using neural networks, genetic algorithm signal processing, linear regression, multiple-linear regression, partial linear regression, deconvolution, or principal components analysis of statistical (test) measurements.
  • One method of calibration involves estimation techniques. To calibrate an instrument using estimation techniques, it is necessary to have a set of exemplary measurements with known concentrations referred to as the calibration set (e.g., reference set). This set consists of m samples, each with n instrument variables contained in an m by n matrix (X), and an m by 1 vector (y), containing the concentrations. If a priori information indicates the relationship between the measurement and concentration is linear, the calibration will attempt to determine an n by 1 transformation or mapping (b), such that
    y=Xb
    is an optimal estimate of y according to a predefined criteria. Numerous suitable estimation techniques useful in the practice of the invention are known in the art. These techniques can be used to provide constant parameters, which can then be used in a mathematical transformation to obtain a measurement value indicative of the concentration of analyte present in the biological system at the times of measurement.
  • In one particular embodiment, the calibration step may be carried out using artificial neural networks or genetic algorithms. The structure of a particular neural network algorithm used in the practice of the invention can vary widely; however, the network should contain an input layer, one or more hidden layers, and one output layer. Such networks can be optimized on training data set, and then applied to a population. There are an infinite number of suitable network types, transfer functions, training criteria, testing and application methods, which will occur to the ordinarily skilled artisan upon reading the instant specification.
  • In the context of the iontophoretic glucose sampling device described hereinabove (which can contain an active collection reservoir—with the GOx enzyme, and a blank collection reservoir; or alternately, two active reservoirs with the GOx enzyme), a preferred neural network algorithm would use, for example, inputs selected from the following to provide a blood glucose measurement: elapsed time since calibration; signal from the active reservoir; signal from the blank reservoir; signal from two active reservoirs (either averaged or summed); calibration time; measured temperature; applied iontophoretic voltage; skin conductance; blood glucose concentration, determined by an independent means, at a defined calibration point; background; background referenced to calibration; and, when operating in the training mode, measured glucose.
  • Whether or not the calibration step is carried out using conventional statistical techniques or neural network algorithms, the calibration step can include a universal calibration process, a single-point calibration process, or a multi-point calibration process. In one embodiment of the invention, a universal calibration process is used, wherein the above mathematical techniques are used to derive a correlation factor (or correlation algorithm) that allows for accurate, dependable quantification of analyte concentration by accounting for varying backgrounds and signal interferences irrespective of the particular biological system being monitored. In this regard, the universal calibrant is selected to provide a close correlation (i.e., quantitative association) between a particular instrument response and a particular analyte concentration, wherein the two variables are correlated.
  • In another embodiment, a single-point calibration is used. More particularly, the single-point calibration process can be used to calibrate measurements obtained by iontophoretic sampling methodologies using a reference measurement obtained by conventional (invasive) methods. Single-point calibration allows one to account for variables that are unique to the particular biological system being monitored, and the particular sensing device that is being used. In this regard, the transdermal sampling device is generally contacted with the biological system (placed on the surface of a subject's skin) upon waking. After the device is put in place, it is preferable to wait a period of time in order allow the device to begin normal operations.
  • Further, the sampling system can be pre-programmed to begin execution of its signal measurements (or other functions) at a designated time. One application of this feature is to have the sampling system in contact with a subject and to program the sampling system to begin sequence execution during the night so that it is available for calibration immediately upon waking. One advantage of this feature is that it removes any need to wait for the sampling system to warm-up before calibrating it.
  • In the context of glucose monitoring, a blood sample can be extracted when the device has attained normal operations, such that the invasive blood sample extraction is taken in a corresponding time period with a measurement cycle. Actual blood glucose levels can then be determined using any conventional method (e.g., calorimetric, electrochemical, spectrophotometric, or the like) to analyze the extracted sample. This actual value is then used as a reference value in the single-point calibration process, wherein the actual value is compared against the corresponding measured value obtained with the transdermal sampling device. In yet another embodiment, a multi-point calibration process is used, wherein the above-described single-point calibration process is repeated at least once to provide a plurality of point calibrations. For example, the multi-point calibration process can be carried out at various time intervals over the course of a continual or continuous measuring period.
  • Continuing with the calibration step, the signals obtained from Step B and/or Step C, supra, can be subjected to further signal processing prior to calibration as follows. Referring particularly to the baseline background subtraction method of the conversion step (Step C), the corrected signal should theoretically be directly proportional to the amount of analyte (glucose) present in the iontophoretically extracted sample. However, sometimes a non-zero intercept is obtained in the correlation between signal and reference glucose value. Accordingly, a constant offset term (which can be positive or negative) is obtained which can be added to the converted signal to account for a non-zero signal at an estimated zero blood glucose concentration. The offset can be added to the active sensor signal; or, in the case of an iontophoretic sampling system that obtains both active and blank signals, the offset can be added to the blank-subtracted active signal.
  • The calibration step can be carried out using, for example, the single-point calibration method described hereinabove. The reference blood glucose concentration thus obtained can then be used in the following conversion factor: b gain = BG c a l + ρ E c a l + OS
    wherein: (Ecal) is the blank-subtracted smoothed sensor signal (in nC) at calibration; (BGcal) is the reference blood glucose concentration (in mg/dL) at calibration; (bgain) is the conversion factor [(mg/dL)/nC]; (OS) is the offset calibration factor constant (in nC) which can be calculated using standard regression analysis; and (ρ) is the calibration offset (in mg/dL). Post calibration data can then be converted using the following function:
    EG t =b gain [E t +OS]−ρ
    wherein (EGt) is the estimated blood glucose concentration (in mg/dL). Other signal values, such as Yt, can be substituted for Et, and Ecal depending upon the amount of prior signal processing performed (see, e.g., Step C, supra).
  • Further signal processing can also be used to correct for time-dependent behavior related to the particular sensor element that is used in the sensing operation. In this regard, signal measurements of certain types (such as the electrochemical signal measurements described herein) exhibit change over time for reasons which are not fully understood. The present invention is not premised on any particular theory with respect to why such time-dependent change occurs. Rather, the invention recognizes that time-dependent behavior can occur, and corrects for this behavior using one or more mathematical functions.
  • Thus, in one embodiment, a corrected measurement can be calculated using a mathematical function which compensates for time-dependent decline in the biosensor signal between measurements during the period of continual or continuous measuring of the analyte concentration. The correction function uses one or more additive decay parameters (αi) and one or more multiplicative decay parameters (εi), (both of which are empirically determined for the biosensor),,and can be expressed as follows: EG t = b gain [ E t ( 1 + ε i t ) + OS ] + α i t - ρ wherein : b gain = BG c a l + ρ - α i t c a l E c a l ( 1 + ε i t c a l ) + OS
    and (tcal) is the calibration point; (EGt) is the estimated blood glucose concentration at time t; (Et) is the analyte signal at time t; (OS) is the constant offset term which accounts for a non-zero signal at an estimated zero blood glucose concentration (as described above); (ε) is a gain term for time-dependent signal decline and can have multiple time segments (e.g., i=1, 2, or 3); (α) is a correction term for a linear time-dependent signal decline in the time segments and can have multiple time segments (e.g., i=1, 2, or 3) ; (t) is the elapsed time, and (ρ) is the calibration offset (in mg/dl).
  • In an alternative embodiment, a corrected measurement can be calculated using a mathematical function which compensates for time-dependent decline in the biosensor signal between measurements, during the period of continual or continuous measuring of the analyte concentration, by correlating signal at the beginning of the measurement series to a unit of decay. The correction function uses an additive decay parameter (α) and a decay correction factor (γ). This equation allows a time-dependent multiplicative correction to be applied to the integrated signal in a manner that amplifies, to a greater extent, those signals that have been observed to decay at a greater rate (e.g., empirically, signals that give lower BGain tend to decay faster). Use of the BGAIN factor, as described herein, can insure that a reasonable calibration factor is obtained.
  • In this embodiment, EGt, the calculated value of blood glucose at the measurement time, is computed as follows: EG t = ( [ BG c a l - α t c a l E c a l + OS - γ t c a l ] + γ t ) * ( E t + OS ) + α t where BGAIN = [ BG c a l - α t c a l E c a l + OS - γ t c a l ]
    wherein: BGcal is the true blood glucose at the calibration point; Ecal, is the analyte signal at calibration; (tcal) is the elapsed time of the calibration point; (EGt) is the estimated blood glucose concentration at time t; (Et) is the analyte signal at time t; (OS) is the constant offset term which accounts for a non-zero signal at an estimated zero blood glucose concentration (as described above); (γ) is a time-dependent correction term for signal decline; (α) is a time-dependent correction term for signal decline; and (t) is the elapsed time.
  • Employing these equations a “time segmentation” can be performed as follows: BGAIN 1 = [ BG cal - α 1 t cal E cal + OS - γ 1 t cal ] if t < t 12 BGAIN 2 = [ BG cal - α 1 t 12 - α 2 ( t cal - t 12 ) E cal + OS - γ 1 t 12 - γ 2 ( t cal - t 12 ) ] if t 12 < t cal < t 23 BGAIN 3 = [ BG cal - α 1 t 12 - α 2 ( t cal - t 12 ) - α 3 ( t cal - t 23 ) E cal + OS - γ 1 t 12 - γ 2 ( t cal - t 12 ) - γ 3 ( t cal - t 23 ) ] if t 23 < t cal EG t = ( BGAIN 1 + γ 1 t ) * ( E t + OS ) + α 1 t if t < t 12 EG t = ( BGAIN 2 + γ 1 t 12 + γ 2 ( t - t 12 ) ) * ( E t + OS ) + α 1 t 12 + α 2 ( t - t 12 ) if t 12 < t < t 23 EG t = ( BGAIN 3 + γ 1 t 12 + γ 2 ( t 23 - t 12 ) + γ 3 ( t - t 23 ) ) * ( E t + OS ) + α 1 t 12 + α 2 ( t 23 - t 12 ) + α 3 ( t - t 23 ) if t 23 < t
    wherein: EGt is the calculated value of blood glucose at the measurement time; BGcal is the true blood glucose at the calibration point, t is the elapsed time (hence tcal is the elapsed time at the calibration point), OS is the offset parameter, αi and γi are the time dependent correction terms to account for the declining signal with time. To avoid a dominant time correction term as the elapsed time increases, the time correction parameters αi and γi are distinct for three different time intervals (“i”): 0 to 6 hours (e.g., i=1), 6 to 10 hours (e.g., i=2), and 10 to 14 hours (e.g., i=3), as shown above. Therefore, t12=6 hours and t23=10 hours.
  • The time segmentation allows for greater flexibility in predicting non-linear signal decay terms.
  • The signal processing methods and techniques described in Steps A through D can be combined in a variety of ways to provide for improved signal processing during analyte measurement. In one embodiment, an active/blank sampling system is used to obtain the raw signal in Step A. These raw signals are then screened in Step B to obtain screened data. These screened data are then subjected to a temperature correction using the K1 temperature correction, and then converted using the baseline subtraction and integration methods of Step C. The converted data are also smoothed (both active and blank) using the smoothing functions of Step C, the smoothed data are temperature corrected using the K2 temperature correction, and a blank subtraction is carried out. The smoothed and corrected data are then converted to the analyte concentration in the biological system using the calibration methods of Step D to perform a single-point calibration, wherein the data is also refined using the offset and time-dependent behavior corrections to obtain a highly accurate analyte concentration value.
  • In another embodiment, if two active reservoirs (A1/A2) are used, a “sensor consistency check” can be employed that detects whether the signals from the reservoirs are changing in concert with one another. This check compares the percentage change from the calibration signal for each reservoir, then calculates the difference in percentage change in signal between the two reservoirs. If this difference is greater than some threshold, then the signals are not “tracking” one another and this data point can be screened as in Step B. This check verifies consistency between the two sensors. A large difference can indicate noise in the signals.
  • In yet another embodiment of the present invention a “Calibration Factor Check” may be employed. This check provides control over unreasonable finger prick measurements or incorrect entries and provides additional assurance that a reasonable calibration slope has been generated. Typically, there are two calibration factors that are calculated at calibration: BGAIN and CAL RATIO. If BGAIN is less than or equal to a predetermined threshold value, or if the CAL RATIO is greater than or equal to a predetermined threshold value, then a calibration error is indicated. Such an error can be displayed to the user, for example, a calibration window can appear on the monitor's display appear. Such an error indicates to the users that the user must perform the calibration again. For the Calibration Factor Check, CAL RATIO can be calculated as follows: CALRATIO = [ BG cal E cal + OS ]
    wherein, BGcal is the true blood glucose at the calibration point; Ecal is the analyte signal at calibration; and (OS) is the constant offset term which accounts for a non-zero signal at an estimated zero blood glucose concentration.
    Step E: Time Forecasting Measurements.
  • The corrected analyte value obtained using the above techniques can be used to predict future (e.g., time forecasting) or past (e.g., calibration) target analyte concentrations in the biological system. In one embodiment, a series of analyte values are obtained by performing any combination of Steps A, B, C, and/or D, supra, in an iterative manner. These measurements are then used to predict unmeasured analyte values at different points in time, future or past.
  • More particularly, the above-described iontophoretic sampling process is carried out in order to obtain three or more measurements of the target analyte. Using these measurements, an additional measurement can be calculated. The additional measurement is preferably calculated using a series function.
  • In the context of blood glucose monitoring, it has been found that the actual (real-time) glucose level in a subject differs from the measured glucose level obtained using a sampling device that extracts glucose from the subject using iontophoresis. The difference is due, in part, to a lag time between extracting the glucose analyte and obtaining a measurement from the extracted glucose. This lag time can vary depending on factors such as the particular subject using the device, the particular area of skin from which glucose is extracted, the type of collection reservoir used, and the amount of current applied. In order to compensate for this inherent lag time, the method of the present invention can utilize data obtained from previous measurements and a mathematical function in order to predict what a future analyte concentration will be. In this case, the predicted future reading can be used as a “real-time value” of the analyte level.
  • In another embodiment, mathematical methods can be used to predict past measurements, such as in the context of making a calibration. More particularly, measurements obtained using the above-described transdermal sampling device can be calibrated against one or more reference measurements obtained by conventional (blood extraction) methods. In such calibration processes, actual blood glucose levels are determined using conventional analytical methods (e.g., calorimetric, electrochemical, spectrophotometric, or the like) to analyze an extracted blood sample. These actual measurements are then compared with corresponding measurements obtained with the transdermal sampling device, and a conversion factor is then determined. In normal operations, the transdermal sampling device is generally first contacted with the biological system (placed on the surface of a subject's skin) upon waking. After the device is put in place, it is preferable to wait a period of time in order allow the device to attain normal operating parameters, after which time the device can be calibrated. However, if a blood sample is extracted at the time when the device is first applied (as would normally be most convenient), there may not be a corresponding signal from the transdermal sampling system which can be compared with the reference value obtained from the extracted blood sample This problem can be overcome using prediction methods which allow one to perform a conventional blood glucose test (via a blood sample extraction) when the device is first applied, and then calibrate the device at a later time against the results of the conventional glucose test.
  • A number of mathematical methods for predicting future or past measurements can be used in the practice of the invention. For example, linear or nonlinear regression analyses, time series analyses, or neural networks can be used to predict such measurements. However, it is preferred that a novel combination of exponential smoothing and a Taylor series analysis be used herein to predict the future or past measurement.
  • A number of other physiological variables may be predicted using the above techniques. For example, these prediction methods can be used to time forecast those physiological variables that cannot be measured in real-time, or that demonstrate frequent fluctuations in their data. Examples of physiological functions and the variables that characterize them include, but are not limited to, cerebral blood flow (in the treatment of stroke patients) which is related to blood viscosity and the concentrations of plasma proteins and clotting factors in the blood stream (Hachinski, V. and Norris, J. W., “The Acute Stroke,” Philadelphia, F A Davis, 1985); pulmonary function (in asthma patients) as measured by lung volumes in the different phases of respiration (Thurlbeck, W. M. (1990) Clin. Chest Med. 11:389); and heart activity (in recurrent cardiac arrest) as measured by electrical activity of the heart (Marriott, HJL, “Practical Electrocardiography”, 8th Ed., Baltimore, Williams & Wilkins, 1983). Other examples of physiological variables that can be predicted, include renal dialysis, where blood concentrations of urea and blood gases are followed. (Warnock, D. G. (1988) Kidney Int. 34:278); and anesthesia treatment, where various parameters (e.g., heart rate, blood pressure, blood concentration of the anesthesia) are monitored to determine when the anesthesia will stop functioning (Vender, J. S., and Gilbert, H. C., “Monitoring the Anesthetized Patient,” in Clinical Anesthesia, 3rd Ed., by Barash et al., Lippincott-Raven Publishers, Philadelphia, 1996).
  • Step F: Controlling a Physiological Effect.
  • The analyte value obtained using the above techniques can also be used to control an aspect of the biological system. e.g., a physiological effect. In one embodiment, an analyte value obtained as described above is used to determine when, and at what level, a constituent should be added to the biological system in order to control the concentration of the target analyte.
  • More particularly, in the context of blood glucose monitoring, use of prediction techniques (Step E, supra) allows for accurate predictions of either real-time or future blood glucose values. This is of particular value in predicting hypoglycemic episodes which can lead to diabetic shock, or even coma. Having a series of measurements obtained from the continual iontophoretic sampling device, and the capability to predict future values, allows a subject to detect blood glucose swings or trends indicative of hypoglycemic or hyperglycemic episodes prior to their reaching a critical level, and to compensate therefor by way of exercise, diet or insulin administration.
  • A feedback control application of the present invention entails using a function to predict real-time blood glucose levels, or measurement values of blood glucose levels at a different time, and then the same to control a pump for insulin delivery to treat hyperglycemia.
  • EXAMPLES
  • The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how to make and use the devices, methods, and formulae of the present invention, and are not intended to limit the scope of what the inventors regard as their invention. Efforts have been made to ensure accuracy with respect to numbers used (e.g., amounts, temperature, etc.) but some experimental errors and deviations should be accounted for. Unless indicated otherwise, parts are parts by weight, molecular weight is weight average molecular weight, temperature is in degrees Centigrade, and pressure is at or near atmospheric.
  • Example 1 Signal Processing for Measurement of Blood Glucose
  • In order to assess the signal processing methods of the present invention, an iontophoretic sampling device was used to extract a series of 525 blood glucose samples from an experimental population of human subjects, and non-processed measurement values were compared against measurement values obtained using the data screening and correction algorithm of the present invention.
  • More particularly, iontophoretic sampling was performed on subjects using a Glucowatch™ (Cygnus, Inc., Redwood City, Calif.) iontophoretic sampling system. This transdermal sampling device, which is designed to be worn like a wrist watch, uses iontophoresis (electroosmosis) to extract glucose analyte into a collection pad worn beneath the watch. Glucose collected into the GlucoWatch™ sampling system triggers an electrochemical reaction with a reagent in the pad, giving rise to a current which is sensed, measured, and converted to a blood glucose concentration. Measurements are taken on a continual basis, wherein combined extraction and sensing (measurement cycles) were set at 30 minutes. Iontophoresis was carried out using two collection pads contacted with Ag/AgCl iontophoretic electrodes, an iontophoretic current density of 0.3 mA/cm2, and the electrical polarity of the electrodes was switched halfway through the 30 minute measurement cycle. Sensing was carried out using platinum-based biosensor electrodes which were contacted with the collection pads. A description of the Glucowatch™ sampling system can be found in publication to Conn, T. E. (Jan. 15, 1997) “Evaluation of a Non-Invasive Glucose Monitoring System for People with Diabetes,” given at the Institute of Electrical and Electronics Engineers (IEEE) meeting entitled “Engineering in Medicine & Biology,” Stanford, Calif., which publication is incorporated herein by reference.
  • Concurrent with obtaining the calculated blood glucose values (from the GlucoWatch™ sampling system), blood samples (finger sticks) were obtained and analyzed for use as reference measurements. As a result, 525 sets of paired measurements (reference and calculated measurements) were obtained. A comparison was then made between the reference measurements and the calculated measurements (either raw, or signal processed using the methods of the invention). Two different sets of data screens were used as follows: (a) maximum temperature change over time (d(temp)/d(time)), perspiration threshold, and a threshold departure from monotonicity (this set of temperature screens is indicated as (+) in Table 1 below); or (b) maximum temperature change over time (d(temp)/d(time)), perspiration threshold, a threshold departure from monotonicity, and a threshold baseline background change over time (this set of temperature screens is indicated as (++) in Table 1 below). The correction algorithm that was used is as follows: EG t = b gain [ E t ( 1 + ε i t ) + OS ] + α i t - ρ wherein : b gain = BG cal + ρ - α cal t E cal ( 1 + ε i t cal ) + OS
    and (tcal) is the calibration point; (EGt) is the estimated blood glucose concentration at time t; (Et) is the analyte signal at time t; (OS) is the constant offset term which accounts for a non-zero signal at an estimated zero blood glucose concentration (as described above); (ε) is a gain term for time-dependent signal decline and can have multiple time segments (e.g., i=1, 2, or 3); (α) is a correction term for a linear time-dependent signal decline in the time segments and can have multiple time segments (e.g., i=1, 2, or 3); (t) is the elapsed time, and (ρ) is the calibration offset (in mg/dl).
  • In the comparison, an Error Grid Analysis (Clarke et al. (1987) Diabetes Care 10:622-628) was used to assess device effectiveness, wherein calculated measurements were plotted against the corresponding reference measurements. An effective blood glucose monitoring device should have greater than approximately 85-90% of the data in the A and B regions of the Error Grid Analysis, with a majority of the data in the A region (Clark et al., supra). The results of the Error Grid Analysis are presented below in Table 1 as (A+B%). As can be seen, the combination of data screening methods and the correction algorithm of the present invention met this effective criteria.
  • Another measure of device accuracy is the mean absolute % error (MPE(%)) which is determined from the mean of individual % error (PE) given by the following function: PE = EG t - BG t BG t
    wherein BGt is the reference glucose measurement and EGt is the calculated glucose measurement. Effective measurements should have a MPE(%) of about 25% or less. The results of the MPE(%) are also depicted in Table 1 As can be seen, the combination of data screening methods and the correction algorithm of the present invention met this effective criteria.
  • The correlation between calculated and measured blood glucose values was also assessed. The correlation coefficient values (R) are also presented in Table 1 below. Effective measurements should have R values of greater than about 0.85. As can be seen, the combination of data screening methods and the correction algorithm of the present invention provide for increased correlation between actual and measured values.
    TABLE 1
    525 Total Paired Data
    Algorithm Screen No. pts. MPE(%) A + B(%) Other(%) R
    0 0 525 54 73 27 0.54
    + + 467 24 90 10 0.87
    + ++ 308 20 91 9 0.90

Claims (15)

1. A method of converting post-calibration data to provide a measurement of analyte amount or concentration in a subject, said method comprising:
obtaining a raw signal from the analyte, wherein (i) interstial fluid of the subject comprises said analyte, (ii) obtaining said raw signal comprises contacting said interstitial fluid with a sensing device, and (iii) said raw signal is related to analyte amount or concentration in the biological system;
subjecting the raw signal to at least one conversion step in order to convert said raw signal to an initial signal output which is indicative of the amount or concentration of analyte;
calibrating the sensing device by performing at least one calibration step that converts the initial signal output to a measurement value indicative of the amount or concentration of analyte present in the biological system; and
converting a raw signal or initial signal output obtained after the calibration of the sensing device to a measurement value indicative of the amount or concentration of analyte present in the subject.
2. The method of claim 1, wherein after calibration of the sensing device the method further comprises obtaining a series of raw signals over time, subjecting each raw signal to at least one conversion step in order to convert said raw signal to an initial signal output which is indicative of the amount or concentration of analyte.
3. The method of claim 1, wherein the converting the raw signal or initial signal output after the calibration of the sensing device further comprises subjecting the raw signal to at least one conversion step to convert the raw signal to an initial signal output, and converting the initial signal output to a measurement value indicative of the amount or concentration of analyte present in the subject.
4. The method of claim 1, wherein said calibrating uses a mathematical transformation to model a relationship between a raw signal and a corresponding measurement value indicative of the amount or concentration of analyte present in the subject.
5. The method of claim 4, wherein said mathematical transformation comprises a mathematical transformation selected from the group consisting of linear regression, non-linear regression, and neural network algorithms.
6. The method of claim 3, wherein said calibrating uses a mathematical transformation to model a relationship between an initial signal output and a corresponding measurement value indicative of the amount or concentration of analyte present in the subject.
7. The method of claim 6, wherein said mathematical transformation comprises a mathematical transformation selected from the group consisting of linear regression non-linear regression, and neural network algorithms.
8. The method of claim 1, wherein said calibrating uses a single-point or multi-point calibration.
9. The method of claim 1, wherein said converting the raw signal or initial signal output obtained after the calibration of the sensing device uses correlation factors, time corrections, and/or constants to obtain a corresponding measurement value indicative of the amount or concentration of analyte present in the subject.
10. The method of claim 1, comprising further signal processing to refine said measurement value indicative of the amount or concentration of analyte present in the subject.
11. The method of claim 10, wherein said further signal processing comprises a signal processing step to correct for signal differences due to variable conditions of the sensing device used to obtain the raw signal.
12. The method of claim 11, wherein said signal processing step is used to correct for signal decline.
13. The method of claim 11, wherein said signal processing step employs a constant offset term.
14. The method of claim 13, wherein said offset is added to the raw signal or initial signal output to account for a non-zero signal at an estimated zero analyte concentration.
15. The method of claim 1, wherein said sensing device comprises an electrochemical sensing element.
US11/583,407 1998-05-13 2006-10-19 Signal processing for measurement of physiological analytes Abandoned US20070038053A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/583,407 US20070038053A1 (en) 1998-05-13 2006-10-19 Signal processing for measurement of physiological analytes

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US8534498P 1998-05-13 1998-05-13
US09/309,728 US6233471B1 (en) 1998-05-13 1999-05-11 Signal processing for measurement of physiological analysis
US89478301A 2001-06-28 2001-06-28
US10/384,443 US20030153821A1 (en) 1998-05-13 2003-03-07 Signal processing for measurement of physiological analytes
US11/583,407 US20070038053A1 (en) 1998-05-13 2006-10-19 Signal processing for measurement of physiological analytes

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/384,443 Division US20030153821A1 (en) 1998-05-13 2003-03-07 Signal processing for measurement of physiological analytes

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/501,898 Division US7800889B2 (en) 2004-10-21 2009-07-13 Outdoor apparatus

Publications (1)

Publication Number Publication Date
US20070038053A1 true US20070038053A1 (en) 2007-02-15

Family

ID=22190986

Family Applications (5)

Application Number Title Priority Date Filing Date
US09/309,728 Expired - Lifetime US6233471B1 (en) 1998-05-13 1999-05-11 Signal processing for measurement of physiological analysis
US09/794,783 Expired - Lifetime US6595919B2 (en) 1998-05-13 2001-02-27 Device for signal processing for measurement of physiological analytes
US10/366,434 Expired - Lifetime US7295867B2 (en) 1998-05-13 2003-02-12 Signal processing for measurement of physiological analytes
US10/384,443 Abandoned US20030153821A1 (en) 1998-05-13 2003-03-07 Signal processing for measurement of physiological analytes
US11/583,407 Abandoned US20070038053A1 (en) 1998-05-13 2006-10-19 Signal processing for measurement of physiological analytes

Family Applications Before (4)

Application Number Title Priority Date Filing Date
US09/309,728 Expired - Lifetime US6233471B1 (en) 1998-05-13 1999-05-11 Signal processing for measurement of physiological analysis
US09/794,783 Expired - Lifetime US6595919B2 (en) 1998-05-13 2001-02-27 Device for signal processing for measurement of physiological analytes
US10/366,434 Expired - Lifetime US7295867B2 (en) 1998-05-13 2003-02-12 Signal processing for measurement of physiological analytes
US10/384,443 Abandoned US20030153821A1 (en) 1998-05-13 2003-03-07 Signal processing for measurement of physiological analytes

Country Status (10)

Country Link
US (5) US6233471B1 (en)
EP (1) EP1077636B1 (en)
JP (2) JP2002514452A (en)
AT (1) ATE258028T1 (en)
CA (1) CA2311487C (en)
DE (1) DE69914319T2 (en)
DK (1) DK1077636T3 (en)
ES (1) ES2213369T3 (en)
PT (1) PT1077636E (en)
WO (1) WO1999058050A1 (en)

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070283334A1 (en) * 2006-06-02 2007-12-06 International Business Machines Corporation Problem detection facility using symmetrical trace data
US20080000779A1 (en) * 2005-12-30 2008-01-03 Medtronic Minimed, Inc. Method and System for Remedying Sensor Malfunctions Detected by Electrochemical Impedance Spectroscopy
WO2008151274A1 (en) * 2007-06-05 2008-12-11 Owen Davis Device and system for montioring contents of perspiration
US20090048584A1 (en) * 1999-04-30 2009-02-19 Medtronic Minimed, Inc. Closed Loop Medicament Pump
US20090247857A1 (en) * 2008-03-28 2009-10-01 Abbott Diabetes Care, Inc. Analyte Sensor Calibration Management
US20100319436A1 (en) * 2009-06-23 2010-12-23 Bayer Healthcare Llc System and Apparatus for Determining Temperatures in a Fluid Analyte System
US7946985B2 (en) 2006-12-29 2011-05-24 Medtronic Minimed, Inc. Method and system for providing sensor redundancy
US7985330B2 (en) 2005-12-30 2011-07-26 Medtronic Minimed, Inc. Method and system for detecting age, hydration, and functional states of sensors using electrochemical impedance spectroscopy
US20110193704A1 (en) * 2009-08-31 2011-08-11 Abbott Diabetes Care Inc. Displays for a medical device
US8114269B2 (en) 2005-12-30 2012-02-14 Medtronic Minimed, Inc. System and method for determining the point of hydration and proper time to apply potential to a glucose sensor
US8115635B2 (en) 2005-02-08 2012-02-14 Abbott Diabetes Care Inc. RF tag on test strips, test strip vials and boxes
CN102469941A (en) * 2010-04-16 2012-05-23 艾伯特糖尿病护理公司 Analyte monitoring device and methods
US8401873B2 (en) 2007-05-30 2013-03-19 Bayer Healthcare Llc Health data management device
US8483967B2 (en) 2009-04-29 2013-07-09 Abbott Diabetes Care Inc. Method and system for providing real time analyte sensor calibration with retrospective backfill
US8497777B2 (en) 2009-04-15 2013-07-30 Abbott Diabetes Care Inc. Analyte monitoring system having an alert
WO2016008997A1 (en) * 2014-07-17 2016-01-21 Roche Diagnostics Gmbh A method and a device for determining a body fluid glucose level of a patient, and a computer program product
CN105486731A (en) * 2015-08-12 2016-04-13 成都市亿泰科技有限公司 Terahertz-enhanced noninvasive blood-sugar detection probe
US9339217B2 (en) 2011-11-25 2016-05-17 Abbott Diabetes Care Inc. Analyte monitoring system and methods of use
US20170065231A1 (en) * 2015-09-04 2017-03-09 Goldensunda Technology Co., Ltd. Noninvasive blood sugar measurement device
US10117614B2 (en) 2006-02-28 2018-11-06 Abbott Diabetes Care Inc. Method and system for providing continuous calibration of implantable analyte sensors
CN111107679A (en) * 2019-12-02 2020-05-05 天津大学 Flexible temperature control system
US11896371B2 (en) 2012-09-26 2024-02-13 Abbott Diabetes Care Inc. Method and apparatus for improving lag correction during in vivo measurement of analyte concentration with analyte concentration variability and range data

Families Citing this family (645)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5771890A (en) 1994-06-24 1998-06-30 Cygnus, Inc. Device and method for sampling of substances using alternating polarity
SE9700384D0 (en) * 1997-02-04 1997-02-04 Biacore Ab Analytical method and apparatus
US7192450B2 (en) 2003-05-21 2007-03-20 Dexcom, Inc. Porous membranes for use with implantable devices
US6558321B1 (en) 1997-03-04 2003-05-06 Dexcom, Inc. Systems and methods for remote monitoring and modulation of medical devices
US9155496B2 (en) 1997-03-04 2015-10-13 Dexcom, Inc. Low oxygen in vivo analyte sensor
US6001067A (en) 1997-03-04 1999-12-14 Shults; Mark C. Device and method for determining analyte levels
US7899511B2 (en) 2004-07-13 2011-03-01 Dexcom, Inc. Low oxygen in vivo analyte sensor
US6862465B2 (en) 1997-03-04 2005-03-01 Dexcom, Inc. Device and method for determining analyte levels
US8527026B2 (en) 1997-03-04 2013-09-03 Dexcom, Inc. Device and method for determining analyte levels
US7657297B2 (en) 2004-05-03 2010-02-02 Dexcom, Inc. Implantable analyte sensor
US20050033132A1 (en) 1997-03-04 2005-02-10 Shults Mark C. Analyte measuring device
US5954643A (en) * 1997-06-09 1999-09-21 Minimid Inc. Insertion set for a transcutaneous sensor
US6558351B1 (en) * 1999-06-03 2003-05-06 Medtronic Minimed, Inc. Closed loop system for controlling insulin infusion
US7267665B2 (en) * 1999-06-03 2007-09-11 Medtronic Minimed, Inc. Closed loop system for controlling insulin infusion
US6036924A (en) 1997-12-04 2000-03-14 Hewlett-Packard Company Cassette of lancet cartridges for sampling blood
CA2265119C (en) 1998-03-13 2002-12-03 Cygnus, Inc. Biosensor, iontophoretic sampling system, and methods of use thereof
US6391005B1 (en) 1998-03-30 2002-05-21 Agilent Technologies, Inc. Apparatus and method for penetration with shaft having a sensor for sensing penetration depth
US8974386B2 (en) 1998-04-30 2015-03-10 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8346337B2 (en) 1998-04-30 2013-01-01 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US6175752B1 (en) 1998-04-30 2001-01-16 Therasense, Inc. Analyte monitoring device and methods of use
US8688188B2 (en) 1998-04-30 2014-04-01 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US9066695B2 (en) 1998-04-30 2015-06-30 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8465425B2 (en) 1998-04-30 2013-06-18 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8480580B2 (en) 1998-04-30 2013-07-09 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US6949816B2 (en) 2003-04-21 2005-09-27 Motorola, Inc. Semiconductor component having first surface area for electrically coupling to a semiconductor chip and second surface area for electrically coupling to a substrate, and method of manufacturing same
ATE245937T1 (en) * 1998-05-13 2003-08-15 Cygnus Therapeutic Systems MONITORING PHYSIOLOGICAL ANALYTES
DK1053043T3 (en) 1998-05-13 2002-11-18 Cygnus Therapeutic Systems Collection units for transdermal sampling systems
PT1077636E (en) * 1998-05-13 2004-06-30 Cygnus Therapeutic Systems SIGNAL PROCESSING FOR PHYSIOLOGICAL ANALYZES MEDICATION
US6180416B1 (en) 1998-09-30 2001-01-30 Cygnus, Inc. Method and device for predicting physiological values
CA2346055C (en) 1998-09-30 2004-06-29 Cygnus, Inc. Method and device for predicting physiological values
WO2000024455A1 (en) * 1998-10-28 2000-05-04 Cygnus, Inc. Kit and method for quality control testing of an iontophoretic sampling system
AU3363000A (en) 1999-02-12 2000-08-29 Cygnus, Inc. Devices and methods for frequent measurement of an analyte present in a biological system
US6360888B1 (en) * 1999-02-25 2002-03-26 Minimed Inc. Glucose sensor package system
US6356775B1 (en) * 1999-04-20 2002-03-12 Kyoho Machine Works. Ltd. Biological data observation system
BR0015716A (en) 1999-11-19 2003-05-06 Spectrx Inc Organic Tissue Interface Device
US6458326B1 (en) 1999-11-24 2002-10-01 Home Diagnostics, Inc. Protective test strip platform
US6895263B2 (en) 2000-02-23 2005-05-17 Medtronic Minimed, Inc. Real time self-adjusting calibration algorithm
US7890295B2 (en) * 2000-02-23 2011-02-15 Medtronic Minimed, Inc. Real time self-adjusting calibration algorithm
EP1267708A4 (en) * 2000-03-29 2006-04-12 Univ Virginia Method, system, and computer program product for the evaluation of glycemic control in diabetes from self-monitoring data
US7606608B2 (en) * 2000-05-02 2009-10-20 Sensys Medical, Inc. Optical sampling interface system for in-vivo measurement of tissue
US20060211931A1 (en) * 2000-05-02 2006-09-21 Blank Thomas B Noninvasive analyzer sample probe interface method and apparatus
US7519406B2 (en) 2004-04-28 2009-04-14 Sensys Medical, Inc. Noninvasive analyzer sample probe interface method and apparatus
US6885883B2 (en) 2000-05-16 2005-04-26 Cygnus, Inc. Methods for improving performance and reliability of biosensors
AU2011205219B2 (en) * 2000-06-01 2011-11-24 Georgetown University Systems and methods for monitoring health and delivering drugs transdermally
AU2014200664B2 (en) * 2000-06-01 2015-05-14 Georgetown University Systems and methods for monitoring health and delivering drugs transdermally
AU2012201079B2 (en) * 2000-06-01 2013-03-28 Georgetown University Systems and methods for monitoring health and delivering drugs transdermally
CA2688795C (en) * 2000-06-01 2014-07-08 Science Application International Corporation Systems and methods for monitoring health and delivering drugs transdermally
CA2408338C (en) * 2000-08-18 2009-09-08 Cygnus, Inc. Methods and devices for prediction of hypoglycemic events
WO2002017210A2 (en) 2000-08-18 2002-02-28 Cygnus, Inc. Formulation and manipulation of databases of analyte and associated values
WO2002018936A2 (en) * 2000-08-28 2002-03-07 Cygnus, Inc. Methods of monitoring glucose levels in a subject and uses thereof
US8641644B2 (en) 2000-11-21 2014-02-04 Sanofi-Aventis Deutschland Gmbh Blood testing apparatus having a rotatable cartridge with multiple lancing elements and testing means
US6760610B2 (en) * 2000-11-23 2004-07-06 Sentec Ag Sensor and method for measurement of physiological parameters
US6560471B1 (en) 2001-01-02 2003-05-06 Therasense, Inc. Analyte monitoring device and methods of use
TW522127B (en) * 2001-02-21 2003-03-01 Daifuku Kk Cargo storage facility
US6562625B2 (en) 2001-02-28 2003-05-13 Home Diagnostics, Inc. Distinguishing test types through spectral analysis
US6541266B2 (en) 2001-02-28 2003-04-01 Home Diagnostics, Inc. Method for determining concentration of an analyte in a test strip
US6525330B2 (en) 2001-02-28 2003-02-25 Home Diagnostics, Inc. Method of strip insertion detection
CA2439822C (en) 2001-03-06 2011-01-11 Pendragon Medical Ltd. Method and device for determining the concentration of a substance in body liquid
US7315767B2 (en) 2001-03-06 2008-01-01 Solianis Holding Ag Impedance spectroscopy based systems and methods
EP1397068A2 (en) 2001-04-02 2004-03-17 Therasense, Inc. Blood glucose tracking apparatus and methods
WO2002100254A2 (en) 2001-06-12 2002-12-19 Pelikan Technologies, Inc. Method and apparatus for lancet launching device integrated onto a blood-sampling cartridge
US9226699B2 (en) 2002-04-19 2016-01-05 Sanofi-Aventis Deutschland Gmbh Body fluid sampling module with a continuous compression tissue interface surface
US9427532B2 (en) 2001-06-12 2016-08-30 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US7041068B2 (en) 2001-06-12 2006-05-09 Pelikan Technologies, Inc. Sampling module device and method
US7981056B2 (en) 2002-04-19 2011-07-19 Pelikan Technologies, Inc. Methods and apparatus for lancet actuation
CA2448902C (en) 2001-06-12 2010-09-07 Pelikan Technologies, Inc. Self optimizing lancing device with adaptation means to temporal variations in cutaneous properties
US7344507B2 (en) 2002-04-19 2008-03-18 Pelikan Technologies, Inc. Method and apparatus for lancet actuation
ES2357887T3 (en) 2001-06-12 2011-05-03 Pelikan Technologies Inc. APPARATUS FOR IMPROVING THE BLOOD OBTAINING SUCCESS RATE FROM A CAPILLARY PUNCTURE.
US8337419B2 (en) 2002-04-19 2012-12-25 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
EP1395185B1 (en) 2001-06-12 2010-10-27 Pelikan Technologies Inc. Electric lancet actuator
US9795747B2 (en) 2010-06-02 2017-10-24 Sanofi-Aventis Deutschland Gmbh Methods and apparatus for lancet actuation
US7682318B2 (en) 2001-06-12 2010-03-23 Pelikan Technologies, Inc. Blood sampling apparatus and method
WO2003000127A2 (en) * 2001-06-22 2003-01-03 Cygnus, Inc. Method for improving the performance of an analyte monitoring system
US6702857B2 (en) 2001-07-27 2004-03-09 Dexcom, Inc. Membrane for use with implantable devices
US20030032874A1 (en) * 2001-07-27 2003-02-13 Dexcom, Inc. Sensor head for use with implantable devices
WO2003012436A2 (en) * 2001-07-31 2003-02-13 Becton Dickinson And Company Method and system for predicting initial analyte values in stored samples
US20050203578A1 (en) * 2001-08-15 2005-09-15 Weiner Michael L. Process and apparatus for treating biological organisms
US8506550B2 (en) * 2001-09-07 2013-08-13 Medtronic Minimed, Inc. Method and system for non-vascular sensor implantation
US6827702B2 (en) 2001-09-07 2004-12-07 Medtronic Minimed, Inc. Safety limits for closed-loop infusion pump control
US20030108976A1 (en) * 2001-10-09 2003-06-12 Braig James R. Method and apparatus for improving clinical accuracy of analyte measurements
US8465466B2 (en) * 2001-10-23 2013-06-18 Medtronic Minimed, Inc Method and system for non-vascular sensor implantation
US7429258B2 (en) * 2001-10-26 2008-09-30 Massachusetts Institute Of Technology Microneedle transport device
AU2002346484A1 (en) * 2001-11-21 2003-06-10 Optiscan Biomedical Corporation Method and apparatus for improving the accuracy of alternative site analyte concentration measurements
ES2321173T3 (en) * 2001-12-19 2009-06-03 Alza Corporation DEPOSIT HOUSING CONTAINING A DRIVER AREA INTEGRATED IN THE INSIDE.
US6980852B2 (en) * 2002-01-25 2005-12-27 Subqiview Inc. Film barrier dressing for intravascular tissue monitoring system
US8260393B2 (en) 2003-07-25 2012-09-04 Dexcom, Inc. Systems and methods for replacing signal data artifacts in a glucose sensor data stream
US7613491B2 (en) 2002-05-22 2009-11-03 Dexcom, Inc. Silicone based membranes for use in implantable glucose sensors
US9282925B2 (en) * 2002-02-12 2016-03-15 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US8010174B2 (en) * 2003-08-22 2011-08-30 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US7828728B2 (en) 2003-07-25 2010-11-09 Dexcom, Inc. Analyte sensor
US9247901B2 (en) 2003-08-22 2016-02-02 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US20050187439A1 (en) * 2003-03-07 2005-08-25 Blank Thomas B. Sampling interface system for in-vivo estimation of tissue analyte concentration
US7697966B2 (en) * 2002-03-08 2010-04-13 Sensys Medical, Inc. Noninvasive targeting system method and apparatus
US8718738B2 (en) * 2002-03-08 2014-05-06 Glt Acquisition Corp. Method and apparatus for coupling a sample probe with a sample site
US6998247B2 (en) * 2002-03-08 2006-02-14 Sensys Medical, Inc. Method and apparatus using alternative site glucose determinations to calibrate and maintain noninvasive and implantable analyzers
US20070149868A1 (en) * 2002-03-08 2007-06-28 Blank Thomas B Method and Apparatus for Photostimulation Enhanced Analyte Property Estimation
US20050054908A1 (en) * 2003-03-07 2005-03-10 Blank Thomas B. Photostimulation method and apparatus in combination with glucose determination
US8504128B2 (en) * 2002-03-08 2013-08-06 Glt Acquisition Corp. Method and apparatus for coupling a channeled sample probe to tissue
JP4189322B2 (en) * 2002-03-08 2008-12-03 センシス メディカル インク Compact instrument for non-invasive measurement of glucose by near infrared spectroscopy
CA2480550C (en) * 2002-03-22 2011-07-12 Cygnus, Inc. Improving performance of an analyte monitoring device
US7547287B2 (en) 2002-04-19 2009-06-16 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7717863B2 (en) 2002-04-19 2010-05-18 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US9314194B2 (en) 2002-04-19 2016-04-19 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US8267870B2 (en) 2002-04-19 2012-09-18 Sanofi-Aventis Deutschland Gmbh Method and apparatus for body fluid sampling with hybrid actuation
US9795334B2 (en) 2002-04-19 2017-10-24 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US7491178B2 (en) * 2002-04-19 2009-02-17 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7909778B2 (en) 2002-04-19 2011-03-22 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7481776B2 (en) 2002-04-19 2009-01-27 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7232451B2 (en) 2002-04-19 2007-06-19 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7297122B2 (en) 2002-04-19 2007-11-20 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7331931B2 (en) 2002-04-19 2008-02-19 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7198606B2 (en) 2002-04-19 2007-04-03 Pelikan Technologies, Inc. Method and apparatus for a multi-use body fluid sampling device with analyte sensing
US7892183B2 (en) 2002-04-19 2011-02-22 Pelikan Technologies, Inc. Method and apparatus for body fluid sampling and analyte sensing
US8372016B2 (en) 2002-04-19 2013-02-12 Sanofi-Aventis Deutschland Gmbh Method and apparatus for body fluid sampling and analyte sensing
US8702624B2 (en) 2006-09-29 2014-04-22 Sanofi-Aventis Deutschland Gmbh Analyte measurement device with a single shot actuator
US7674232B2 (en) 2002-04-19 2010-03-09 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US8579831B2 (en) 2002-04-19 2013-11-12 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US7229458B2 (en) 2002-04-19 2007-06-12 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US8360992B2 (en) 2002-04-19 2013-01-29 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US8221334B2 (en) 2002-04-19 2012-07-17 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US7976476B2 (en) 2002-04-19 2011-07-12 Pelikan Technologies, Inc. Device and method for variable speed lancet
US9248267B2 (en) 2002-04-19 2016-02-02 Sanofi-Aventis Deustchland Gmbh Tissue penetration device
US8784335B2 (en) 2002-04-19 2014-07-22 Sanofi-Aventis Deutschland Gmbh Body fluid sampling device with a capacitive sensor
US7371247B2 (en) 2002-04-19 2008-05-13 Pelikan Technologies, Inc Method and apparatus for penetrating tissue
US7901362B2 (en) 2002-04-19 2011-03-08 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7291117B2 (en) 2002-04-19 2007-11-06 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7648468B2 (en) 2002-04-19 2010-01-19 Pelikon Technologies, Inc. Method and apparatus for penetrating tissue
US6801804B2 (en) 2002-05-03 2004-10-05 Aciont, Inc. Device and method for monitoring and controlling electrical resistance at a tissue site undergoing iontophoresis
KR100472092B1 (en) * 2002-05-14 2005-03-08 주식회사 헬스피아 A blood sugar test device using a wireless phone and a method to transmit the blood sugar level to internet server
US7226978B2 (en) 2002-05-22 2007-06-05 Dexcom, Inc. Techniques to improve polyurethane membranes for implantable glucose sensors
US7099713B2 (en) 2002-06-28 2006-08-29 Battelle Memorial Institute Skin conduction and transport systems
WO2004005908A1 (en) 2002-07-02 2004-01-15 Matsushita Electric Industrial Co., Ltd. Biosensor, biosensor chip, and biosensor device
EP1534121B1 (en) * 2002-08-13 2014-01-22 University Of Virginia Patent Foundation Method, system, and computer program product for the processing of self-monitoring blood glucose(smbg)data to enhance diabetic self-management
US7366564B2 (en) 2002-08-23 2008-04-29 The United States Of America As Represented By The Secretary Of The Navy Nonlinear blind demixing of single pixel underlying radiation sources and digital spectrum local thermometer
DE60234138D1 (en) * 2002-09-04 2009-12-03 Solianis Holding Ag METHOD AND APPARATUS FOR GLUCOSE MEASUREMENT
EP1691672B1 (en) * 2002-09-24 2009-01-07 Solianis Holding AG Device for the measurement of glucose concentrations
US7736309B2 (en) * 2002-09-27 2010-06-15 Medtronic Minimed, Inc. Implantable sensor method and system
US7993108B2 (en) 2002-10-09 2011-08-09 Abbott Diabetes Care Inc. Variable volume, shape memory actuated insulin dispensing pump
CA2501825C (en) 2002-10-09 2009-12-01 Therasense, Inc. Fluid delivery device, system and method
US7727181B2 (en) 2002-10-09 2010-06-01 Abbott Diabetes Care Inc. Fluid delivery device with autocalibration
US7381184B2 (en) 2002-11-05 2008-06-03 Abbott Diabetes Care Inc. Sensor inserter assembly
US20060129035A1 (en) * 2002-12-27 2006-06-15 Kaoru Asano Devices, methods, and systems for measuring analytes extracted through skin
US8574895B2 (en) 2002-12-30 2013-11-05 Sanofi-Aventis Deutschland Gmbh Method and apparatus using optical techniques to measure analyte levels
US7811231B2 (en) 2002-12-31 2010-10-12 Abbott Diabetes Care Inc. Continuous glucose monitoring system and methods of use
US20050159656A1 (en) * 2003-03-07 2005-07-21 Hockersmith Linda J. Method and apparatus for presentation of noninvasive glucose concentration information
JP4381705B2 (en) * 2003-03-26 2009-12-09 シスメックス株式会社 Transcutaneous analyte extraction system and analysis system, and transcutaneous analyte extraction method and analysis method
US7134999B2 (en) 2003-04-04 2006-11-14 Dexcom, Inc. Optimized sensor geometry for an implantable glucose sensor
CN100427025C (en) * 2003-04-10 2008-10-22 宇东科技股份有限公司 Method for judging concentration of lood sugar
US7415299B2 (en) * 2003-04-18 2008-08-19 The Regents Of The University Of California Monitoring method and/or apparatus
US7679407B2 (en) 2003-04-28 2010-03-16 Abbott Diabetes Care Inc. Method and apparatus for providing peak detection circuitry for data communication systems
US7875293B2 (en) 2003-05-21 2011-01-25 Dexcom, Inc. Biointerface membranes incorporating bioactive agents
EP1628567B1 (en) 2003-05-30 2010-08-04 Pelikan Technologies Inc. Method and apparatus for fluid injection
US20040253736A1 (en) * 2003-06-06 2004-12-16 Phil Stout Analytical device with prediction module and related methods
ES2490740T3 (en) 2003-06-06 2014-09-04 Sanofi-Aventis Deutschland Gmbh Apparatus for blood fluid sampling and analyte detection
US7258673B2 (en) * 2003-06-06 2007-08-21 Lifescan, Inc Devices, systems and methods for extracting bodily fluid and monitoring an analyte therein
US20040249254A1 (en) * 2003-06-06 2004-12-09 Joel Racchini Devices, systems and methods for extracting bodily fluid and monitoring an analyte therein
US8066639B2 (en) 2003-06-10 2011-11-29 Abbott Diabetes Care Inc. Glucose measuring device for use in personal area network
WO2006001797A1 (en) 2004-06-14 2006-01-05 Pelikan Technologies, Inc. Low pain penetrating
US7366556B2 (en) * 2003-12-05 2008-04-29 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
WO2005019795A2 (en) * 2003-07-25 2005-03-03 Dexcom, Inc. Electrochemical sensors including electrode systems with increased oxygen generation
EP1649260A4 (en) * 2003-07-25 2010-07-07 Dexcom Inc Electrode systems for electrochemical sensors
WO2007120442A2 (en) 2003-07-25 2007-10-25 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US8423113B2 (en) 2003-07-25 2013-04-16 Dexcom, Inc. Systems and methods for processing sensor data
US7467003B2 (en) * 2003-12-05 2008-12-16 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US7460898B2 (en) * 2003-12-05 2008-12-02 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
EP1648298A4 (en) 2003-07-25 2010-01-13 Dexcom Inc Oxygen enhancing membrane systems for implantable devices
US7424318B2 (en) * 2003-12-05 2008-09-09 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US8369919B2 (en) 2003-08-01 2013-02-05 Dexcom, Inc. Systems and methods for processing sensor data
US6931327B2 (en) 2003-08-01 2005-08-16 Dexcom, Inc. System and methods for processing analyte sensor data
US8886273B2 (en) 2003-08-01 2014-11-11 Dexcom, Inc. Analyte sensor
US8285354B2 (en) 2003-08-01 2012-10-09 Dexcom, Inc. System and methods for processing analyte sensor data
US20190357827A1 (en) 2003-08-01 2019-11-28 Dexcom, Inc. Analyte sensor
US7591801B2 (en) 2004-02-26 2009-09-22 Dexcom, Inc. Integrated delivery device for continuous glucose sensor
US7519408B2 (en) 2003-11-19 2009-04-14 Dexcom, Inc. Integrated receiver for continuous analyte sensor
US9135402B2 (en) 2007-12-17 2015-09-15 Dexcom, Inc. Systems and methods for processing sensor data
US8761856B2 (en) 2003-08-01 2014-06-24 Dexcom, Inc. System and methods for processing analyte sensor data
US8626257B2 (en) 2003-08-01 2014-01-07 Dexcom, Inc. Analyte sensor
US8160669B2 (en) 2003-08-01 2012-04-17 Dexcom, Inc. Transcutaneous analyte sensor
US8275437B2 (en) 2003-08-01 2012-09-25 Dexcom, Inc. Transcutaneous analyte sensor
US8676287B2 (en) 2003-08-01 2014-03-18 Dexcom, Inc. System and methods for processing analyte sensor data
US8845536B2 (en) 2003-08-01 2014-09-30 Dexcom, Inc. Transcutaneous analyte sensor
US7774145B2 (en) 2003-08-01 2010-08-10 Dexcom, Inc. Transcutaneous analyte sensor
KR20060082852A (en) * 2003-08-15 2006-07-19 애니머스 테크놀로지스 엘엘씨 Microprocessors, devices, and methods for use in monitoring of physiological analytes
US7189341B2 (en) * 2003-08-15 2007-03-13 Animas Technologies, Llc Electrochemical sensor ink compositions, electrodes, and uses thereof
US20070066873A1 (en) 2003-08-22 2007-03-22 Apurv Kamath Systems and methods for processing analyte sensor data
US7920906B2 (en) 2005-03-10 2011-04-05 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US20140121989A1 (en) 2003-08-22 2014-05-01 Dexcom, Inc. Systems and methods for processing analyte sensor data
US20070234300A1 (en) * 2003-09-18 2007-10-04 Leake David W Method and Apparatus for Performing State-Table Driven Regression Testing
US7433727B2 (en) * 2003-09-24 2008-10-07 Legacy Good Samaritan Hospital And Medical Center Implantable biosensor
EP1671096A4 (en) 2003-09-29 2009-09-16 Pelikan Technologies Inc Method and apparatus for an improved sample capture device
EP1680014A4 (en) 2003-10-14 2009-01-21 Pelikan Technologies Inc Method and apparatus for a variable user interface
US7299082B2 (en) 2003-10-31 2007-11-20 Abbott Diabetes Care, Inc. Method of calibrating an analyte-measurement device, and associated methods, devices and systems
USD902408S1 (en) 2003-11-05 2020-11-17 Abbott Diabetes Care Inc. Analyte sensor control unit
US9247900B2 (en) 2004-07-13 2016-02-02 Dexcom, Inc. Analyte sensor
AU2003283714A1 (en) * 2003-11-27 2005-06-24 Solianis Holding Ag Techniques for determining glucose levels
US8197406B2 (en) * 2003-12-02 2012-06-12 Biovotion Ag Device and method for measuring a property of living tissue
US8425416B2 (en) * 2006-10-04 2013-04-23 Dexcom, Inc. Analyte sensor
US11633133B2 (en) 2003-12-05 2023-04-25 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US8532730B2 (en) * 2006-10-04 2013-09-10 Dexcom, Inc. Analyte sensor
ATE480761T1 (en) 2003-12-05 2010-09-15 Dexcom Inc CALIBRATION METHODS FOR A CONTINUOUSLY WORKING ANALYTICAL SENSOR
US8425417B2 (en) 2003-12-05 2013-04-23 Dexcom, Inc. Integrated device for continuous in vivo analyte detection and simultaneous control of an infusion device
US8423114B2 (en) 2006-10-04 2013-04-16 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US8287453B2 (en) 2003-12-05 2012-10-16 Dexcom, Inc. Analyte sensor
US8364231B2 (en) * 2006-10-04 2013-01-29 Dexcom, Inc. Analyte sensor
US8364230B2 (en) * 2006-10-04 2013-01-29 Dexcom, Inc. Analyte sensor
WO2005057175A2 (en) 2003-12-09 2005-06-23 Dexcom, Inc. Signal processing for continuous analyte sensor
US7384397B2 (en) * 2003-12-30 2008-06-10 Medtronic Minimed, Inc. System and method for sensor recalibration
US7822454B1 (en) 2005-01-03 2010-10-26 Pelikan Technologies, Inc. Fluid sampling device with improved analyte detecting member configuration
WO2005065414A2 (en) 2003-12-31 2005-07-21 Pelikan Technologies, Inc. Method and apparatus for improving fluidic flow and sample capture
CN1636505B (en) * 2004-01-09 2011-11-09 希森美康株式会社 Extracting implement, extracting apparatus, and apparatus for measuring blood sugar rate
US7637868B2 (en) * 2004-01-12 2009-12-29 Dexcom, Inc. Composite material for implantable device
EP1561418B1 (en) * 2004-02-03 2011-08-17 Sysmex Corporation Analyzer, cartridge, cartridge kit
BRPI0507376A (en) 2004-02-06 2007-07-10 Bayer Healthcare Llc oxidizable species as an internal reference for biosensors and method of use
CA2556331A1 (en) 2004-02-17 2005-09-29 Therasense, Inc. Method and system for providing data communication in continuous glucose monitoring and management system
WO2009048462A1 (en) 2007-10-09 2009-04-16 Dexcom, Inc. Integrated insulin delivery system with continuous glucose sensor
US20050197554A1 (en) * 2004-02-26 2005-09-08 Michael Polcha Composite thin-film glucose sensor
US8808228B2 (en) 2004-02-26 2014-08-19 Dexcom, Inc. Integrated medicament delivery device for use with continuous analyte sensor
AU2005230470A1 (en) 2004-03-31 2005-10-20 Bayer Healthcare Llc Method and apparatus for implementing threshold based correction functions for biosensors
US20080033275A1 (en) * 2004-04-28 2008-02-07 Blank Thomas B Method and Apparatus for Sample Probe Movement Control
US8868147B2 (en) * 2004-04-28 2014-10-21 Glt Acquisition Corp. Method and apparatus for controlling positioning of a noninvasive analyzer sample probe
US8277713B2 (en) 2004-05-03 2012-10-02 Dexcom, Inc. Implantable analyte sensor
US8792955B2 (en) 2004-05-03 2014-07-29 Dexcom, Inc. Transcutaneous analyte sensor
US20050245799A1 (en) * 2004-05-03 2005-11-03 Dexcom, Inc. Implantable analyte sensor
US7706873B2 (en) * 2004-05-05 2010-04-27 Mario Ammirati System and method for controlled delivery of a therapeutic agent to a target location within an internal body tissue
US8828203B2 (en) 2004-05-20 2014-09-09 Sanofi-Aventis Deutschland Gmbh Printable hydrogels for biosensors
WO2005112547A2 (en) * 2004-05-20 2005-12-01 Medisim Ltd. Temperature measurement device
WO2005120365A1 (en) 2004-06-03 2005-12-22 Pelikan Technologies, Inc. Method and apparatus for a fluid sampling device
US9775553B2 (en) 2004-06-03 2017-10-03 Sanofi-Aventis Deutschland Gmbh Method and apparatus for a fluid sampling device
CA3090413C (en) 2004-06-04 2023-10-10 Abbott Diabetes Care Inc. Glucose monitoring and graphical representations in a data management system
JP4499787B2 (en) * 2004-06-07 2010-07-07 ソリアニス・ホールディング・アーゲー Method and apparatus for determining parameters of biological tissue
US20060001551A1 (en) 2004-06-30 2006-01-05 Ulrich Kraft Analyte monitoring system with wireless alarm
US20060001538A1 (en) * 2004-06-30 2006-01-05 Ulrich Kraft Methods of monitoring the concentration of an analyte
JP2008504881A (en) * 2004-07-01 2008-02-21 ヴィヴォメディカル, インコーポレイテッド Noninvasive glucose measurement
US20060015020A1 (en) * 2004-07-06 2006-01-19 Dexcom, Inc. Systems and methods for manufacture of an analyte-measuring device including a membrane system
US20060016700A1 (en) 2004-07-13 2006-01-26 Dexcom, Inc. Transcutaneous analyte sensor
US7640048B2 (en) 2004-07-13 2009-12-29 Dexcom, Inc. Analyte sensor
US8565848B2 (en) 2004-07-13 2013-10-22 Dexcom, Inc. Transcutaneous analyte sensor
US20060020192A1 (en) 2004-07-13 2006-01-26 Dexcom, Inc. Transcutaneous analyte sensor
US7783333B2 (en) 2004-07-13 2010-08-24 Dexcom, Inc. Transcutaneous medical device with variable stiffness
EP2335584B1 (en) 2004-07-13 2015-06-17 DexCom, Inc. Transcutaneous analyte sensor
US8452368B2 (en) 2004-07-13 2013-05-28 Dexcom, Inc. Transcutaneous analyte sensor
WO2006127694A2 (en) 2004-07-13 2006-11-30 Dexcom, Inc. Analyte sensor
JP4817692B2 (en) * 2004-08-04 2011-11-16 シスメックス株式会社 Analysis equipment
US7728821B2 (en) 2004-08-06 2010-06-01 Touchtable, Inc. Touch detecting interactive display
US7719523B2 (en) 2004-08-06 2010-05-18 Touchtable, Inc. Bounding box gesture recognition on a touch detecting interactive display
US7724242B2 (en) 2004-08-06 2010-05-25 Touchtable, Inc. Touch driven method and apparatus to integrate and display multiple image layers forming alternate depictions of same subject matter
JP4742543B2 (en) * 2004-09-08 2011-08-10 凸版印刷株式会社 DNA chip device
US7608042B2 (en) * 2004-09-29 2009-10-27 Intellidx, Inc. Blood monitoring system
US20060229531A1 (en) * 2005-02-01 2006-10-12 Daniel Goldberger Blood monitoring system
US20070191716A1 (en) * 2004-09-29 2007-08-16 Daniel Goldberger Blood monitoring system
US8224414B2 (en) * 2004-10-28 2012-07-17 Echo Therapeutics, Inc. System and method for analyte sampling and analysis with hydrogel
CA2584699C (en) * 2004-10-28 2015-12-08 Sontra Medical Corporation System and method for analyte sampling and analysis with hydrogel
JP2006167428A (en) * 2004-11-16 2006-06-29 Sysmex Corp Analyte extraction device, analyzer, analyte extraction method, and analysis method
CA2591237A1 (en) * 2004-12-09 2006-06-15 Flexible Medical Systems, Llc Apparatus and method for continuous real-time trace biomolecular sampling, analysis and delivery
US7697967B2 (en) 2005-12-28 2010-04-13 Abbott Diabetes Care Inc. Method and apparatus for providing analyte sensor insertion
US9398882B2 (en) 2005-09-30 2016-07-26 Abbott Diabetes Care Inc. Method and apparatus for providing analyte sensor and data processing device
US9743862B2 (en) 2011-03-31 2017-08-29 Abbott Diabetes Care Inc. Systems and methods for transcutaneously implanting medical devices
US8029441B2 (en) 2006-02-28 2011-10-04 Abbott Diabetes Care Inc. Analyte sensor transmitter unit configuration for a data monitoring and management system
US8571624B2 (en) 2004-12-29 2013-10-29 Abbott Diabetes Care Inc. Method and apparatus for mounting a data transmission device in a communication system
US20090105569A1 (en) 2006-04-28 2009-04-23 Abbott Diabetes Care, Inc. Introducer Assembly and Methods of Use
US9259175B2 (en) 2006-10-23 2016-02-16 Abbott Diabetes Care, Inc. Flexible patch for fluid delivery and monitoring body analytes
US7883464B2 (en) 2005-09-30 2011-02-08 Abbott Diabetes Care Inc. Integrated transmitter unit and sensor introducer mechanism and methods of use
US20100331646A1 (en) * 2009-06-30 2010-12-30 Abbott Diabetes Care Inc. Health Management Devices and Methods
US9572534B2 (en) 2010-06-29 2017-02-21 Abbott Diabetes Care Inc. Devices, systems and methods for on-skin or on-body mounting of medical devices
US9351669B2 (en) 2009-09-30 2016-05-31 Abbott Diabetes Care Inc. Interconnect for on-body analyte monitoring device
US9636450B2 (en) 2007-02-19 2017-05-02 Udo Hoss Pump system modular components for delivering medication and analyte sensing at seperate insertion sites
US9788771B2 (en) 2006-10-23 2017-10-17 Abbott Diabetes Care Inc. Variable speed sensor insertion devices and methods of use
US8333714B2 (en) 2006-09-10 2012-12-18 Abbott Diabetes Care Inc. Method and system for providing an integrated analyte sensor insertion device and data processing unit
US7731657B2 (en) 2005-08-30 2010-06-08 Abbott Diabetes Care Inc. Analyte sensor introducer and methods of use
US10226207B2 (en) 2004-12-29 2019-03-12 Abbott Diabetes Care Inc. Sensor inserter having introducer
US8512243B2 (en) 2005-09-30 2013-08-20 Abbott Diabetes Care Inc. Integrated introducer and transmitter assembly and methods of use
US8652831B2 (en) 2004-12-30 2014-02-18 Sanofi-Aventis Deutschland Gmbh Method and apparatus for analyte measurement test time
CN100518641C (en) * 2005-01-19 2009-07-29 希森美康株式会社 Analyzer and cartridge for extracting analyte
US20060217602A1 (en) * 2005-03-04 2006-09-28 Alan Abul-Haj Method and apparatus for noninvasive targeting
US20090076360A1 (en) 2007-09-13 2009-03-19 Dexcom, Inc. Transcutaneous analyte sensor
US8133178B2 (en) 2006-02-22 2012-03-13 Dexcom, Inc. Analyte sensor
EP1863559A4 (en) 2005-03-21 2008-07-30 Abbott Diabetes Care Inc Method and system for providing integrated medication infusion and analyte monitoring system
WO2006105146A2 (en) 2005-03-29 2006-10-05 Arkal Medical, Inc. Devices, systems, methods and tools for continuous glucose monitoring
JP5129119B2 (en) * 2005-04-05 2013-01-23 コーニング インコーポレイテッド Label-free biosensors and cells
US20060223051A1 (en) * 2005-04-05 2006-10-05 Ye Fang System and method for performing G protein coupled receptor (GPCR) cell assays using waveguide-grating sensors
US8744546B2 (en) 2005-05-05 2014-06-03 Dexcom, Inc. Cellulosic-based resistance domain for an analyte sensor
US20060234369A1 (en) * 2005-04-14 2006-10-19 Cardiac Pacemakers, Inc. Implantable biosensor
US8060174B2 (en) 2005-04-15 2011-11-15 Dexcom, Inc. Analyte sensing biointerface
US8112240B2 (en) 2005-04-29 2012-02-07 Abbott Diabetes Care Inc. Method and apparatus for providing leak detection in data monitoring and management systems
US7768408B2 (en) 2005-05-17 2010-08-03 Abbott Diabetes Care Inc. Method and system for providing data management in data monitoring system
US7620437B2 (en) * 2005-06-03 2009-11-17 Abbott Diabetes Care Inc. Method and apparatus for providing rechargeable power in data monitoring and management systems
ES2717135T3 (en) 2005-07-20 2019-06-19 Ascensia Diabetes Care Holdings Ag Method to signal the user to add an additional sample to a test strip, method to measure the temperature of a sample and methods to determine the concentration of an analyte based on controlled amperometry
CA2620586A1 (en) 2005-08-31 2007-03-08 Boris P. Kovatchev Improving the accuracy of continuous glucose sensors
ES2575660T3 (en) * 2005-09-09 2016-06-30 F. Hoffmann-La Roche Ag System, tools, devices and program for diabetic care
US8880138B2 (en) 2005-09-30 2014-11-04 Abbott Diabetes Care Inc. Device for channeling fluid and methods of use
US7756561B2 (en) 2005-09-30 2010-07-13 Abbott Diabetes Care Inc. Method and apparatus for providing rechargeable power in data monitoring and management systems
KR101577176B1 (en) 2005-09-30 2015-12-14 바이엘 헬스케어 엘엘씨 Gated voltammetry analyte determination
US9521968B2 (en) 2005-09-30 2016-12-20 Abbott Diabetes Care Inc. Analyte sensor retention mechanism and methods of use
US7468125B2 (en) * 2005-10-17 2008-12-23 Lifescan, Inc. System and method of processing a current sample for calculating a glucose concentration
US8066866B2 (en) * 2005-10-17 2011-11-29 Lifescan, Inc. Methods for measuring physiological fluids
US7583190B2 (en) 2005-10-31 2009-09-01 Abbott Diabetes Care Inc. Method and apparatus for providing data communication in data monitoring and management systems
US7766829B2 (en) 2005-11-04 2010-08-03 Abbott Diabetes Care Inc. Method and system for providing basal profile modification in analyte monitoring and management systems
US9713447B2 (en) * 2005-11-10 2017-07-25 Biovotion Ag Device for determining the glucose level in body tissue
US7729737B2 (en) * 2005-11-22 2010-06-01 Isense Corporation Method and apparatus for background current arrangements for a biosensor
US20080200838A1 (en) * 2005-11-28 2008-08-21 Daniel Goldberger Wearable, programmable automated blood testing system
US20070123801A1 (en) * 2005-11-28 2007-05-31 Daniel Goldberger Wearable, programmable automated blood testing system
US8333874B2 (en) * 2005-12-09 2012-12-18 Flexible Medical Systems, Llc Flexible apparatus and method for monitoring and delivery
US11298058B2 (en) 2005-12-28 2022-04-12 Abbott Diabetes Care Inc. Method and apparatus for providing analyte sensor insertion
CA2636034A1 (en) 2005-12-28 2007-10-25 Abbott Diabetes Care Inc. Medical device insertion
US8150628B2 (en) * 2005-12-30 2012-04-03 The Invention Science Fund I, Llc Establishing a biological recording timeline by artificial marking
US20070156347A1 (en) * 2005-12-30 2007-07-05 Searete Llc Using a biological recording to obtain time values
US20070156345A1 (en) * 2005-12-30 2007-07-05 Hyde Roderick A Modulating a biological recording with another biological recording
US9757061B2 (en) 2006-01-17 2017-09-12 Dexcom, Inc. Low oxygen in vivo analyte sensor
US7736310B2 (en) 2006-01-30 2010-06-15 Abbott Diabetes Care Inc. On-body medical device securement
US8344966B2 (en) 2006-01-31 2013-01-01 Abbott Diabetes Care Inc. Method and system for providing a fault tolerant display unit in an electronic device
RU2455925C2 (en) 2006-02-27 2012-07-20 БАЙЕР ХЕЛТКЭА ЭлЭлСи Determination of investigated substance with correction to temperature for systems of biosensors
US7826879B2 (en) 2006-02-28 2010-11-02 Abbott Diabetes Care Inc. Analyte sensors and methods of use
US20080154107A1 (en) * 2006-12-20 2008-06-26 Jina Arvind N Device, systems, methods and tools for continuous glucose monitoring
US20090131778A1 (en) * 2006-03-28 2009-05-21 Jina Arvind N Devices, systems, methods and tools for continuous glucose monitoring
US20100049021A1 (en) * 2006-03-28 2010-02-25 Jina Arvind N Devices, systems, methods and tools for continuous analyte monitoring
US7618369B2 (en) 2006-10-02 2009-11-17 Abbott Diabetes Care Inc. Method and system for dynamically updating calibration parameters for an analyte sensor
US7630748B2 (en) 2006-10-25 2009-12-08 Abbott Diabetes Care Inc. Method and system for providing analyte monitoring
US9675290B2 (en) 2012-10-30 2017-06-13 Abbott Diabetes Care Inc. Sensitivity calibration of in vivo sensors used to measure analyte concentration
US8529751B2 (en) 2006-03-31 2013-09-10 Lifescan, Inc. Systems and methods for discriminating control solution from a physiological sample
US7620438B2 (en) 2006-03-31 2009-11-17 Abbott Diabetes Care Inc. Method and system for powering an electronic device
US9392969B2 (en) 2008-08-31 2016-07-19 Abbott Diabetes Care Inc. Closed loop control and signal attenuation detection
US8224415B2 (en) 2009-01-29 2012-07-17 Abbott Diabetes Care Inc. Method and device for providing offset model based calibration for analyte sensor
US7653425B2 (en) 2006-08-09 2010-01-26 Abbott Diabetes Care Inc. Method and system for providing calibration of an analyte sensor in an analyte monitoring system
US8374668B1 (en) 2007-10-23 2013-02-12 Abbott Diabetes Care Inc. Analyte sensor with lag compensation
US7801582B2 (en) 2006-03-31 2010-09-21 Abbott Diabetes Care Inc. Analyte monitoring and management system and methods therefor
US8473022B2 (en) 2008-01-31 2013-06-25 Abbott Diabetes Care Inc. Analyte sensor with time lag compensation
US9326709B2 (en) 2010-03-10 2016-05-03 Abbott Diabetes Care Inc. Systems, devices and methods for managing glucose levels
US8219173B2 (en) 2008-09-30 2012-07-10 Abbott Diabetes Care Inc. Optimizing analyte sensor calibration
US8140312B2 (en) 2007-05-14 2012-03-20 Abbott Diabetes Care Inc. Method and system for determining analyte levels
US8226891B2 (en) 2006-03-31 2012-07-24 Abbott Diabetes Care Inc. Analyte monitoring devices and methods therefor
JP5025159B2 (en) * 2006-04-28 2012-09-12 シスメックス株式会社 Biological component measuring device
US7966859B2 (en) 2006-05-03 2011-06-28 Bayer Healthcare Llc Underfill detection system for a biosensor
US8092385B2 (en) * 2006-05-23 2012-01-10 Intellidx, Inc. Fluid access interface
US7920907B2 (en) 2006-06-07 2011-04-05 Abbott Diabetes Care Inc. Analyte monitoring system and method
US20070287991A1 (en) * 2006-06-08 2007-12-13 Mckay William F Devices and methods for detection of markers of axial pain with or without radiculopathy
US8114023B2 (en) 2006-07-28 2012-02-14 Legacy Emanuel Hospital & Health Center Analyte sensing and response system
US20110054391A1 (en) * 2006-07-28 2011-03-03 Ward W Kenneth Analyte sensing and response system
US20080058726A1 (en) * 2006-08-30 2008-03-06 Arvind Jina Methods and Apparatus Incorporating a Surface Penetration Device
US8562528B2 (en) 2006-10-04 2013-10-22 Dexcom, Inc. Analyte sensor
US8298142B2 (en) 2006-10-04 2012-10-30 Dexcom, Inc. Analyte sensor
US8275438B2 (en) 2006-10-04 2012-09-25 Dexcom, Inc. Analyte sensor
US8478377B2 (en) 2006-10-04 2013-07-02 Dexcom, Inc. Analyte sensor
US8447376B2 (en) 2006-10-04 2013-05-21 Dexcom, Inc. Analyte sensor
US8449464B2 (en) 2006-10-04 2013-05-28 Dexcom, Inc. Analyte sensor
US7831287B2 (en) 2006-10-04 2010-11-09 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
EP2957908A1 (en) * 2006-10-05 2015-12-23 Lifescan Scotland Limited Methods for determining an analyte concentration using signal processing algorithms
US9046480B2 (en) 2006-10-05 2015-06-02 Lifescan Scotland Limited Method for determining hematocrit corrected analyte concentrations
JP5244116B2 (en) 2006-10-24 2013-07-24 バイエル・ヘルスケア・エルエルシー Transient decay current measurement method
AU2007308804A1 (en) 2006-10-26 2008-05-02 Abbott Diabetes Care, Inc. Method, system and computer program product for real-time detection of sensitivity decline in analyte sensors
US8579853B2 (en) 2006-10-31 2013-11-12 Abbott Diabetes Care Inc. Infusion devices and methods
US20080306353A1 (en) * 2006-11-03 2008-12-11 Douglas Joel S Calculation device for metabolic control of critically ill and/or diabetic patients
US8079955B2 (en) * 2006-11-28 2011-12-20 Isense Corporation Method and apparatus for managing glucose control
US8092386B1 (en) * 2006-12-22 2012-01-10 Pacesetter, Inc. Method and implantable system for blood-glucose concentration monitoring
US8738107B2 (en) 2007-05-10 2014-05-27 Medtronic Minimed, Inc. Equilibrium non-consuming fluorescence sensor for real time intravascular glucose measurement
DK2989975T3 (en) 2007-02-06 2018-09-24 Medtronic Minimed Inc OPTICAL SYSTEMS AND PROCEDURES FOR RATIOMETRIC MEASUREMENT OF BLOOD GLUCOSE CONCENTRATION
US8088097B2 (en) 2007-11-21 2012-01-03 Glumetrics, Inc. Use of an equilibrium intravascular sensor to achieve tight glycemic control
US8121857B2 (en) 2007-02-15 2012-02-21 Abbott Diabetes Care Inc. Device and method for automatic data acquisition and/or detection
US20080199894A1 (en) 2007-02-15 2008-08-21 Abbott Diabetes Care, Inc. Device and method for automatic data acquisition and/or detection
US8930203B2 (en) 2007-02-18 2015-01-06 Abbott Diabetes Care Inc. Multi-function analyte test device and methods therefor
US8732188B2 (en) 2007-02-18 2014-05-20 Abbott Diabetes Care Inc. Method and system for providing contextual based medication dosage determination
US8123686B2 (en) 2007-03-01 2012-02-28 Abbott Diabetes Care Inc. Method and apparatus for providing rolling data in communication systems
EP2124723A1 (en) * 2007-03-07 2009-12-02 Echo Therapeutics, Inc. Transdermal analyte monitoring systems and methods for analyte detection
US20080228056A1 (en) 2007-03-13 2008-09-18 Michael Blomquist Basal rate testing using frequent blood glucose input
US20080234562A1 (en) * 2007-03-19 2008-09-25 Jina Arvind N Continuous analyte monitor with multi-point self-calibration
CA2681412A1 (en) 2007-03-26 2008-10-02 Dexcom, Inc. Analyte sensor
JP2008253560A (en) * 2007-04-05 2008-10-23 Shinichi Yoshida Device for detecting pseudohypoglycemia and issuing alarm
WO2009096992A1 (en) 2007-04-14 2009-08-06 Abbott Diabetes Care, Inc. Method and apparatus for providing data processing and control in medical communication system
US9008743B2 (en) 2007-04-14 2015-04-14 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in medical communication system
US7768387B2 (en) 2007-04-14 2010-08-03 Abbott Diabetes Care Inc. Method and apparatus for providing dynamic multi-stage signal amplification in a medical device
CA2683959C (en) 2007-04-14 2017-08-29 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in medical communication system
WO2008130896A1 (en) 2007-04-14 2008-10-30 Abbott Diabetes Care, Inc. Method and apparatus for providing data processing and control in medical communication system
CA2683930A1 (en) 2007-04-14 2008-10-23 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in medical communication system
EP2064542B1 (en) * 2007-04-19 2011-08-17 Corning Incorporated Live-cell signals of pathogen intrusion and methods thereof
US20080269714A1 (en) 2007-04-25 2008-10-30 Medtronic Minimed, Inc. Closed loop/semi-closed loop therapy modification system
US20080269723A1 (en) * 2007-04-25 2008-10-30 Medtronic Minimed, Inc. Closed loop/semi-closed loop therapy modification system
US8461985B2 (en) 2007-05-08 2013-06-11 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US8665091B2 (en) 2007-05-08 2014-03-04 Abbott Diabetes Care Inc. Method and device for determining elapsed sensor life
US8456301B2 (en) 2007-05-08 2013-06-04 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US7928850B2 (en) 2007-05-08 2011-04-19 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US8560038B2 (en) 2007-05-14 2013-10-15 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8600681B2 (en) 2007-05-14 2013-12-03 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US10002233B2 (en) 2007-05-14 2018-06-19 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8239166B2 (en) 2007-05-14 2012-08-07 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8260558B2 (en) 2007-05-14 2012-09-04 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US9125548B2 (en) 2007-05-14 2015-09-08 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8444560B2 (en) 2007-05-14 2013-05-21 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US8103471B2 (en) 2007-05-14 2012-01-24 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US7996158B2 (en) 2007-05-14 2011-08-09 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US7751907B2 (en) 2007-05-24 2010-07-06 Smiths Medical Asd, Inc. Expert system for insulin pump therapy
US8221345B2 (en) 2007-05-30 2012-07-17 Smiths Medical Asd, Inc. Insulin pump based expert system
WO2008150917A1 (en) 2007-05-31 2008-12-11 Abbott Diabetes Care, Inc. Insertion devices and methods
US8197650B2 (en) 2007-06-07 2012-06-12 Sensor Innovations, Inc. Silicon electrochemical sensors
WO2008154312A1 (en) 2007-06-08 2008-12-18 Dexcom, Inc. Integrated medicament delivery device for use with continuous analyte sensor
US20080312518A1 (en) * 2007-06-14 2008-12-18 Arkal Medical, Inc On-demand analyte monitor and method of use
CA2690870C (en) * 2007-06-21 2017-07-11 Abbott Diabetes Care Inc. Health monitor
EP3533387A3 (en) 2007-06-21 2019-11-13 Abbott Diabetes Care, Inc. Health management devices and methods
US8160900B2 (en) 2007-06-29 2012-04-17 Abbott Diabetes Care Inc. Analyte monitoring and management device and method to analyze the frequency of user interaction with the device
WO2009009448A1 (en) * 2007-07-11 2009-01-15 Silveri Michael A Amperometric sensor
US8298391B2 (en) * 2007-07-11 2012-10-30 Silveri Michael A Amperometric sensor
US8834366B2 (en) 2007-07-31 2014-09-16 Abbott Diabetes Care Inc. Method and apparatus for providing analyte sensor calibration
US7768386B2 (en) 2007-07-31 2010-08-03 Abbott Diabetes Care Inc. Method and apparatus for providing data processing and control in a medical communication system
US20090036759A1 (en) * 2007-08-01 2009-02-05 Ault Timothy E Collapsible noninvasive analyzer method and apparatus
US20090309617A1 (en) * 2007-08-24 2009-12-17 Ye Fang Biosensor antibody functional mapping
US9968742B2 (en) 2007-08-29 2018-05-15 Medtronic Minimed, Inc. Combined sensor and infusion set using separated sites
US20120046533A1 (en) 2007-08-29 2012-02-23 Medtronic Minimed, Inc. Combined sensor and infusion sets
US8142640B2 (en) * 2007-09-06 2012-03-27 Eci Technology, Inc. Chloride analysis in acid copper plating baths
US7935076B2 (en) 2007-09-07 2011-05-03 Asante Solutions, Inc. Activity sensing techniques for an infusion pump system
US7879026B2 (en) * 2007-09-07 2011-02-01 Asante Solutions, Inc. Controlled adjustment of medicine dispensation from an infusion pump device
PL2040072T3 (en) * 2007-09-22 2013-06-28 Hoffmann La Roche Analysis system for measuring the concentration of an analyte in a bodily fluid
US8778168B2 (en) * 2007-09-28 2014-07-15 Lifescan, Inc. Systems and methods of discriminating control solution from a physiological sample
US20090093011A1 (en) * 2007-10-05 2009-04-09 Ye Fang Biosensors for ligand-directed functional selectivity
US8703428B2 (en) * 2007-10-06 2014-04-22 Corning Incorporated Single-cell label-free assay
US8426148B2 (en) 2007-10-06 2013-04-23 Corning Incorporated Label-free methods using a resonant waveguide grating biosensor to determine GPCR signaling pathways
US20090325211A1 (en) * 2007-10-06 2009-12-31 Ye Fang System and method for dual-detection of a cellular response
US20090099427A1 (en) * 2007-10-12 2009-04-16 Arkal Medical, Inc. Microneedle array with diverse needle configurations
US8216138B1 (en) 2007-10-23 2012-07-10 Abbott Diabetes Care Inc. Correlation of alternative site blood and interstitial fluid glucose concentrations to venous glucose concentration
US8409093B2 (en) 2007-10-23 2013-04-02 Abbott Diabetes Care Inc. Assessing measures of glycemic variability
US8377031B2 (en) 2007-10-23 2013-02-19 Abbott Diabetes Care Inc. Closed loop control system with safety parameters and methods
WO2009055736A1 (en) 2007-10-25 2009-04-30 Dexcom, Inc. Systems and methods for processing sensor data
US8417312B2 (en) 2007-10-25 2013-04-09 Dexcom, Inc. Systems and methods for processing sensor data
RU2706691C2 (en) * 2007-12-10 2019-11-20 Асцензия Диабетс Кэар Холдингс АГ Method of determining analyte concentration
WO2009076302A1 (en) 2007-12-10 2009-06-18 Bayer Healthcare Llc Control markers for auto-detection of control solution and methods of use
US9839395B2 (en) 2007-12-17 2017-12-12 Dexcom, Inc. Systems and methods for processing sensor data
US20090164239A1 (en) 2007-12-19 2009-06-25 Abbott Diabetes Care, Inc. Dynamic Display Of Glucose Information
US20090177147A1 (en) 2008-01-07 2009-07-09 Michael Blomquist Insulin pump with insulin therapy coaching
US20090181409A1 (en) * 2008-01-10 2009-07-16 Ye Fang Optical biosensor method for cell-cell interaction
EP2249693A1 (en) * 2008-01-11 2010-11-17 Solianis Holding Ag A method and device for determining a property of living tissue
US8603768B2 (en) 2008-01-17 2013-12-10 Lifescan, Inc. System and method for measuring an analyte in a sample
EP2252196A4 (en) 2008-02-21 2013-05-15 Dexcom Inc Systems and methods for processing, transmitting and displaying sensor data
US8759013B2 (en) 2008-03-05 2014-06-24 Corning Incorporated Dual-target biosensor cell assays
US8313898B2 (en) 2008-03-05 2012-11-20 Corning Incorporated Dual-target biosensor cell assays
US8846575B2 (en) 2008-03-05 2014-09-30 Corning Incorporated High-throughput high-information content label-free cell biology screening methods
US8396528B2 (en) 2008-03-25 2013-03-12 Dexcom, Inc. Analyte sensor
US20090247855A1 (en) 2008-03-28 2009-10-01 Dexcom, Inc. Polymer membranes for continuous analyte sensors
US8682408B2 (en) 2008-03-28 2014-03-25 Dexcom, Inc. Polymer membranes for continuous analyte sensors
US8583204B2 (en) 2008-03-28 2013-11-12 Dexcom, Inc. Polymer membranes for continuous analyte sensors
EP2982383B1 (en) 2008-04-10 2019-05-15 Abbott Diabetes Care, Inc. Method for sterilizing an analyte sensor
US8754611B2 (en) 2008-04-11 2014-06-17 Apple Inc. Diffusion-limited adaptive battery charging
WO2009126900A1 (en) 2008-04-11 2009-10-15 Pelikan Technologies, Inc. Method and apparatus for analyte detecting device
US8591410B2 (en) 2008-05-30 2013-11-26 Abbott Diabetes Care Inc. Method and apparatus for providing glycemic control
US7826382B2 (en) 2008-05-30 2010-11-02 Abbott Diabetes Care Inc. Close proximity communication device and methods
US8924159B2 (en) 2008-05-30 2014-12-30 Abbott Diabetes Care Inc. Method and apparatus for providing glycemic control
US8551320B2 (en) 2008-06-09 2013-10-08 Lifescan, Inc. System and method for measuring an analyte in a sample
US8876755B2 (en) 2008-07-14 2014-11-04 Abbott Diabetes Care Inc. Closed loop control system interface and methods
WO2010014963A2 (en) * 2008-07-31 2010-02-04 Government Of The United States As Represented By The Secretary Of The Army Universal models for predicting glucose concentration in humans
US8762306B2 (en) * 2008-08-14 2014-06-24 The University Of Toledo Neural network for glucose therapy recommendation
US7959598B2 (en) 2008-08-20 2011-06-14 Asante Solutions, Inc. Infusion pump systems and methods
US8734422B2 (en) 2008-08-31 2014-05-27 Abbott Diabetes Care Inc. Closed loop control with improved alarm functions
US8622988B2 (en) 2008-08-31 2014-01-07 Abbott Diabetes Care Inc. Variable rate closed loop control and methods
US9943644B2 (en) 2008-08-31 2018-04-17 Abbott Diabetes Care Inc. Closed loop control with reference measurement and methods thereof
US20100057040A1 (en) 2008-08-31 2010-03-04 Abbott Diabetes Care, Inc. Robust Closed Loop Control And Methods
EP2326944B1 (en) 2008-09-19 2020-08-19 Dexcom, Inc. Particle-containing membrane and particulate electrode for analyte sensors
US8986208B2 (en) 2008-09-30 2015-03-24 Abbott Diabetes Care Inc. Analyte sensor sensitivity attenuation mitigation
US9326707B2 (en) 2008-11-10 2016-05-03 Abbott Diabetes Care Inc. Alarm characterization for analyte monitoring devices and systems
CA2743440C (en) 2008-12-08 2017-07-18 Bayer Healthcare Llc Biosensor system with signal adjustment
US8103456B2 (en) 2009-01-29 2012-01-24 Abbott Diabetes Care Inc. Method and device for early signal attenuation detection using blood glucose measurements
US9375169B2 (en) 2009-01-30 2016-06-28 Sanofi-Aventis Deutschland Gmbh Cam drive for managing disposable penetrating member actions with a single motor and motor and control system
US8560082B2 (en) 2009-01-30 2013-10-15 Abbott Diabetes Care Inc. Computerized determination of insulin pump therapy parameters using real time and retrospective data processing
US9402544B2 (en) 2009-02-03 2016-08-02 Abbott Diabetes Care Inc. Analyte sensor and apparatus for insertion of the sensor
DK2409253T3 (en) * 2009-03-16 2019-03-25 Hoffmann La Roche METHOD OF AUTOMATICALLY CREATING A USER-SPECIFIC TARGET DATA RECORDING REGISTER FOR DISCONTINUOUS BLOOD SUGAR MEASUREMENT AND DATA PROCESSOR AND BLOOD SUCCESS MEASURER
US9446194B2 (en) 2009-03-27 2016-09-20 Dexcom, Inc. Methods and systems for promoting glucose management
US8753290B2 (en) * 2009-03-27 2014-06-17 Intellectual Inspiration, Llc Fluid transfer system and method
US8630692B2 (en) 2009-04-30 2014-01-14 Pacesetter, Inc. Method and implantable system for blood-glucose concentration monitoring using parallel methodologies
WO2010121229A1 (en) 2009-04-16 2010-10-21 Abbott Diabetes Care Inc. Analyte sensor calibration management
US9226701B2 (en) 2009-04-28 2016-01-05 Abbott Diabetes Care Inc. Error detection in critical repeating data in a wireless sensor system
US8467972B2 (en) 2009-04-28 2013-06-18 Abbott Diabetes Care Inc. Closed loop blood glucose control algorithm analysis
EP2424426B1 (en) 2009-04-29 2020-01-08 Abbott Diabetes Care, Inc. Method and system for providing data communication in continuous glucose monitoring and management system
WO2010138856A1 (en) 2009-05-29 2010-12-02 Abbott Diabetes Care Inc. Medical device antenna systems having external antenna configurations
US8613892B2 (en) 2009-06-30 2013-12-24 Abbott Diabetes Care Inc. Analyte meter with a moveable head and methods of using the same
WO2011005764A1 (en) * 2009-07-06 2011-01-13 Ada Technologies, Inc. Electrochemical device and method for long-term measurement of hypohalites
EP3173014B1 (en) 2009-07-23 2021-08-18 Abbott Diabetes Care, Inc. Real time management of data relating to physiological control of glucose levels
EP3932309A1 (en) 2009-07-23 2022-01-05 Abbott Diabetes Care, Inc. Continuous analyte measurement system
US8641671B2 (en) 2009-07-30 2014-02-04 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
WO2011014851A1 (en) 2009-07-31 2011-02-03 Abbott Diabetes Care Inc. Method and apparatus for providing analyte monitoring system calibration accuracy
EP2290371A1 (en) 2009-08-27 2011-03-02 F. Hoffmann-La Roche AG Calibration method for prospective calibration of a measuring device
EP2473098A4 (en) 2009-08-31 2014-04-09 Abbott Diabetes Care Inc Analyte signal processing device and methods
AU2010286917B2 (en) 2009-08-31 2016-03-10 Abbott Diabetes Care Inc. Medical devices and methods
EP2473099A4 (en) 2009-08-31 2015-01-14 Abbott Diabetes Care Inc Analyte monitoring system and methods for managing power and noise
US9320461B2 (en) 2009-09-29 2016-04-26 Abbott Diabetes Care Inc. Method and apparatus for providing notification function in analyte monitoring systems
JP2013506503A (en) 2009-09-30 2013-02-28 グルメトリクス, インコーポレイテッド Sensor with antithrombogenic coating
US9357951B2 (en) 2009-09-30 2016-06-07 Dexcom, Inc. Transcutaneous analyte sensor
US20110082356A1 (en) 2009-10-01 2011-04-07 Medtronic Minimed, Inc. Analyte sensor apparatuses having interference rejection membranes and methods for making and using them
WO2011053881A1 (en) 2009-10-30 2011-05-05 Abbott Diabetes Care Inc. Method and apparatus for detecting false hypoglycemic conditions
US9858386B2 (en) * 2009-11-02 2018-01-02 Universita Degli Studi Di Padova Method to recalibrate continuous glucose monitoring data on-line
US8467843B2 (en) 2009-11-04 2013-06-18 Glumetrics, Inc. Optical sensor configuration for ratiometric correction of blood glucose measurement
BR112012009291A2 (en) 2009-11-10 2016-05-31 Bayer Healthcare Llc underfill recognition system for a biosensor
US20110288388A1 (en) 2009-11-20 2011-11-24 Medtronic Minimed, Inc. Multi-conductor lead configurations useful with medical device systems and methods for making and using them
US8882701B2 (en) 2009-12-04 2014-11-11 Smiths Medical Asd, Inc. Advanced step therapy delivery for an ambulatory infusion pump and system
US20110152658A1 (en) * 2009-12-17 2011-06-23 Glumetrics, Inc. Identification of aberrant measurements of in vivo glucose concentration using temperature
US8660628B2 (en) 2009-12-21 2014-02-25 Medtronic Minimed, Inc. Analyte sensors comprising blended membrane compositions and methods for making and using them
USD924406S1 (en) 2010-02-01 2021-07-06 Abbott Diabetes Care Inc. Analyte sensor inserter
JP5750123B2 (en) * 2010-02-11 2015-07-15 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア System, device and method for delivering a biological agent or drug to a subject
US20110207789A1 (en) * 2010-02-19 2011-08-25 Ye Fang Methods related to casein kinase ii (ck2) inhibitors and the use of purinosome-disrupting ck2 inhibitors for anti-cancer therapy agents
WO2011105178A1 (en) * 2010-02-26 2011-09-01 アークレイ株式会社 Analysis device, analysis method, and analysis system
US10448872B2 (en) 2010-03-16 2019-10-22 Medtronic Minimed, Inc. Analyte sensor apparatuses having improved electrode configurations and methods for making and using them
MX2012010860A (en) * 2010-03-22 2013-03-05 Bayer Healthcare Llc Residual compensation for a biosensor.
CN102548476A (en) 2010-03-24 2012-07-04 雅培糖尿病护理公司 Medical device inserters and processes of inserting and using medical devices
US20120197358A1 (en) * 2010-04-09 2012-08-02 Prescott Marvin A Light Therapy for Treating or Managing Diabetes and Metabolic Syndrome
US8965476B2 (en) 2010-04-16 2015-02-24 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US9164076B2 (en) 2010-06-07 2015-10-20 Bayer Healthcare Llc Slope-based compensation including secondary output signals
US9222910B2 (en) 2010-06-07 2015-12-29 Bayer Healthcare Llc Underfill management system for a biosensor
US8636711B2 (en) 2010-06-14 2014-01-28 Legacy Emanuel Hospital & Health Center Stabilized glucagon solutions and uses therefor
US8635046B2 (en) 2010-06-23 2014-01-21 Abbott Diabetes Care Inc. Method and system for evaluating analyte sensor response characteristics
US9215995B2 (en) 2010-06-23 2015-12-22 Medtronic Minimed, Inc. Sensor systems having multiple probes and electrode arrays
US11064921B2 (en) 2010-06-29 2021-07-20 Abbott Diabetes Care Inc. Devices, systems and methods for on-skin or on-body mounting of medical devices
US10092229B2 (en) 2010-06-29 2018-10-09 Abbott Diabetes Care Inc. Calibration of analyte measurement system
US8828329B2 (en) 2010-10-01 2014-09-09 Church & Dwight, Co., Inc. Electronic analyte assaying device
EP2624745A4 (en) 2010-10-07 2018-05-23 Abbott Diabetes Care, Inc. Analyte monitoring devices and methods
WO2012075331A2 (en) * 2010-12-01 2012-06-07 Pinnacle Technology, Inc. Tissue implantable microbiosensor
US9877673B2 (en) 2010-12-10 2018-01-30 Clinitech, Llc Transdermal sampling and analysis device
US9451913B2 (en) 2010-12-10 2016-09-27 Touchtek Labs, Llc Transdermal sampling and analysis device
GB2500550A (en) 2010-12-16 2013-09-25 Sensor Innovations Inc Electrochemical sensors
US8887556B2 (en) 2011-02-15 2014-11-18 Michael A. Silveri Amperometric sensor system
EP3583901A3 (en) 2011-02-28 2020-01-15 Abbott Diabetes Care, Inc. Devices, systems, and methods associated with analyte monitoring devices and devices incorporating the same
US10136845B2 (en) 2011-02-28 2018-11-27 Abbott Diabetes Care Inc. Devices, systems, and methods associated with analyte monitoring devices and devices incorporating the same
US9101305B2 (en) 2011-03-09 2015-08-11 Medtronic Minimed, Inc. Glucose sensor product and related manufacturing and packaging methods
EP3575796B1 (en) 2011-04-15 2020-11-11 DexCom, Inc. Advanced analyte sensor calibration and error detection
US9008744B2 (en) 2011-05-06 2015-04-14 Medtronic Minimed, Inc. Method and apparatus for continuous analyte monitoring
EP2747650B1 (en) 2011-08-26 2023-04-05 Dexcom, Inc. Polymer membranes for continuous analyte sensors
EP3586831A1 (en) 2011-09-21 2020-01-01 Ascensia Diabetes Care Holdings AG Analysis compensation including segmented signals
US9622691B2 (en) 2011-10-31 2017-04-18 Abbott Diabetes Care Inc. Model based variable risk false glucose threshold alarm prevention mechanism
US9069536B2 (en) 2011-10-31 2015-06-30 Abbott Diabetes Care Inc. Electronic devices having integrated reset systems and methods thereof
US9989522B2 (en) * 2011-11-01 2018-06-05 Medtronic Minimed, Inc. Methods and materials for modulating start-up time and air removal in dry sensors
JP6443802B2 (en) 2011-11-07 2018-12-26 アボット ダイアベティス ケア インコーポレイテッドAbbott Diabetes Care Inc. Analyte monitoring apparatus and method
EP2747638A1 (en) * 2011-11-22 2014-07-02 Koninklijke Philips N.V. Mental balance or imbalance estimation system and method
US9317656B2 (en) 2011-11-23 2016-04-19 Abbott Diabetes Care Inc. Compatibility mechanisms for devices in a continuous analyte monitoring system and methods thereof
US8710993B2 (en) 2011-11-23 2014-04-29 Abbott Diabetes Care Inc. Mitigating single point failure of devices in an analyte monitoring system and methods thereof
US9968284B2 (en) 2011-12-02 2018-05-15 Clinitech, Llc Anti-interferent barrier layers for non-invasive transdermal sampling and analysis device
FI4056105T3 (en) 2011-12-11 2023-12-28 Abbott Diabetes Care Inc Analyte sensor devices
US9588113B2 (en) 2012-02-22 2017-03-07 Church & Dwight Co., Inc. Methods for electronic analyte assaying
WO2013138369A1 (en) 2012-03-16 2013-09-19 Dexcom, Inc. Systems and methods for processing analyte sensor data
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
GB2502287B (en) * 2012-05-21 2016-11-23 Dermal Diagnostics Ltd Cumulative measurement of an analyte
US9493807B2 (en) 2012-05-25 2016-11-15 Medtronic Minimed, Inc. Foldover sensors and methods for making and using them
US9238100B2 (en) 2012-06-07 2016-01-19 Tandem Diabetes Care, Inc. Device and method for training users of ambulatory medical devices
EP2867672B1 (en) 2012-06-28 2019-01-09 Bio-rad Laboratories, Inc. Multi-protein quantitation standard
US20140012115A1 (en) 2012-07-03 2014-01-09 Medtronic Minimed, Inc. Plasma deposited adhesion promoter layers for use with analyte sensors
US8454557B1 (en) 2012-07-19 2013-06-04 Asante Solutions, Inc. Infusion pump system and method
US10132793B2 (en) 2012-08-30 2018-11-20 Abbott Diabetes Care Inc. Dropout detection in continuous analyte monitoring data during data excursions
US9968306B2 (en) 2012-09-17 2018-05-15 Abbott Diabetes Care Inc. Methods and apparatuses for providing adverse condition notification with enhanced wireless communication range in analyte monitoring systems
US9081068B2 (en) 2012-09-18 2015-07-14 Apple Inc. Method and apparatus for determining a capacity of a battery
US9788765B2 (en) 2012-09-28 2017-10-17 Dexcom, Inc. Zwitterion surface modifications for continuous sensors
WO2014055718A1 (en) 2012-10-04 2014-04-10 Aptima, Inc. Clinical support systems and methods
US9833191B2 (en) 2012-11-07 2017-12-05 Bigfoot Biomedical, Inc. Computer-based diabetes management
US10466247B2 (en) 2012-11-20 2019-11-05 Becton, Dickinson And Company System and method for diagnosing sensor performance using analyte-independent ratiometric signals
US10194840B2 (en) 2012-12-06 2019-02-05 Medtronic Minimed, Inc. Microarray electrodes useful with analyte sensors and methods for making and using them
US9427523B2 (en) 2012-12-10 2016-08-30 Bigfoot Biomedical, Inc. Infusion pump system and method
US20140276536A1 (en) 2013-03-14 2014-09-18 Asante Solutions, Inc. Infusion Pump System and Methods
US10426383B2 (en) 2013-01-22 2019-10-01 Medtronic Minimed, Inc. Muting glucose sensor oxygen response and reducing electrode edge growth with pulsed current plating
US9446186B2 (en) 2013-03-01 2016-09-20 Bigfoot Biomedical, Inc. Operating an infusion pump system
US10357606B2 (en) 2013-03-13 2019-07-23 Tandem Diabetes Care, Inc. System and method for integration of insulin pumps and continuous glucose monitoring
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump
US10820860B2 (en) 2013-03-14 2020-11-03 One Drop Biosensor Technologies, Llc On-body microsensor for biomonitoring
US9008745B2 (en) 2013-03-14 2015-04-14 Sano Intelligence, Inc. On-body microsensor for biomonitoring
US10898116B2 (en) * 2013-03-15 2021-01-26 Cambridge Medical Technologies LLC Methods of manufacture to optimize performance of transdermal sampling and analysis device
US9474475B1 (en) 2013-03-15 2016-10-25 Abbott Diabetes Care Inc. Multi-rate analyte sensor data collection with sample rate configurable signal processing
JP6352954B2 (en) * 2013-03-15 2018-07-04 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Method and device for using information from recovery pulses in electrochemical analyte measurement, apparatus and system incorporating them
WO2014152034A1 (en) 2013-03-15 2014-09-25 Abbott Diabetes Care Inc. Sensor fault detection using analyte sensor data pattern comparison
KR101732300B1 (en) * 2013-03-15 2017-05-02 에프. 호프만-라 로슈 아게 Methods of failsafing electrochemical measurements of an analyte as well as devices, apparatuses and systems incorporating the same
KR101730288B1 (en) 2013-03-15 2017-04-25 에프. 호프만-라 로슈 아게 Methods of electrochemically measuring an analyte with a test sequence having a pulsed dc block as well as devices, apparatuses and systems incorporating the same
US10016561B2 (en) 2013-03-15 2018-07-10 Tandem Diabetes Care, Inc. Clinical variable determination
US10433773B1 (en) 2013-03-15 2019-10-08 Abbott Diabetes Care Inc. Noise rejection methods and apparatus for sparsely sampled analyte sensor data
US10004434B1 (en) 2013-03-15 2018-06-26 Georgetown University Microfluidic systems for electrochemical transdermal analyte sensing using a capillary-located electrode
US9486171B2 (en) 2013-03-15 2016-11-08 Tandem Diabetes Care, Inc. Predictive calibration
CA2907426A1 (en) 2013-03-16 2014-09-25 Empatica Srl Apparatus for electrodermal activity measurement with current compensation
US9446187B2 (en) 2013-06-03 2016-09-20 Bigfoot Biomedical, Inc. Infusion pump system and method
US9457141B2 (en) 2013-06-03 2016-10-04 Bigfoot Biomedical, Inc. Infusion pump system and method
US9835578B2 (en) * 2013-06-27 2017-12-05 Lifescan Scotland Limited Temperature compensation for an analyte measurement determined from a specified sampling time derived from a sensed physical characteristic of the sample containing the analyte
US9561324B2 (en) 2013-07-19 2017-02-07 Bigfoot Biomedical, Inc. Infusion pump system and method
WO2015035304A1 (en) 2013-09-06 2015-03-12 Tandem Diabetes Care, Inc. System and method for mitigating risk in automated medicament dosing
US20150122647A1 (en) 2013-11-07 2015-05-07 Medtronic Minimed, Inc. Enzyme matrices for use with ethylene oxide sterilization
US10569015B2 (en) 2013-12-02 2020-02-25 Bigfoot Biomedical, Inc. Infusion pump system and method
US10379125B2 (en) 2013-12-27 2019-08-13 Becton, Dickinson And Company System and method for dynamically calibrating and measuring analyte concentration in diabetes management monitors
WO2015102745A1 (en) 2013-12-31 2015-07-09 Abbott Diabetes Care Inc. Self-powered analyte sensor and devices using the same
US20150257687A1 (en) 2014-03-13 2015-09-17 Sano Intelligence, Inc. System for monitoring body chemistry
US10595754B2 (en) 2014-03-13 2020-03-24 Sano Intelligence, Inc. System for monitoring body chemistry
WO2015153482A1 (en) 2014-03-30 2015-10-08 Abbott Diabetes Care Inc. Method and apparatus for determining meal start and peak events in analyte monitoring systems
US10188793B2 (en) 2014-06-10 2019-01-29 Bigfoot Biomedical, Inc. Insulin on board calculation, schedule and delivery
US9629901B2 (en) 2014-07-01 2017-04-25 Bigfoot Biomedical, Inc. Glucagon administration system and methods
US9669160B2 (en) 2014-07-30 2017-06-06 Tandem Diabetes Care, Inc. Temporary suspension for closed-loop medicament therapy
EP3234563A1 (en) * 2014-12-18 2017-10-25 Radiometer Medical ApS Method for calibrating a device for measuring the concentration of creatinine
JP6435053B2 (en) * 2014-12-18 2018-12-05 ラジオメーター・メディカル・アー・ペー・エス Calibration method for creatinine concentration measuring device
DE102015003254A1 (en) * 2015-03-16 2016-09-22 Fresenius Medical Care Deutschland Gmbh Textile fabric for application to the skin and / or a wound of a patient and transdermal patch and arrangement of a transdermal patch and an evaluation unit
US11330987B2 (en) 2015-04-06 2022-05-17 Thomas Jefferson University Implantable vital sign sensor
US11000195B2 (en) 2015-04-06 2021-05-11 Thomas Jefferson University Implantable vital sign sensor
US10335043B2 (en) 2015-04-06 2019-07-02 Thomas Jefferson University Implantable vital sign sensor
WO2016164199A1 (en) 2015-04-06 2016-10-13 Thomas Jefferson University Implantable vital sign sensor
US9878097B2 (en) 2015-04-29 2018-01-30 Bigfoot Biomedical, Inc. Operating an infusion pump system
US10213139B2 (en) 2015-05-14 2019-02-26 Abbott Diabetes Care Inc. Systems, devices, and methods for assembling an applicator and sensor control device
US10674944B2 (en) 2015-05-14 2020-06-09 Abbott Diabetes Care Inc. Compact medical device inserters and related systems and methods
US11553883B2 (en) 2015-07-10 2023-01-17 Abbott Diabetes Care Inc. System, device and method of dynamic glucose profile response to physiological parameters
US11219390B2 (en) 2015-08-03 2022-01-11 Georgetown University Apparatus and method for delivery of antimicrobial during a transdermal sampling and delivery process
WO2017027432A1 (en) 2015-08-07 2017-02-16 Aptima, Inc. Systems and methods to support medical therapy decisions
US10569016B2 (en) 2015-12-29 2020-02-25 Tandem Diabetes Care, Inc. System and method for switching between closed loop and open loop control of an ambulatory infusion pump
US20170188905A1 (en) 2015-12-30 2017-07-06 Dexcom, Inc. Biointerface layer for analyte sensors
CN106990232B (en) * 2016-01-01 2019-05-28 海南欣泰康医药科技有限公司 Blood Kit analysis system and analysis method
US10987468B2 (en) 2016-01-05 2021-04-27 Bigfoot Biomedical, Inc. Operating multi-modal medicine delivery systems
US10449294B1 (en) 2016-01-05 2019-10-22 Bigfoot Biomedical, Inc. Operating an infusion pump system
WO2017123954A1 (en) * 2016-01-15 2017-07-20 University Of Cincinnati Advanced electroporation devices and methods for analyte access in biofluids
CN108778125B (en) * 2016-03-30 2022-02-18 德克斯康公司 Systems, devices, and methods for analyte monitoring systems
CN109414227A (en) 2016-04-26 2019-03-01 巴斯大学 Multiplexing for non-invasive monitoring substance is percutaneously extracted and detection device and its application method
US10324058B2 (en) 2016-04-28 2019-06-18 Medtronic Minimed, Inc. In-situ chemistry stack for continuous glucose sensors
US11179078B2 (en) 2016-06-06 2021-11-23 Medtronic Minimed, Inc. Polycarbonate urea/urethane polymers for use with analyte sensors
JP6778058B2 (en) * 2016-08-31 2020-10-28 シスメックス株式会社 Sensor assembly, test substance monitoring system and test substance monitoring method
CN106361288A (en) * 2016-09-28 2017-02-01 湖南老码信息科技有限责任公司 Summer dermatitis prediction method and system based on incremental neural network model
CN106596962B (en) * 2016-11-01 2018-07-03 武汉璟泓万方堂医药科技股份有限公司 A kind of CODE definite value modification methods based on the attenuation of blood sugar test paper test value
US10783801B1 (en) 2016-12-21 2020-09-22 Aptima, Inc. Simulation based training system for measurement of team cognitive load to automatically customize simulation content
WO2018136898A1 (en) 2017-01-23 2018-07-26 Abbott Diabetes Care Inc. Systems, devices and methods for analyte sensor insertion
US11134868B2 (en) 2017-03-17 2021-10-05 Medtronic Minimed, Inc. Metal pillar device structures and methods for making and using them in electrochemical and/or electrocatalytic applications
US11596330B2 (en) 2017-03-21 2023-03-07 Abbott Diabetes Care Inc. Methods, devices and system for providing diabetic condition diagnosis and therapy
US10856784B2 (en) 2017-06-30 2020-12-08 Medtronic Minimed, Inc. Sensor initialization methods for faster body sensor response
CN111246797A (en) 2017-10-24 2020-06-05 德克斯康公司 Pre-attached analyte sensors
US11331022B2 (en) 2017-10-24 2022-05-17 Dexcom, Inc. Pre-connected analyte sensors
CN109991194B (en) * 2017-12-29 2022-04-26 天津先阳科技发展有限公司 Method for inhibiting temperature interference in diffuse reflection spectrum, spectrum analysis method and device
US20190223771A1 (en) 2018-01-23 2019-07-25 Medtronic Minimed, Inc. Implantable polymer surfaces exhibiting reduced in vivo inflammatory responses
US11186859B2 (en) 2018-02-07 2021-11-30 Medtronic Minimed, Inc. Multilayer electrochemical analyte sensors and methods for making and using them
US11583213B2 (en) 2018-02-08 2023-02-21 Medtronic Minimed, Inc. Glucose sensor electrode design
US11220735B2 (en) 2018-02-08 2022-01-11 Medtronic Minimed, Inc. Methods for controlling physical vapor deposition metal film adhesion to substrates and surfaces
KR102142647B1 (en) * 2018-03-28 2020-08-07 주식회사 아이센스 Artificial Neural Network Model-Based Methods, Apparatus, Learning starategy and Systems for Analyte Analysis
WO2019222499A1 (en) 2018-05-16 2019-11-21 Medtronic Minimed, Inc. Thermally stable glucose limiting membrane for glucose sensors
US11076786B2 (en) * 2018-10-01 2021-08-03 The Florida International University Board Of Trustees Wound monitoring sensors and use thereof
JP7253230B2 (en) * 2019-01-18 2023-04-06 国立大学法人山形大学 sweat component sensor
EP3948677A1 (en) * 2019-03-27 2022-02-09 Sanofi Residual semi-recurrent neural networks
US11633129B2 (en) 2019-04-05 2023-04-25 Cambridge Medical Technologies LLC Non-invasive transdermal sampling and analysis device incorporating redox cofactors
GB201913131D0 (en) * 2019-05-31 2019-10-30 Governing Council Of The Univ Of Toronto System and method for filtering time-varying data for physiological signal prediction
USD1002852S1 (en) 2019-06-06 2023-10-24 Abbott Diabetes Care Inc. Analyte sensor device
US11718865B2 (en) 2019-07-26 2023-08-08 Medtronic Minimed, Inc. Methods to improve oxygen delivery to implantable sensors
US11523757B2 (en) 2019-08-01 2022-12-13 Medtronic Minimed, Inc. Micro-pillar working electrodes design to reduce backflow of hydrogen peroxide in glucose sensor
US11375931B2 (en) 2019-08-08 2022-07-05 Cambridge Medical Technologies LLC Non-invasive transdermal sampling and analysis device incorporating an electrochemical bioassay
US20210106260A1 (en) * 2019-10-11 2021-04-15 The Regents Of The University Of California Mediator-free biochemical sensing device and method for noninvasively and electrochemically sensing in vivo biochemicals
US20220031205A1 (en) 2020-07-31 2022-02-03 Medtronic Minimed, Inc. Sensor identification and integrity check design
US20220133190A1 (en) 2020-10-29 2022-05-05 Medtronic Minimed, Inc. Glucose biosensors comprising direct electron transfer enzymes and methods of making and using them
CN112432988B (en) * 2020-11-25 2023-03-03 重庆迈联医疗科技有限公司 Temperature correction method of electrochemical test system
USD999913S1 (en) 2020-12-21 2023-09-26 Abbott Diabetes Care Inc Analyte sensor inserter
US20220240823A1 (en) 2021-01-29 2022-08-04 Medtronic Minimed, Inc. Interference rejection membranes useful with analyte sensors
CN112986365B (en) * 2021-02-19 2023-10-13 三诺生物传感股份有限公司 Electrochemical measurement correction method and system
US20220338768A1 (en) 2021-04-09 2022-10-27 Medtronic Minimed, Inc. Hexamethyldisiloxane membranes for analyte sensors
USD988882S1 (en) 2021-04-21 2023-06-13 Informed Data Systems Inc. Sensor assembly
EP4082436A1 (en) * 2021-04-29 2022-11-02 Roche Diabetes Care GmbH Method for determining a reliability of an analyte sensor
US20230053254A1 (en) 2021-08-13 2023-02-16 Medtronic Minimed, Inc. Dry electrochemical impedance spectroscopy metrology for conductive chemical layers
US20230113175A1 (en) 2021-10-08 2023-04-13 Medtronic Minimed, Inc. Immunosuppressant releasing coatings
US20230123613A1 (en) 2021-10-14 2023-04-20 Medtronic Minimed, Inc. Sensors for 3-hydroxybutyrate detection
US20230172497A1 (en) 2021-12-02 2023-06-08 Medtronic Minimed, Inc. Ketone limiting membrane and dual layer membrane approach for ketone sensing
US20240023849A1 (en) 2022-07-20 2024-01-25 Medtronic Minimed, Inc. Acrylate hydrogel membrane for dual function of diffusion limiting membrane as well as attenuation to the foreign body response
CN117292807B (en) * 2023-11-24 2024-02-06 华中科技大学同济医学院附属同济医院 Clinical blood sugar management quality control system

Citations (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4178916A (en) * 1977-09-26 1979-12-18 Mcnamara Elger W Diabetic insulin alarm system
US4509531A (en) * 1982-07-28 1985-04-09 Teledyne Industries, Inc. Personal physiological monitor
US4703756A (en) * 1986-05-06 1987-11-03 The Regents Of The University Of California Complete glucose monitoring system with an implantable, telemetered sensor module
US4975581A (en) * 1989-06-21 1990-12-04 University Of New Mexico Method of and apparatus for determining the similarity of a biological analyte from a model constructed from known biological fluids
US5036861A (en) * 1990-01-11 1991-08-06 Sembrowich Walter L Method and apparatus for non-invasively monitoring plasma glucose levels
US5063081A (en) * 1988-11-14 1991-11-05 I-Stat Corporation Method of manufacturing a plurality of uniform microfabricated sensing devices having an immobilized ligand receptor
US5076273A (en) * 1988-09-08 1991-12-31 Sudor Partners Method and apparatus for determination of chemical species in body fluid
US5086229A (en) * 1989-01-19 1992-02-04 Futrex, Inc. Non-invasive measurement of blood glucose
US5139023A (en) * 1989-06-02 1992-08-18 Theratech Inc. Apparatus and method for noninvasive blood glucose monitoring
US5140985A (en) * 1989-12-11 1992-08-25 Schroeder Jon M Noninvasive blood glucose measuring device
US5250419A (en) * 1988-12-16 1993-10-05 L'oreal Method for the direct measurement of at least one chemical parameter of skin using a biosensor
US5267152A (en) * 1989-10-28 1993-11-30 Yang Won S Non-invasive method and apparatus for measuring blood glucose concentration
US5279543A (en) * 1988-01-29 1994-01-18 The Regents Of The University Of California Device for iontophoretic non-invasive sampling or delivery of substances
US5355880A (en) * 1992-07-06 1994-10-18 Sandia Corporation Reliable noninvasive measurement of blood gases
US5362307A (en) * 1989-01-24 1994-11-08 The Regents Of The University Of California Method for the iontophoretic non-invasive-determination of the in vivo concentration level of an inorganic or organic substance
US5435309A (en) * 1993-08-10 1995-07-25 Thomas; Edward V. Systematic wavelength selection for improved multivariate spectral analysis
US5443080A (en) * 1993-12-22 1995-08-22 Americate Transtech, Inc. Integrated system for biological fluid constituent analysis
US5448992A (en) * 1992-12-10 1995-09-12 Sunshine Medical Instruments, Inc. Method and apparatus for non-invasive phase sensitive measurement of blood glucose concentration
US5458140A (en) * 1993-11-15 1995-10-17 Non-Invasive Monitoring Company (Nimco) Enhancement of transdermal monitoring applications with ultrasound and chemical enhancers
US5462051A (en) * 1994-08-31 1995-10-31 Colin Corporation Medical communication system
US5497772A (en) * 1993-11-19 1996-03-12 Alfred E. Mann Foundation For Scientific Research Glucose monitoring system
US5507288A (en) * 1994-05-05 1996-04-16 Boehringer Mannheim Gmbh Analytical system for monitoring a substance to be analyzed in patient-blood
US5735273A (en) * 1995-09-12 1998-04-07 Cygnus, Inc. Chemical signal-impermeable mask
US5752512A (en) * 1995-05-10 1998-05-19 Massachusetts Institute Of Technology Apparatus and method for non-invasive blood analyte measurement
US5771890A (en) * 1994-06-24 1998-06-30 Cygnus, Inc. Device and method for sampling of substances using alternating polarity
US5791344A (en) * 1993-11-19 1998-08-11 Alfred E. Mann Foundation For Scientific Research Patient monitoring system
US5800420A (en) * 1994-11-04 1998-09-01 Elan Medical Technologies Limited Analyte-controlled liquid delivery device and analyte monitor
US5822715A (en) * 1997-01-10 1998-10-13 Health Hero Network Diabetes management system and method for controlling blood glucose
US5830132A (en) * 1993-08-24 1998-11-03 Robinson; Mark R. Robust accurate non-invasive analyte monitor
US5995860A (en) * 1995-07-06 1999-11-30 Thomas Jefferson University Implantable sensor and system for measurement and control of blood constituent levels
US6014577A (en) * 1995-12-19 2000-01-11 Abbot Laboratories Device for the detection of analyte and administration of a therapeutic substance
US6021339A (en) * 1997-09-26 2000-02-01 Nec Corporation Urine testing apparatus capable of simply and accurately measuring a partial urine to indicate urinary glucose value of total urine
US6024699A (en) * 1998-03-13 2000-02-15 Healthware Corporation Systems, methods and computer program products for monitoring, diagnosing and treating medical conditions of remotely located patients
US6049727A (en) * 1996-07-08 2000-04-11 Animas Corporation Implantable sensor and system for in vivo measurement and control of fluid constituent levels
US6059736A (en) * 1998-02-24 2000-05-09 Tapper; Robert Sensor controlled analysis and therapeutic delivery system
US6088608A (en) * 1997-10-20 2000-07-11 Alfred E. Mann Foundation Electrochemical sensor and integrity tests therefor
US6134461A (en) * 1998-03-04 2000-10-17 E. Heller & Company Electrochemical analyte
US6144869A (en) * 1998-05-13 2000-11-07 Cygnus, Inc. Monitoring of physiological analytes
US6159147A (en) * 1997-02-28 2000-12-12 Qrs Diagnostics, Llc Personal computer card for collection of real-time biological data
US6175752B1 (en) * 1998-04-30 2001-01-16 Therasense, Inc. Analyte monitoring device and methods of use
US6180416B1 (en) * 1998-09-30 2001-01-30 Cygnus, Inc. Method and device for predicting physiological values
US6233471B1 (en) * 1998-05-13 2001-05-15 Cygnus, Inc. Signal processing for measurement of physiological analysis
US6248067B1 (en) * 1999-02-05 2001-06-19 Minimed Inc. Analyte sensor and holter-type monitor system and method of using the same
US6270455B1 (en) * 1997-03-28 2001-08-07 Health Hero Network, Inc. Networked system for interactive communications and remote monitoring of drug delivery
US6275717B1 (en) * 1997-06-16 2001-08-14 Elan Corporation, Plc Device and method of calibrating and testing a sensor for in vivo measurement of an analyte
US6299578B1 (en) * 1995-12-28 2001-10-09 Cygnus, Inc. Methods for monitoring a physiological analyte
US6326160B1 (en) * 1998-09-30 2001-12-04 Cygnus, Inc. Microprocessors for use in a device for predicting physiological values

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3857771A (en) * 1967-02-27 1974-12-31 Beckman Instruments Inc Rate sensing batch analyzer
JPS56150343A (en) * 1980-04-23 1981-11-20 Olympus Optical Co Ltd Data processing system for electrophoresis image
JP2684871B2 (en) 1991-05-16 1997-12-03 日本電気株式会社 Body fluid component measuring method and measuring device
WO1995002357A1 (en) 1993-07-16 1995-01-26 Cygnus Therapeutic Systems Noninvasive glucose monitor
EP0649628B1 (en) 1993-10-22 1999-01-07 Siemens-Elema AB Processes and devices for continuously monitoring levels of anolyte
US5569186A (en) 1994-04-25 1996-10-29 Minimed Inc. Closed loop infusion pump system with removable glucose sensor
JP3328290B2 (en) * 1994-06-24 2002-09-24 シグナス, インコーポレイテッド Ion introduction sampling apparatus and method
JP2002515786A (en) * 1996-06-28 2002-05-28 ソントラ メディカル,エル.ピー. Ultrasound enhancement of transdermal delivery
JP4368060B2 (en) 1998-02-17 2009-11-18 アボット・ラボラトリーズ Interstitial fluid collection and monitoring device
JP3978489B2 (en) * 1998-02-26 2007-09-19 アークレイ株式会社 Blood measuring device
WO1999058973A1 (en) * 1998-05-13 1999-11-18 Cygnus, Inc. Method and device for predicting physiological values
AU3363000A (en) 1999-02-12 2000-08-29 Cygnus, Inc. Devices and methods for frequent measurement of an analyte present in a biological system
US6424847B1 (en) 1999-02-25 2002-07-23 Medtronic Minimed, Inc. Glucose monitor calibration methods

Patent Citations (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4178916A (en) * 1977-09-26 1979-12-18 Mcnamara Elger W Diabetic insulin alarm system
US4509531A (en) * 1982-07-28 1985-04-09 Teledyne Industries, Inc. Personal physiological monitor
US4703756A (en) * 1986-05-06 1987-11-03 The Regents Of The University Of California Complete glucose monitoring system with an implantable, telemetered sensor module
US5279543A (en) * 1988-01-29 1994-01-18 The Regents Of The University Of California Device for iontophoretic non-invasive sampling or delivery of substances
US5730714A (en) * 1988-01-29 1998-03-24 The Regents Of The University Of California Method for the iontophoretic non-invasive determination of the in vivo concentration level of glucose
US5076273A (en) * 1988-09-08 1991-12-31 Sudor Partners Method and apparatus for determination of chemical species in body fluid
US5063081A (en) * 1988-11-14 1991-11-05 I-Stat Corporation Method of manufacturing a plurality of uniform microfabricated sensing devices having an immobilized ligand receptor
US5250419A (en) * 1988-12-16 1993-10-05 L'oreal Method for the direct measurement of at least one chemical parameter of skin using a biosensor
US5086229A (en) * 1989-01-19 1992-02-04 Futrex, Inc. Non-invasive measurement of blood glucose
US5362307A (en) * 1989-01-24 1994-11-08 The Regents Of The University Of California Method for the iontophoretic non-invasive-determination of the in vivo concentration level of an inorganic or organic substance
US5139023A (en) * 1989-06-02 1992-08-18 Theratech Inc. Apparatus and method for noninvasive blood glucose monitoring
US4975581A (en) * 1989-06-21 1990-12-04 University Of New Mexico Method of and apparatus for determining the similarity of a biological analyte from a model constructed from known biological fluids
US5267152A (en) * 1989-10-28 1993-11-30 Yang Won S Non-invasive method and apparatus for measuring blood glucose concentration
US5140985A (en) * 1989-12-11 1992-08-25 Schroeder Jon M Noninvasive blood glucose measuring device
US5036861A (en) * 1990-01-11 1991-08-06 Sembrowich Walter L Method and apparatus for non-invasively monitoring plasma glucose levels
US5355880A (en) * 1992-07-06 1994-10-18 Sandia Corporation Reliable noninvasive measurement of blood gases
US5630413A (en) * 1992-07-06 1997-05-20 Sandia Corporation Reliable noninvasive measurement of blood gases
US5448992A (en) * 1992-12-10 1995-09-12 Sunshine Medical Instruments, Inc. Method and apparatus for non-invasive phase sensitive measurement of blood glucose concentration
US5435309A (en) * 1993-08-10 1995-07-25 Thomas; Edward V. Systematic wavelength selection for improved multivariate spectral analysis
US5830132A (en) * 1993-08-24 1998-11-03 Robinson; Mark R. Robust accurate non-invasive analyte monitor
US5458140A (en) * 1993-11-15 1995-10-17 Non-Invasive Monitoring Company (Nimco) Enhancement of transdermal monitoring applications with ultrasound and chemical enhancers
US5722397A (en) * 1993-11-15 1998-03-03 Altea Technologies, Inc. Enhancement of transdermal monitoring applications with ultrasound and chemical enhancers
US5660163A (en) * 1993-11-19 1997-08-26 Alfred E. Mann Foundation For Scientific Research Glucose sensor assembly
US5497772A (en) * 1993-11-19 1996-03-12 Alfred E. Mann Foundation For Scientific Research Glucose monitoring system
US5791344A (en) * 1993-11-19 1998-08-11 Alfred E. Mann Foundation For Scientific Research Patient monitoring system
US5443080A (en) * 1993-12-22 1995-08-22 Americate Transtech, Inc. Integrated system for biological fluid constituent analysis
US5507288B1 (en) * 1994-05-05 1997-07-08 Boehringer Mannheim Gmbh Analytical system for monitoring a substance to be analyzed in patient-blood
US5507288A (en) * 1994-05-05 1996-04-16 Boehringer Mannheim Gmbh Analytical system for monitoring a substance to be analyzed in patient-blood
US6023629A (en) * 1994-06-24 2000-02-08 Cygnus, Inc. Method of sampling substances using alternating polarity of iontophoretic current
US5771890A (en) * 1994-06-24 1998-06-30 Cygnus, Inc. Device and method for sampling of substances using alternating polarity
US5462051A (en) * 1994-08-31 1995-10-31 Colin Corporation Medical communication system
US5820622A (en) * 1994-11-04 1998-10-13 Elan Medical Technologies Limited Analyte-controlled liquid delivery device and analyte monitor
US5800420A (en) * 1994-11-04 1998-09-01 Elan Medical Technologies Limited Analyte-controlled liquid delivery device and analyte monitor
US5807375A (en) * 1994-11-04 1998-09-15 Elan Medical Technologies Limited Analyte-controlled liquid delivery device and analyte monitor
US5752512A (en) * 1995-05-10 1998-05-19 Massachusetts Institute Of Technology Apparatus and method for non-invasive blood analyte measurement
US6122536A (en) * 1995-07-06 2000-09-19 Animas Corporation Implantable sensor and system for measurement and control of blood constituent levels
US5995860A (en) * 1995-07-06 1999-11-30 Thomas Jefferson University Implantable sensor and system for measurement and control of blood constituent levels
US5735273A (en) * 1995-09-12 1998-04-07 Cygnus, Inc. Chemical signal-impermeable mask
US5827183A (en) * 1995-09-12 1998-10-27 Cygnus, Inc. Method of measuring chemical concentration iontophoretically using impermeable mask
US6014577A (en) * 1995-12-19 2000-01-11 Abbot Laboratories Device for the detection of analyte and administration of a therapeutic substance
US6299578B1 (en) * 1995-12-28 2001-10-09 Cygnus, Inc. Methods for monitoring a physiological analyte
US6049727A (en) * 1996-07-08 2000-04-11 Animas Corporation Implantable sensor and system for in vivo measurement and control of fluid constituent levels
US5822715A (en) * 1997-01-10 1998-10-13 Health Hero Network Diabetes management system and method for controlling blood glucose
US6159147A (en) * 1997-02-28 2000-12-12 Qrs Diagnostics, Llc Personal computer card for collection of real-time biological data
US6270455B1 (en) * 1997-03-28 2001-08-07 Health Hero Network, Inc. Networked system for interactive communications and remote monitoring of drug delivery
US6275717B1 (en) * 1997-06-16 2001-08-14 Elan Corporation, Plc Device and method of calibrating and testing a sensor for in vivo measurement of an analyte
US6021339A (en) * 1997-09-26 2000-02-01 Nec Corporation Urine testing apparatus capable of simply and accurately measuring a partial urine to indicate urinary glucose value of total urine
US6088608A (en) * 1997-10-20 2000-07-11 Alfred E. Mann Foundation Electrochemical sensor and integrity tests therefor
US6059736A (en) * 1998-02-24 2000-05-09 Tapper; Robert Sensor controlled analysis and therapeutic delivery system
US6134461A (en) * 1998-03-04 2000-10-17 E. Heller & Company Electrochemical analyte
US6024699A (en) * 1998-03-13 2000-02-15 Healthware Corporation Systems, methods and computer program products for monitoring, diagnosing and treating medical conditions of remotely located patients
US6175752B1 (en) * 1998-04-30 2001-01-16 Therasense, Inc. Analyte monitoring device and methods of use
US6565509B1 (en) * 1998-04-30 2003-05-20 Therasense, Inc. Analyte monitoring device and methods of use
US6990366B2 (en) * 1998-04-30 2006-01-24 Therasense, Inc. Analyte monitoring device and methods of use
US6233471B1 (en) * 1998-05-13 2001-05-15 Cygnus, Inc. Signal processing for measurement of physiological analysis
US6144869A (en) * 1998-05-13 2000-11-07 Cygnus, Inc. Monitoring of physiological analytes
US6180416B1 (en) * 1998-09-30 2001-01-30 Cygnus, Inc. Method and device for predicting physiological values
US6326160B1 (en) * 1998-09-30 2001-12-04 Cygnus, Inc. Microprocessors for use in a device for predicting physiological values
US6248067B1 (en) * 1999-02-05 2001-06-19 Minimed Inc. Analyte sensor and holter-type monitor system and method of using the same

Cited By (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090048584A1 (en) * 1999-04-30 2009-02-19 Medtronic Minimed, Inc. Closed Loop Medicament Pump
US8115635B2 (en) 2005-02-08 2012-02-14 Abbott Diabetes Care Inc. RF tag on test strips, test strip vials and boxes
US8542122B2 (en) 2005-02-08 2013-09-24 Abbott Diabetes Care Inc. Glucose measurement device and methods using RFID
US8223021B2 (en) 2005-02-08 2012-07-17 Abbott Diabetes Care Inc. RF tag on test strips, test strip vials and boxes
US8390455B2 (en) 2005-02-08 2013-03-05 Abbott Diabetes Care Inc. RF tag on test strips, test strip vials and boxes
US8358210B2 (en) 2005-02-08 2013-01-22 Abbott Diabetes Care Inc. RF tag on test strips, test strip vials and boxes
US8114269B2 (en) 2005-12-30 2012-02-14 Medtronic Minimed, Inc. System and method for determining the point of hydration and proper time to apply potential to a glucose sensor
US20080000779A1 (en) * 2005-12-30 2008-01-03 Medtronic Minimed, Inc. Method and System for Remedying Sensor Malfunctions Detected by Electrochemical Impedance Spectroscopy
US8608924B2 (en) 2005-12-30 2013-12-17 Medtronic Minimed, Inc. System and method for determining the point of hydration and proper time to apply potential to a glucose sensor
US7985330B2 (en) 2005-12-30 2011-07-26 Medtronic Minimed, Inc. Method and system for detecting age, hydration, and functional states of sensors using electrochemical impedance spectroscopy
US8114268B2 (en) 2005-12-30 2012-02-14 Medtronic Minimed, Inc. Method and system for remedying sensor malfunctions detected by electrochemical impedance spectroscopy
US10117614B2 (en) 2006-02-28 2018-11-06 Abbott Diabetes Care Inc. Method and system for providing continuous calibration of implantable analyte sensors
US11872039B2 (en) 2006-02-28 2024-01-16 Abbott Diabetes Care Inc. Method and system for providing continuous calibration of implantable analyte sensors
US20070283334A1 (en) * 2006-06-02 2007-12-06 International Business Machines Corporation Problem detection facility using symmetrical trace data
US7946985B2 (en) 2006-12-29 2011-05-24 Medtronic Minimed, Inc. Method and system for providing sensor redundancy
US20110218489A1 (en) * 2006-12-29 2011-09-08 Medtronic Minimed, Inc. Method and System for Providing Sensor Redundancy
US8679016B2 (en) 2006-12-29 2014-03-25 Medtronic Minimed, Inc. Method and system for providing sensor redundancy
US9189598B2 (en) 2007-05-30 2015-11-17 Bayer Healthcare Llc Fluid analyte meter
US10347371B2 (en) 2007-05-30 2019-07-09 Ascensia Diabetes Care Holdings Ag Fluid analyte meter system
US8401873B2 (en) 2007-05-30 2013-03-19 Bayer Healthcare Llc Health data management device
WO2008151274A1 (en) * 2007-06-05 2008-12-11 Owen Davis Device and system for montioring contents of perspiration
US9320462B2 (en) 2008-03-28 2016-04-26 Abbott Diabetes Care Inc. Analyte sensor calibration management
US10463288B2 (en) 2008-03-28 2019-11-05 Abbott Diabetes Care Inc. Analyte sensor calibration management
WO2009121040A3 (en) * 2008-03-28 2010-01-07 Abbott Diabetes Care Inc. Analyte sensor calibration management
US20090247857A1 (en) * 2008-03-28 2009-10-01 Abbott Diabetes Care, Inc. Analyte Sensor Calibration Management
US11779248B2 (en) 2008-03-28 2023-10-10 Abbott Diabetes Care Inc. Analyte sensor calibration management
US9730623B2 (en) 2008-03-28 2017-08-15 Abbott Diabetes Care Inc. Analyte sensor calibration management
US8718739B2 (en) 2008-03-28 2014-05-06 Abbott Diabetes Care Inc. Analyte sensor calibration management
US8346335B2 (en) 2008-03-28 2013-01-01 Abbott Diabetes Care Inc. Analyte sensor calibration management
US8965477B2 (en) 2009-02-26 2015-02-24 Abbott Diabetes Care Inc. Analyte monitoring device and methods
US9724029B2 (en) 2009-02-26 2017-08-08 Abbott Diabetes Care Inc. Analyte monitoring device and methods
US9178752B2 (en) 2009-04-15 2015-11-03 Abbott Diabetes Care Inc. Analyte monitoring system having an alert
US8730058B2 (en) 2009-04-15 2014-05-20 Abbott Diabetes Care Inc. Analyte monitoring system having an alert
US8497777B2 (en) 2009-04-15 2013-07-30 Abbott Diabetes Care Inc. Analyte monitoring system having an alert
US10009244B2 (en) 2009-04-15 2018-06-26 Abbott Diabetes Care Inc. Analyte monitoring system having an alert
US9310230B2 (en) 2009-04-29 2016-04-12 Abbott Diabetes Care Inc. Method and system for providing real time analyte sensor calibration with retrospective backfill
US8483967B2 (en) 2009-04-29 2013-07-09 Abbott Diabetes Care Inc. Method and system for providing real time analyte sensor calibration with retrospective backfill
US9664644B2 (en) 2009-06-23 2017-05-30 Ascensia Diabetes Care Holdings Ag System and apparatus for determining temperatures in a fluid analyte system
US9097650B2 (en) 2009-06-23 2015-08-04 Bayer Healthcare Llc System and apparatus for determining temperatures in a fluid analyte system
US8617381B2 (en) 2009-06-23 2013-12-31 Bayer Healthcare Llc System and apparatus for determining temperatures in a fluid analyte system
US20100319436A1 (en) * 2009-06-23 2010-12-23 Bayer Healthcare Llc System and Apparatus for Determining Temperatures in a Fluid Analyte System
US9186113B2 (en) 2009-08-31 2015-11-17 Abbott Diabetes Care Inc. Displays for a medical device
US10918342B1 (en) 2009-08-31 2021-02-16 Abbott Diabetes Care Inc. Displays for a medical device
US9549694B2 (en) 2009-08-31 2017-01-24 Abbott Diabetes Care Inc. Displays for a medical device
US20110193704A1 (en) * 2009-08-31 2011-08-11 Abbott Diabetes Care Inc. Displays for a medical device
US11730429B2 (en) 2009-08-31 2023-08-22 Abbott Diabetes Care Inc. Displays for a medical device
US9814416B2 (en) 2009-08-31 2017-11-14 Abbott Diabetes Care Inc. Displays for a medical device
US11241175B2 (en) 2009-08-31 2022-02-08 Abbott Diabetes Care Inc. Displays for a medical device
US11202586B2 (en) 2009-08-31 2021-12-21 Abbott Diabetes Care Inc. Displays for a medical device
US9226714B2 (en) 2009-08-31 2016-01-05 Abbott Diabetes Care Inc. Displays for a medical device
US10123752B2 (en) 2009-08-31 2018-11-13 Abbott Diabetes Care Inc. Displays for a medical device
USRE47315E1 (en) 2009-08-31 2019-03-26 Abbott Diabetes Care Inc. Displays for a medical device
US10881355B2 (en) 2009-08-31 2021-01-05 Abbott Diabetes Care Inc. Displays for a medical device
US10772572B2 (en) 2009-08-31 2020-09-15 Abbott Diabetes Care Inc. Displays for a medical device
US8816862B2 (en) 2009-08-31 2014-08-26 Abbott Diabetes Care Inc. Displays for a medical device
US10456091B2 (en) 2009-08-31 2019-10-29 Abbott Diabetes Care Inc. Displays for a medical device
US8514086B2 (en) 2009-08-31 2013-08-20 Abbott Diabetes Care Inc. Displays for a medical device
US10285632B2 (en) 2010-04-16 2019-05-14 Abbott Diabetes Care Inc. Analyte monitoring device and methods
CN102469941A (en) * 2010-04-16 2012-05-23 艾伯特糖尿病护理公司 Analyte monitoring device and methods
US10082493B2 (en) 2011-11-25 2018-09-25 Abbott Diabetes Care Inc. Analyte monitoring system and methods of use
US11391723B2 (en) 2011-11-25 2022-07-19 Abbott Diabetes Care Inc. Analyte monitoring system and methods of use
US9339217B2 (en) 2011-11-25 2016-05-17 Abbott Diabetes Care Inc. Analyte monitoring system and methods of use
US11896371B2 (en) 2012-09-26 2024-02-13 Abbott Diabetes Care Inc. Method and apparatus for improving lag correction during in vivo measurement of analyte concentration with analyte concentration variability and range data
RU2686048C2 (en) * 2014-07-17 2019-04-23 Ф.Хоффманн-Ля Рош Аг Method and device for determining glucose level in patient's physiological liquid and computer program product
WO2016008997A1 (en) * 2014-07-17 2016-01-21 Roche Diagnostics Gmbh A method and a device for determining a body fluid glucose level of a patient, and a computer program product
US11627894B2 (en) 2014-07-17 2023-04-18 Roche Diabetes Care, Inc. Method and a device for determining a body fluid glucose level of a patient, and a computer program product
CN105486731A (en) * 2015-08-12 2016-04-13 成都市亿泰科技有限公司 Terahertz-enhanced noninvasive blood-sugar detection probe
US20170065231A1 (en) * 2015-09-04 2017-03-09 Goldensunda Technology Co., Ltd. Noninvasive blood sugar measurement device
CN111107679A (en) * 2019-12-02 2020-05-05 天津大学 Flexible temperature control system

Also Published As

Publication number Publication date
US20030153821A1 (en) 2003-08-14
CA2311487A1 (en) 1999-11-18
US7295867B2 (en) 2007-11-13
US20030153820A1 (en) 2003-08-14
US20010016682A1 (en) 2001-08-23
EP1077636A1 (en) 2001-02-28
JP2004000655A (en) 2004-01-08
WO1999058050A1 (en) 1999-11-18
DK1077636T3 (en) 2004-05-24
JP2002514452A (en) 2002-05-21
DE69914319D1 (en) 2004-02-26
PT1077636E (en) 2004-06-30
US6595919B2 (en) 2003-07-22
CA2311487C (en) 2004-02-10
US6233471B1 (en) 2001-05-15
EP1077636B1 (en) 2004-01-21
ATE258028T1 (en) 2004-02-15
ES2213369T3 (en) 2004-08-16
JP4545398B2 (en) 2010-09-15
DE69914319T2 (en) 2004-11-18

Similar Documents

Publication Publication Date Title
US7295867B2 (en) Signal processing for measurement of physiological analytes
US6272364B1 (en) Method and device for predicting physiological values
US7174199B2 (en) Monitoring a physiological analytes
US7405055B2 (en) Method and device for predicting physiological values
US6180416B1 (en) Method and device for predicting physiological values

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION